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ABSTRACT 
 
 
Refractive laser eye surgery is a specialised field in ophthalmology which aims to 
correct the refractive disorder of an eye. The most established technique is LASIK, 
which has shown good results for the treatment of simple myopia. Complex refractive 
disorders, such as compound myopic astigmatism, have shown less predictable 
refractive outcomes, and in some cases the severe over- or under-correction can even 
worsen the preoperative situation and damage the eye. 
 
In its first stage, this research aimed to develop a software system able to present and 
analyse refractive outcomes. Over 2 prototype stages, this research has led to an 
operational system named IBRA (Internet Based Refractive Analysis), offering web-
based data collection and refractive and vector analysis. 
 
In a second stage, Nomogram calculation formulas were developed and integrated into 
IBRA. These formulas were created from linear regression and best-fit analyses of 
spherical and cylindrical outcome data stored in IBRA. The purpose of the nomogram 
calculations was to provide surgeons with adjustment factors that could be used to 
improve the refractive outcome of patients with complex refractive disorders. 
 
Two extensive clinical audits and a randomized controlled trial were performed at 
Moorfields Eye Hospital to evaluate the IBRA nomogram adjustments. This research 
showed that IBRA was able to achieve a positive health change. In addition, results 
from the audits and trial contributed to the knowledge of nomogram adjustments and 
provided a framework in which future investigations on nomogram and treatment 
modifications could be performed.  
 
In addition to the above clinical studies, two evaluations were performed with the use of 
IBRA and data logging techniques to investigate users‟ behaviour relating to the 
management of data entry processes and the use of analysis functions. This research 
revealed the best method for entering refractive data, and was able to identify the most 
important analysis methods. 
 
Finally, the use of IBRA and its user-interface were investigated with a user satisfaction 
survey. The results from this questionnaire based study showed a high acceptance of the 
web-based platform of IBRA and indicated points for improvement (Documentation). 
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1. INTRODUCTION 
 
1.1. Background 
Refractive vision disorders such as myopia (short-sightedness) and astigmatism 
(abnormality in the shape of the cornea) can be corrected with refractive laser eye 
surgery. 
 
A refractive laser unit consists of a laser source, a system of optical instruments and 
controller software. The algorithm that describes the relation between the laser power 
and the amount of surface ablation (removal of corneal tissue) necessary to achieve the 
refractive change bases mainly on empirical data. Although mechanically perfected over 
the last 10 years, the treatment algorithm of the controller software has not kept up and 
suffers from optimisation. Imprecision in the treatment can result in an outcome that is 
over- or undercorrected, and may even worsen the preoperative situation and damage 
the patient‟s eye. As a consequence, intensive care and re-treatments are necessary. 
 
The collection and analysis of refractive outcome data has become an increasingly 
important requirement of refractive surgery practice. Not surprisingly, the forthcoming 
Quality Standard and Revalidation initiatives of The Royal College of Ophthalmologists 
underpin this importance in the provision of auditable outcomes of surgery. 
 
One of the most critical factors that can affect the outcome after laser vision correction 
is the nomogram that the surgeon uses. A nomogram is a unique group of detailed 
treatment settings that is programmed into the laser. The best results are achieved when 
the treatment is tailored for each person based on age, gender, prescription, and other 
factors. 
 
Although there are software systems on the market that can analyse refractive data and 
perform nomogram optimisation, such systems use an unspecific general approach. A 
system that performs both general and patient-individual nomogram modifications, 
using 2-3 different calculation technologies, has not yet been developed. In addition, the 
use of modified nomograms has never been evaluated scientifically with controlled 
randomised trials or audit cycles. 
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1.2. Aim of the research 
The aim of the research is to record, analyse and improve the health outcome in patients 
undergoing laser vision correction. 
 
 
1.3. Objectives of the research 
Basic objectives: 
 To perform an extensive literature and software review. 
 To establish requirements in the area of refractive eye laser surgery. 
 To analyse the management of data entry processes. 
 To evaluate user preferences and user satisfaction. 
 To present and publish the results of this research. 
 
Main clinical objectives of the research: 
1. To develop a system that can combine data collection and analysis and offer 
tools for standardised outcome presentation. 
2. To make the system easily accessible, secure, safe, flexible and capable of future 
developments. 
3. To develop and integrate means (algorithms, formula) that can provide 
information on how refractive laser treatments could be improved. 
4. To test the system in a clinical (private practice) environment with real patient 
treatments. 
5. To evaluate the system impact on patient‟s health. 
6. To improve the understanding of nomogram adjustments. 
 
 
1.4. Administrative organisation and settings 
A prototype of the system and a functional successor were developed and clinically 
tested at the Eye Clinic, Cantonal Hospital, Lucerne, Switzerland, and further revised in 
accordance to the needs. 
 
Additional system development, methodological support and system evaluations were 
performed at the Centre for Health Informatics, City University London, United 
Kingdom. 
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New treatment algorithms with formulas for individual nomogram calculations were 
created and implemented in collaboration with the Refractive Laser Unit at Moorfields 
Eye Hospital NHS Foundation Trust, London. 
 
The clinical evaluation included a randomised controlled trial, which was performed in 
accordance with National Ethical Commission guidelines and the Research & 
Development Department at Moorfields Eye Hospital. A user-centred system evaluation 
was performed at the Centre for Health Informatics, City University London. 
 
The analysis of the results was performed at the Centre for Health Informatics, London. 
Statistical support was provided by medical statisticians at Moorfields Eye Hospital. 
 
Summary of participating organizations: 
 Centre for Health Informatics, School of Informatics, City University London. 
 Refractive Surgery Unit, Moorfields Eye Hospital, London. 
 Department of Research and Development, Moorfields Eye Hospital 
 Department of Corneal and External Eye Disease, Moorfields Eye Hospital 
 Statistical Advice Unit, Moorfields Eye Hospital, London 
 Health and Safety Executive's Research Ethics Committee 
 
 
1.5. Opportunities 
This was the first research that had integrated different refractive outcome analysis 
techniques in one system, and which undertook extensive user-centred and patient-
related system evaluations. 
 
The main promises of this research were: 
 To create a calculation formula which can improve the patient‟s health outcome. 
 To improve the understanding of laser treatments for refractive disorders. 
 To have a major impact on the surgeon‟s management of eye laser surgery. 
 To contribute to the knowledge of refractive data collection, data analysis and 
nomogram adjustment. 
 To increase the cost-effectiveness of current treatments in reducing the re-
treatment rate and additional follow-ups. 
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1.6. Organisation of the Thesis 
This thesis is organised in 8 chapters. The first chapter states the background, aim and 
objectives of the investigation. 
 
Chapter 2 describes the domain of laser vision correction and provides important 
information on refractive disorders, principles of laser treatments and refractive 
outcome analyses. 
 
Chapter 3 reports the results from the literature review on refractive analysis and 
nomogram adjustments, presents the different refractive analysis software currently 
available, and outlines the reviewed program languages evaluated for the system 
development. 
 
In Chapter 4 the thesis continues by discussing the initial needs for the analysis system 
and presents the development of a prototype system called „Proexcimer‟. 
 
Chapter 5 describes the range of new needs that led to the development of the research 
system called „IBRA‟ (Internet Based Refractive Analysis). All parts of IBRA are 
presented with screenshots and are discussed. 
 
Chapter 6 reports on 5 evolutions performed to test the IBRA system from both a 
clinical and a user point of view. The results of clinical audits, randomised clinical trial, 
survey and data logging processes are presented in scientific format. 
 
In Chapter 7 the results of system development and evaluation are discussed, and 
compared with the aims and objectives of the research. 
 
Chapter 8 provides a conclusion of the work carried out in this study and the results 
achieved. 
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DOMAIN OF REFRACTIVE LASER EYE SURGERY 
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2. DOMAIN OF REFRACTIVE LASER EYE SURGERY 
 
Refractive laser eye surgery is a specialised field of eye surgery which focuses on 
improving the optical state of the eye using an excimer laser beam to reshape the 
surface of the cornea. This change in the cornea compensates the ocular disease. 
 
This chapter will provide basic information on topics from the field of refractive laser 
eye surgery which were used in this research, including: 
 Refractive disorders (Section 2.1.) 
 Principles and techniques of laser vision correction (Section 2.2.) 
 Range of refractive data and refractive analysis (Section 2.3.) 
 
 
2.1. Refractive disorders 
Typical indications for laser treatment are refractive vision disorders such as myopia 
(short-sightedness), hyperopia (long-sightedness) and astigmatism (an abnormality in 
the shape of the surface of the cornea). 
 
2.1.1. Myopia 
If one thinks of the eye as camera, then the retina would be the film and the cornea the 
lens (objective). The camera is able to produce a sharp image when the lens is able to 
focus the light rays on the film plane. The eye works in a similar way. If the light rays 
are focused on the retina the image is sharp. 
 
Myopia is a vision disorder in which the light rays are focused on a single point that lies 
in front of the retina (within the globe). The image is blurred. This can occur in 2 
situations. Firstly, the axial length of the eye is too big; the eye “is too long”. This 
situation is called axial myopia (Figure 2.1.1.). Secondly, the cornea is focusing the 
light rays too strongly. This situation is called refractive myopia. 
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Figure 2.1.1. Left image: In myopia, the light rays are focused on a single point that lies in front of the 
retina (within the globe). Images from distant objects are blurred. Right image: Correction of myopia with 
a (biconcave) minus lens. 
 
 
Mild to moderate myopia can be corrected with spectacles. The spectacles have to move 
the point of focus further back so it can reach the retina. The types of lenses used for 
this purpose have a biconcave curvature and are called minus (diverging) lenses. 
 
The degree of myopia is measured in diopters [D] by the strength (or optical power) of a 
corrective minus lens. Low myopia usually describes myopia of -3.00 D or less. Myopia 
is common and is regarded as physiological if less than -6.00 D. 
 
The incidence of myopia varies with age, country, sex, race, ethnicity, occupation, 
environment, and other factors (Verma 2005 and Fredrick 2002). In Western Europe a 
review found that 26.6% aged 40 or over have at least -1.00 D of myopia and 4.6% have 
at least -5.00 D (Kempen 2004). 
 
Of those with high myopia (-6.00 D or more) there is a subset who are at risk of 
degenerative changes with increased prevalence of retinal detachment, choroidal 
neovascularisation and open angle glaucoma (Oxford Handbook of Ophthalmology). 
Myopia has also been found in association with genetic disorders like Down's 
syndrome, Marfan‟s syndrome or albinism. 
 
2.1.2. Hyperopia 
The focal point of incoming light in the hyperopic eye, which is too “short”, lies behind 
the retina (Figure 2.1.2.), which means that distant objects are seen fairly clearly, whilst 
near objects are represented in a distinctly blurred manner. 
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Figure 2.1.2. In hyperopia the light rays are focused behind the retina (outside the globe). 
 
 
2.1.3. Astigmatism 
Astigmatism is a refractive disorder that results from a common abnormality in the 
shape of the cornea. The human cornea is usually dome-shaped, like part of a football, 
but with astigmatism, the cornea has an ellipsoidal shape, more like part of a rugby ball. 
This will cause blurred and distorted vision. 
 
Similar to an ellipse being described by 2 axes (a major and minor axis) the ellipsoid 
cornea is described by 2 radii. The meridian with the smaller radius is also called the 
steeper axis, which lies perpendicular to the meridian with the bigger radius, which is 
called the flatter axis. Each radius has a different refraction and all the light that passes 
through an astigmatic cornea will therefore produce two focal planes, instead of one. 
Usually, one of the focal planes is in front of the retina, with the other one behind 
(Figure 2.1.3.). This situation is called mixed astigmatism. In simple astigmatism one of 
the two focal points is focused on the retina.  
 
Astigmatism can be combined with myopia. This situation is called myopic 
astigmatism. Simple myopic astigmatism is a situation with one focal point in front of 
the retina and one focal point on the retinal plane (Alio 1995). 
 
Astigmatism is mainly hereditary and the prevalence increases with age (Robert 2003 
and Asano 2005). Astigmatism is not a rare condition and remains lifelong. 
Approximately 17% of eyes of a normal population have at least 2 diopters of 
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astigmatism, but only 1% of eyes have more than 4 diopters. Higher amounts, especially 
irregular forms of astigmatism, may cause blurred vision, squinting or headaches, and 
occasionally can be very difficult to correct with spectacles or contact lenses. 
 
The diagnosis of astigmatism is made by subjective refraction (the process to determine 
the best corrective lenses) and corneal topography (a procedure that scans the shape of 
the cornea, Figure 2.1.4.). 
 
 
     
Figure 2.1.3. The “rugby ball” shaped cornea of an eye with astigmatism produces 2 focal planes. Left 
image: Both planes are in front of the retina in simple myopic astigmatism. Right image: The planes are 
in front and behind the retina in mixed astigmatism (red and blue lines). 
 
 
   
Figure 2.1.4. Topographic image of an eye with corneal astigmatism (bow tie figure). Left image: before 
laser surgery; Right image: same eye 3 months after LASIK showing flattening of the central cornea 
(greener=flatter) and disappearing of the bow tie figure. 
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Astigmatic corrections are more challenging than purely spherical corrections. 
Astigmatism can be corrected by spectacles with a cylindrical lens, a lens that has 
different radii of curvature. Such lenses are more complex to prescribe and more 
expensive to produce. Patients with higher amounts of astigmatism may require contact 
lenses to achieve good visual acuity. 
 
 
2.2. Principles and techniques of laser vision correction 
Glasses and contact lenses have drawbacks: they are a hindrance in certain professions 
and activities (e.g. chef, actor, sports). Reducing the dependence on spectacles or 
contacts promises an improvement in quality of life. For many people, the prospect of 
going through life without glasses or contact lenses is reason enough to consider 
intervention of this kind. Intolerance to contact lenses can be a further incentive for 
wanting refractive surgery. 
 
Over the past 20 years, refractive surgery has undergone a turbulent development. 
Despite intensive scientific monitoring there is no long-term experience reaching back 
more than 10-15 years of more recent procedures. 
 
A wide range of corrective methods is available in refractive surgery. A basic 
distinction is made between corneal procedures and lens procedures. In corneal 
procedures (Table 2.2.1.) the refractive strength of the cornea can be modified using the 
excimer laser. Most common procedures are Femto-LASIK (Laser Assisted In-Situ 
Keratomileusis) and LASEK (Laser Assisted Sub-Epithelium Keratomileusis). Lens 
procedures correct the vision disorder through an additional lens which is implanted 
into the eye, or through a lens replacement. 
 
 
 Myopia Hyperopia Astigmatism 
LASIK up to -8.0 D up to +3.0 D up to 4.0 D 
LASEK up to -6.0 D up to +1.0 D up to 3.0 D 
Table 2.2.1. Indications for corneal procedures 
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2.2.1. LASIK (Laser assisted in-situ keratomileusis) 
Laser assisted in-situ keratomileusis (LASIK) is one of the most frequently performed 
elective procedures to correct myopia. Around 100,000 LASIK procedures are 
performed per year in the United Kingdom, and over 12 million procedures have been 
performed worldwide since the introduction in 1993 (Maurino 2008). It is a highly 
effective (private) outpatient procedure. 
 
The majority of people with focusing errors of the eye are able to have LASIK. 
However, some people are not able to have laser eye correction. Possible reasons for 
this include ocular surface diseases, thin corneas, early cataract or focusing errors 
outside the range that can be corrected by laser. 
 
Generally, suitable patients for LASIK have: 
 An age of 21 or more (the eye is still growing until this age).  
 Myopia up to -8 dioptres and hyperopia up to +3 dioptres.  
 Regular astigmatism (up to 4 dioptres).  
 A stable spectacle or contact lens prescription for at least 12 months.  
 Good vision in both eyes with glasses or contact lenses. 
 
A typical LASIK procedure consists of multiple steps. The whole intervention takes 
place using anaesthetic eye drops and lasts about 10-15 minutes per eye. 
 
Flap creation 
First of all, a thin flap of corneal tissue is prepared. For this procedure two different 
techniques can be used: a mechanical microkeratome or a Femto laser. A 
microkeratome is a precision surgical instrument with an oscillating blade designed for 
creating a flap. The hand piece (Figure 2.2.1.) mainly consists of an engine connected to 
a controller unit, which analyses the resistance of the oscillation of the blade with the 
aim to prevent blockage. The head of the microkeratome contains the single use blade. 
It can be mounted on a disposable holder unit for flap creation. During the cut, the eye 
is temporarily fixed using a suction ring, which is felt as a slight pressure in the eye. A 
negative pressure of up to 80 mmHg is used for this fixation, rarely leading to 
conjunctival or choroidal haemorrhages. The blade of the microkeratome smoothly 
moves forward and cuts a corneal flap with a specific depth. After the cut, the holder is 
removed and the flap lifted (Figure 2.2.2.). 
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Figure 2.2.1. Microkeratome hand piece (AMO) and head with holder and support unit, fixed to the 
cornea by a vacuum. 
 
 
Figure 2.2.2. Creating a corneal flap with a microkeratome.  
 
 
In recent years, the “bladeless” technique has gained popularity, mainly for hygienic 
reasons. This method uses a Femto laser (Figure 2.2.3.) to create a corneal flap. A 
Femto laser is an expensive piece of equipment (approximately £250,000 per unit) and 
operates with a high energy laser with a wavelength of 1050nm. 
 
The beam of the Femto laser is focused to create a micro air bubble (explosion) in the 
corneal stroma. The bubble naturally expands and separates the corneal fibres and 
layers. If multiple air bubbles are placed next to each other, two corneal planes can be 
separated. The anterior plane can be used as the corneal flap. With this technique the 
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surgeon can customize the corneal flap for every individual patient. The term „Femto-
LASIK‟ is used for LASIK treatments with Femto laser flap creation. 
 
 
       
Figure 2.2.3. Creation of a corneal flap with a Femto laser (Ziemer). 
 
 
 
Corneal ablation with the Excimer laser 
To reshape the cornea an excimer laser is used. Computer-controlled pulses of excimer 
laser light are applied to the inner layers of the cornea (also called corneal stroma). This 
removal of corneal stromal tissue (also called ablation) reshapes the cornea and changes 
the refractive power of the cornea (Figure 2.2.4.). This procedure takes between 30 and 
90 seconds. In this process the smallest, unintentional eye movements are also 
registered by the laser and automatically corrected. 
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Figure 2.2.4. The laser beam removes corneal stromal tissue to change the refraction. 
 
 
Once the ablation has been completed the corneal flap is replaced and positioned, and 
antibiotic and anti-inflammatory eye drops are applied. Further fixation, e.g. with 
sutures, is not necessary. Slightly blurred vision and slight watering of the eye are both 
normal following the intervention. After just a few hours, sufficient visual acuity is 
achieved so that glasses or contact lenses are no longer required. The vision stabilises 
after 4-8 weeks.  
 
Most new generation Excimer laser units offer wavefront (customised) treatments. 
Using wavefront measurements (Figure 2.2.5.) the unique imperfections of each 
individual eye, just like a fingerprint, can be determined. The wavefront data then is 
used to calculate an individual treatment profile, allowing higher ablation precision. 
 
 
Figure 2.2.5. Wavefront measurements of an eye 
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From a technical and engineering point of view, the Excimer laser unit (Figure 2.2.6.) is 
a highly expensive treatment unit (£350,000) and consists of hardware and software. 
 
The hardware is the part that produces a laser beam with 192nm wavelength. This beam 
is directed via a system of highly precise optical instruments (mirrors and lenses) to a 
binocular microscope where it finally is focused on the patient's eye. 
 
 
Figure 2.2.6. Excimer laser unit for laser vision correction used for this research (VISX S4). 
 
The software part controls the mirrors, the lens positions and the laser power that is 
needed for the refractive treatment. A calculation algorithm (nomogram) describes the 
relation between the laser power and the surface ablation. The nomograms mainly base 
on empirical data. 
 
 
Risks and complications of LASIK 
No surgical procedure is ever risk-free. Fortunately, sight-threatening complications 
from laser vision correction are rare. Serious complications occur in less than 1% and 
many LASIK complications can be resolved with additional surgery or medical 
treatment. A list of possible complications is shown in Table 2.2.2. Visual aberrations 
summarise symptoms such as glare, double vision, ghosting, halos, starbursts, loss of 
contrast sensitivity, and problems with low-light or night vision. 
 
 
 
31 
 
Complications Symptoms Treatments 
Incomplete corrections Blurry, less-than-perfect 
vision 
Glasses or contact lenses; eye drops; re-
treatment 
Decentred ablations Visual aberrations Eye drops; re-treatment 
Oversize pupils 
(pupils > treatment zone) 
Visual aberrations Eye drops; re-treatment 
Haze Visual aberrations Eye drops; re-treatment 
Irregular flap 
(folds, wrinkles, striae) 
Visual aberrations Surgical correction; second laser 
procedure 
Dry eye Dry, itchy or scratchy eyes, 
often with redness and sense 
of foreign object in eye, and 
sometimes pain 
Prescription dry eye medication; 
artificial tears; punctal occlusion 
(blockage of tear ducts in order to retain 
tear film on eye) 
Diffuse lamellar keratitis 
(eye inflammation) 
Visual aberrations Eye drops; surgical rinsing of cells 
Epithelial ingrowth Visual aberrations Surgical removal of epithelium 
Infection Redness, oozing of eyes, 
sometimes pain 
Eye drops; oral medications 
Table 2.2.2. Complications, symptoms and treatments in LASIK (Keith Croes). 
 
 
 
2.2.2. LASEK (Laser assisted in-situ keratomileusis) 
LASEK is an alternative laser refractive procedure. LASEK is known as a „surface 
procedure‟ and may be safer if the cornea is relatively thin, or if any other medical 
conditions mean that LASIK is not the best option. 
 
Instead of creating a corneal „flap‟ on the surface of the cornea, the very superficial 
layer of corneal epithelial cells is treated with alcohol and moved to the side, allowing 
the underlying cornea to be re-shaped by the refractive laser with wavefront technology 
(Figure 2.2.7.). Afterwards, the epithelium can be smoothed over the lasered corneal 
surface. The surface cells then grow back across the cornea within a few days. Finally, a 
bandage contact lens protects the surface layer that has not yet grown together securely 
until it has completely healed, and is then removed. 
 
Generally, the recovery period is longer than for LASIK, and in the first days following 
treatment, patients may experience a foreign body sensation and may suffer from eye 
pain and photophobia. The improved vision is not appreciated until the epithelium has 
fully healed, usually after about a week. The long-term results for low to moderate 
short-sightedness are very similar to LASIK. 
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Figure 2.2.7. LASEK procedure. 
 
 
2.2.3. Planning and programming laser treatments 
Refractive eye laser surgery requires careful preoperative assessment and an extensive 
planning of the treatment (Figure 2.2.8.). 
 
A typical procedure of a Femto-LASIK treatment consists of the following steps: 
 Pre-assessment and consenting 
 Deciding on a treatment plan, ablation pattern and target refraction. 
 Programming the Femto laser for flap creation 
 Programming the Excimer laser for corneal ablation 
 Follow-up visits 
 
Pre-assessment and consenting 
The pre-assessment for laser surgery comprises a comprehensive examination of the 
eyes and a discussion of visual needs with a Consultant Ophthalmic Surgeon. The 
examination includes an exact determination of best-corrected and uncorrected visual 
acuity with refraction, measurement of intraocular pressure and nocturnal pupil 
diameter, slit lamp examination of the eye lids, cornea, lens, optic nerve and retina, and 
testing of the extraocular muscles. A laser scan of the corneal surface (topography) is 
also carried out routinely and sometimes wavefront measurements are added. 
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At the end of the assessment, the surgeon discusses the findings with the patient and 
determines the suitability for laser vision correction. Sometimes the surgeon has to 
advise against undergoing laser surgery. Additional information is provided on the 
benefits, risks and possible complications (Table 2.2.2.) of laser vision correction, on 
the predictability of visual and refractive outcomes, and on the cost of the treatment. 
Finally, once the patient agrees to go ahead, a consent form is signed by the patient 
acknowledging being informed completely and with understanding. 
 
Deciding on a treatment plan, ablation pattern and target refraction 
At this stage the surgeon can suggest a certain method of correction (LASIK or 
LASEK) and has the chance to discuss treatment targets with the patient. In most cases, 
patients request emmetropia, enabling them to see distant objects clearly without the 
need for glasses. The spherical equivalent of emmetropia is zero. 
 
Depending on the vision disorder, different patterns of ablation (the way the corneal 
tissue is removed by the laser) are applied. For example, myopia is treated with a 
spherical ablation. This is a straightforward treatment process with a uniform, disc-like 
ablation of the corneal stroma. 
 
The ablation pattern for the treatment of astigmatism is much more demanding. 
Basically, the steeper axis of the cylinder is flattened by torical ablation. Flattening of 
the steeper axis alone, without reshaping the flatter axis, results in hyperopic shift (the 
eye gets less myopic). This can be a desired side effect in the treatment of myopia, but 
is usually not desirable because of its unpredictability (McDonnell 1991). 
 
Over the years newer ablation patterns have been developed, notably the bitoric ablation 
pattern (Chayet 1998, DeOrtueta 2008) and the cross-cylinder ablation pattern 
(Vinciguerra 2000 and 1999). In the cross-cylinder ablation technique the amount of 
astigmatism is divided in two: half of the correction is treated on the flatter meridian 
and half is treated on the steeper meridian. This method does not lead to unpredictable 
hyperopic shifts. The treatment pattern for combined myopia and astigmatism is a 
combination of a spherical and cross-cylinder ablation. 
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Figure 2.2.8. Planning stages of LASIK treatments. 
 
 
Programming the Femto laser for flap creation  
Modern Femto lasers allow programming and modifying of nearly every parameter 
defining the corneal flap. The flap diameter and thickness are the most important 
parameters determined for each patient individually. The flap diameter depends on the 
ablation pattern and is slightly bigger for the treatment of hyperopic eyes. The thickness 
depends on the surgeon‟s preference and experience. Thinner flaps allow more corneal 
tissue to be treated but are more difficult to lift. Further parameters that can be 
programmed include the shape of the flap (round or oval), the marginal profile (convex, 
concave, perpendicular) and the position of the flap (centred, off-set). It requires years 
of experience to find the ideal programming of the flap parameters for each patient 
(Faktorovich 2008). 
  
Programming the Excimer laser for corneal ablation 
In a successful LASIK treatment, the induced refractive change equals the preoperative 
refractive error. Although the excimer laser‟s nomogram provides good support in 
deciding on the best possible amount of ablation and its profile, one particular 
parameter has to be adjusted patient-individually. This parameter is the diameter of the 
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ablation, also called the optical zone (OZ). The optical zone has to be increased in eyes 
with bigger nocturnal pupil diameter, in hyperopic eyes and in eyes that receive a 
peripheral blend zone. Finally, the amount of ablation can be boosted or decreased, 
based on the surgeon‟s preference.  
 
Follow-up visits 
Following surgery, patients are seen the next day to check the position of the corneal 
flap. Additional reviews can be arranged at 1 week and 1 month following surgery. The 
refractive change of the eye usually stabilises after 4-6 weeks. The final review is 
undertaken at 3 months, including comprehensive examination with refraction and 
topography. Most patients are discharged at this time. 
 
 
2.3. Refractive outcome analysis 
Regular postoperative refractive analysis is good medical practice and can identify 
factors which, together with individual treatment and wound healing factors, could 
influence the refractive outcome.  
 
The Royal College of Ophthalmologists (2007) and NICE (IPG164, 2006) have 
published guidelines regarding good medical practice in refractive laser eye surgery. 
They advise undertaking a careful audit of results following laser in-situ keratomileusis 
(LASIK), on a regular basis. 
 
Standards have been proposed regarding how refractive outcomes should be calculated 
and presented (Waring 2000), and commercially available software facilitates this 
outcome analysis and nomogram changes (see chapter 3). 
 
The basic principle of outcome analysis and nomogram adjustment is a process 
consisting of 3 stages (Figure 2.3.1.), normally facilitated by the refractive outcome 
analysis software: 
 
 Refractive data collection: recording of treatment data, preoperative and 
postoperative refractive and visual data, and data on complications and patient 
satisfaction. 
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 Analysis of the data: results from demographics calculations, Waring graphs, 
vector analysis, and others; more details on methods of analysis are given in 
Chapter 3 and 5. 
 
 Transformation of the results into nomogram tables and adjustment factors: use 
of linear and non-linear regression analysis, nomogram graphs and tables. 
 
Other methods include back-calculation to model strategies for pre-treatment 
adjustment of the ablation sphere to eliminate unpromising new approaches before 
clinical trials (Arnalich-Montiel 2009). 
 
 
 
 
Figure 2.3.1. Stages of refractive outcome analysis in refractive laser surgery. 
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2.4. Summary 
This chapter provides information on refractive vision disorders, types of laser 
treatments, benefits and risks of laser vision correction, and the importance of pre-
assessment and postoperative outcome analysis.  
 
Typical indications for a refractive eye laser treatment are vision disorders such as 
myopia (short-sightedness) and astigmatism (an abnormality in the shape of the surface 
of the cornea). Laser assisted in-situ keratomileusis with Femto laser flap creation 
(Femto-LASIK) is the most frequently performed elective procedure and has become 
the standard in laser vision correction. 
 
Postoperative refractive outcome analysis is a complex procedure consisting of 3 main 
stages: data collection, outcome analysis and nomogram calculation. 
 
The current state of quality of refractive laser surgery has been presented in review 
articles on LASIK (Sutton 2010) and LASEK (O'Keefe 2010). 
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REVIEW OF LITERATURE, SOFTWARE AND PROGRAM LANGUAGES 
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3. REVIEW OF LITERATURE, SOFTWARE AND PROGRAM LANGUAGES 
 
A review of literature and software was performed extensively at the beginning of the 
prototype development in 2002, at the beginning of the evaluations in 2008 and 
following completion of the evaluations in 2010. 
 
3.1. Literature review on refractive analysis 
The focus of the thematic literature review was on the handling and analysis of 
refractive data, on the presentation of refractive outcomes, and on refractive calculation 
models (nomograms) for treatment optimisation. We were selective in this review focus, 
and only wanted to include articles that reported on refractive data in laser eye surgery, 
such as LASIK or LASEK. 
 
Between 2002 and 2008 many articles on laser eye treatments and techniques for their 
improvement were published. Surprisingly, only a few new articles reporting on this 
topic were found in a Medline search since 2008. This could be linked to the fact that 
this field has not seen significant technical changes over the last 2 years, and that the 
refractive outcomes from LASIK and LASEK have reached a high precision (Sutton 
2010 and O'Keefe 2010). 
 
For the search in Medline (PubMed) and Google we have used a range of different key 
words, and their combination. These search criteria are listed in Table 3.1.1., which also 
shows the results from the first selection round. 
 
In total, 429 documents were found on refractive data handling, analysis and 
optimisation. Although this seems to be a high number of publications, in fact, this 
number is rather low when comparing to other fields of Ophthalmology dealing with 
refractive outcomes, for example LASIK for myopia (2130 results) or standard cataract 
surgery (11206 results). This relative shortage of evidence-based literature is mainly a 
result of circumstances, given that laser vision correction is performed exclusively in 
private practice. This business field has some distinctive characteristics, some of which 
are: 
 Laser surgery is part of a highly competitive business with a strong view on 
reputation. Refractive surgeons prefer not to be identified in undertaking 
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experimental work (research). This bears the risk of damaging reputations. The 
general tenor is to remain out of studies. 
 If the outcome of a study is not good, it may not be published. This may help to 
reduce the risk of negative news and damage to the prestige that could ultimately 
bring about a significant cut to revenue. 
 If the research results are very good, the journal reviewers may not believe them. 
Research results could be manipulated to promote private business (marketing 
issues). 
 Research takes time, during which a surgeon could be consulting or operating on 
patients, again resulting in extra income. Time used for research does not 
provide earnings; on the contrary, it increases spending. 
 Dealing with private practice participants is more complicated than the 
management of NHS participants in research projects. 
 
We rejected 393 of 429 articles because the link to laser eye surgery was weak or 
absent. The topics of the excluded articles showed a wide range, including refractive 
analysis following cataract surgery, corneal grafting, corneal incisional surgery, testing 
of refractive equipment, reporting on epidemiological findings, intraocular lens power 
calculation, and refractive treatment of keratoconus. 
 
The remaining 36 documents were marked for full inspection, and graded on their 
relevance to this research (Table 3.1.1.). The detailed analysis of these articles showed 
that some of the articles were presenting obsolete technology (e.g. older versions of 
laser units and ablation profiles), or technology that has become standard in the 
meantime (we described these articles with the term „historic‟). Many of the reviewed 
articles presented results that are valid only for specific equipment, for example laser 
units Schwind, Technolas, Nidek or Alcon; or the use of a specific (overnight) contact 
lens called Paragon. Some of the articles presented results that can only be achieved in 
combination with additional procedures, e.g. LASIK in combination with a cataract 
operation, and some of the articles with important findings did not describe the 
methodology well enough for us to repeat the technique or use the calculation algorithm 
for our research. However, some of the articles graded as partially relevant (+) were 
used in this thesis and cited in the corresponding sections. 
 
 
41 
Search criteria 
/ other key words 
Res Exc Inc Full inspection 
Authors (Year) 
Relevance 
Refractive data 
/ Calculations 
/ Algorithm 
/ Presentation 
 
Refractive outcome 
/ Analysis 
/ Reporting 
/ Presentation 
 
207 195 12 Kaye (2002) 
Naeser (2001) 
Holladay (2001) 
Kaye (2001) 
Calossi (1993) 
Arbelaez (2009) 
Feltham (2008) 
Anderson (2003) 
Nakano (2003) 
Waring (2000) 
Huang (1999) 
Hefetz (1997) 
+ 
- (very complete) 
- (very complex) 
- (very complex) 
- (historic) 
- (only Schwind) 
- (mainly Technolas) 
- (only Technolas) 
- (only Nidek) 
+++ 
+ 
- (historic) 
Vector analysis 
 
125 115 
 
10 Suominen (2003) 
Thibos (2001) 
Alpins (2001) 
Huang (2000) 
Corones (1999) 
Alpins (1997) 
Shah (1997) 
Naeser (1997) 
Alpins (1997) 
Neumann (1989) 
+ 
- (very complex) 
+++ 
- (too general) 
- (historic) 
- (integrated in 2001) 
- (historic) 
- (too theoretical) 
- (integrated in 2001) 
- (for AK only) 
Nomogram 
/ Outcome 
/ Treatment 
/ Adjustment 
/ Improvement 
 
97 83 14 Arnalich-Montiel (2009) 
Lapid-Gortzak (2008) 
De Ortueta (2008) 
González-Méijome (2007) 
Mrochen (2006) 
Zaldivar (2005) 
Feiz (2005) 
Caster (2004) 
Anderson (2004) 
Ortiz (2003) 
Moniz (2002) 
Reviglio (2000) 
Ditzen (1999) 
Probst (1998) 
+ 
- (no details provided) 
- (only Schwind) 
- (only Paragon) 
+++ 
+ 
- (IOL related) 
- (only Alcon) 
- (only Technolas) 
+ (but too general) 
- (too general) 
- (mainly results) 
- (historic) 
- (historic) 
Total 429 393 36   
Table 3.1.1. Overview of the selection process for the literature review, with the search criteria, the 
results (Res) from Medline search, the excluded documents (Exc), the remaining documents (Inc) that 
were used for inspection, and the relevance. 
 
Finally, only 3 articles matched the search terms and topic sufficiently, providing 
specific, significant and generalisable information for this research. We believe that 
these publications provide essential information on refractive analyses and were 
therefore used as reference. For many refractive surgeons, these articles have become 
part of their „key literature‟ in reporting refractive outcomes, calculating nomograms 
and analysing refractive astigmatic data with the method of vector analysis. 
 
3.1.1. Waring Graphs (Reporting refractive outcomes) 
The main article linked to the presentation of refractive results is written by George 
Waring and has the title “Standard graphs for reporting refractive surgery”, published in 
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J Refract Surg, 2000;16:459-466. Mr Waring writes about his experience in refractive 
analysis, and presents his ideas on how refractive data should be analysed and presented 
in publications.  He proposes a set of six standard graphs (Figure 3.1.1.) which should 
be included in any paper reporting the results of a series of cases. Generally, the graphs 
can easily be produced by anyone with widely available software (Microsoft EXCEL). 
This standardized system of reporting outcomes allows comparison between the results 
of different publications. The graphs of different articles can be arranged side by side, 
allowing a direct visual evaluation of the outcomes of surgical procedures. Although 
originally proposed by Prof Neuhann (Comment: Prof. Neuhann did not publish the 
concept in a journal, but he spoke about the idea of graphs and refractive outcome 
reporting at Congresses and in private personal communications), the concept of 6 
standard graphs, as presented by Waring, has become a “gold standard” and the concept 
has been taken on by many surgeons in their routine praxis. Therefore, any software that 
analyses refractive data and produces outcome graphs has to implement at least some of 
the Waring recommendations. 
 
 
Figure 3.1.1. Set of 6 standard Waring graphs (copy of original publication). 
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3.1.2. Nomograms adjustments 
The key article for nomogram adjustment is authored by Michael Mrochen et al, and has 
the title “Nomograms for the improvement of refractive outcomes”, published in 
Ophthalmologe 2006;103:331-8. The authors of this study analysed the clinical 
relevance and limitations of nomograms in case series on a theoretical basis. Their 
results suggest that the use of individual nomograms can significantly improve the 
predictability of refractive outcomes. However, the investigations demonstrate that a 
homogeneous data distribution within cohorts was a key factor for predictable 
nomogram calculations. The authors concluded that nomograms are helpful for 
improving refractive outcomes, but are limited to approximately 90% of outcomes 
within +/-0.5 D of the target. 
 
3.1.3. Vector analysis with the Alpins method 
The most important literature on vector analysis is authored by Noel Alpins with the 
title “Astigmatism analysis by the Alpins method”, published in J Cataract Refract Surg, 
2001;27(1):31-49. The aim of Mr Alpins‟s method is to determine the effectiveness of 
correcting astigmatism by laser refractive surgery by a vectorial astigmatism outcome 
analysis. For the calculations the method uses 3 fundamental vectors: the target induced 
astigmatism vector (TIA), the surgically induced astigmatism vector (SIA) and the 
difference vector (DV). TIA is the astigmatic change (by magnitude and axis) the 
surgery was intended to induce. This can be seen as a golf scenario where the player 
intends to hit a ball from a starting point into the hole. SIA represents the amount and 
axis of astigmatic change the surgery actually induces. In “golf language” this would 
mean where the ball effectively landed after the hit.  Finally, DV is the astigmatic 
change that would enable the initial surgery to achieve its intended target. This is the 
required hit of the ball needed to bring it from the (unintended) landing point to the 
target point (hole). The vectors can be drawn on a double angle vector diagram (Figure 
3.1.2.). By examining individual vector relationships to the TIA (e.g. the correction 
index, index of success, and flattening index), a comprehensive astigmatism analysis is 
completed. Each index provides information necessary for understanding any astigmatic 
change. 
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Figure 3.1.2. Double angle vector diagram (produced with the IBRA system) showing TIA (green line), 
SIA (red line) and DV (black line). 
 
 
3.2. Review of refractive analysis systems 
A review of refractive analysis software over the years showed parallels to the literature 
review, with minimal changes since 2008. Five different software systems were 
available on the market in 2008. An April 2010 review showed that 4 of the 5 products 
are still available, and 3 of 4 products are upgraded on a regular basis (Outcome 
Analysis, Datagraph-med and ASSORT Software).  The Refractive Surgery Outcomes 
Information System was removed from the market in 2009 and its successor 
(EUREQUO) has just been introduced, showing a delay of almost 1 year. The most up-
to-date review also showed that no other company has invested in the development of 
outcome software in the field of refractive laser eye surgery. 
 
In the following subsections we will summarise key figures of all 5 software systems 
that had an influence on refractive surgeons over the last 10 years (Table 3.2.1.); and on 
the IBRA system development generally. Each system is described with information 
about the company, the surgeon involved in the development of the system, the features 
and costs. Images from print screens (where available) show the user interface. 
Start 
Target 
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Outcome Analysis and Datagraph-med were available as (case restricted) demo versions 
and were tested in 2008. 
 
As per 2008/2009, three of the systems offered refractive outcome analysis and were 
able to produce the set of 6 standard Waring graphs. The main focus of the ASSORT 
Software was on analysis of refractive data with the method of vector analysis. The 
RSOIS system was intended to be a refractive database with some (minimal) outcome 
analysis functions (calculation of mean and standard deviation) without presenting 
results in graphical form. 
 
 
Software 
(Author) 
Developed 
by surgeons 
Refractive 
analysis 
Vector 
analysis 
Individual 
nomogram 
Web- 
based 
Eva 
 
Costs 
 
Outcome Analysis 
(P. Binder) 
Yes Yes No No No No $ 4000 
Datagraph-med 
(S. Pieger) 
No Yes No No No No € 1750 
Refractive Surgery Cons. 
(J. Holladay) 
Yes Yes Yes No No No $ 8000 
ASSORT and Vector 
(N. Alpins) 
Yes No Yes No No No $ 4900 
RSOIS 
(ESCRS) 
No No No No Yes No € 150 
        
IBRA System 
(B. Zuberbuhler) 
Yes Yes Yes Yes Yes Yes £ 400? 
Table 3.2.1. Overview of commercially available refractive analysis software systems (up-dated in 2009). 
For comparison the IBRA system with the aimed features. Eva=Evaluated. The costs are for a single user 
licence. 
 
 
3.2.1. Outcomes Analysis Software 
This software is produced by Outcomes Analysis Software, Inc., 2500 6th Avenue, Ste. 
307 San Diego, CA 92103, USA. The system is developed by Dr Perry Binder, a well 
known and established American refractive surgeon.  The system is a FileMaker Pro 
Runtime application, and is regularly updated. A single user license (unlimited use) 
costs USD 4,000.00 and runs on a single computer only. The software has limited server 
and network operationability (as provide by the FileMaker Pro Server version). The 
software can record all relevant patient and surgical data via a clear user-interface with 
multiple data entry pages (Figure 3.2.1.). The system is able to perform complex 
refractive analysis, to calculate nomograms and to produce a variety of charts, including 
the set of Waring charts (Figure 3.2.2.). The software does not offer vector analysis 
46 
based on the Alpins method. The functionality, user interface satisfaction and clinical 
effectiveness of the software have not been scientifically evaluated. 
 
     
Figure 3.2.1. Two screenshots from the “Outcome Analysis Program Version 4.0”, showing the fields for 
the collection of patient information (left) and surgical information (right). 
 
     
Figure 3.2.2. Two screenshots from the “Outcome Analysis Software”, showing the charts that can be 
produced by the software (left) and one example of a spherical equivalent histogram (right). 
 
 
3.2.2. Datagraph-med 
This system is produced by Pieger GmbH, Treidelsweg 8, D-90530 Wendelstein, 
Germany.  Behind the company and the programming is the owner Stefan Pieger, who 
is an electronic engineer. No eye surgeons were involved in the concept or core 
programming of the system although eye surgeons would surely have tested the system 
after completion, and provided important feedback. Other than the Outcomes Analysis 
Software, Datagraph-med is developed in co-operation with ZEISS, one of the global 
providers of optical and opto-electronic technology. Therefore, the software system is 
optimised for ZEISS‟s own refractive laser units, the MEL-80, and offers an interface 
that can import some of the treatment data (not all of it, and no pre- or postoperative 
refractive data) directly from the MEL-80 laser into the analysis software. As the market 
share of ZEISS MEL-80 lasers in the UK is less than 3%, only a minority of refractive 
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surgeons can take advantage of this. The price for a user license is EUR 1,750.00 for 
one installation. The software is regularly updated. 
 
Technically, the programming is based on a Microsoft Access and Microsoft Office 
system, which needs to be (pre-) installed on the PC to run the software application. The 
system features include a database for the collection of pre- and postoperative data, a 
refractive analysis tool that can create the Waring graphs, and a (general) nomogram 
calculation tool (Figure 3.2.3.). The software does not offer vector analysis or complex 
network functionality.  The system has not been evaluated regarding user satisfaction, 
functionality or effectiveness, although some of the features of the system have been 
presented by Mirshahi and Kohnen in a German ophthalmological journal (Mirshahi 
2002). 
 
     
Figure 3.2.3. Two screenshots from the “Datagraph-med Version 3.90”, showing a refractive analysis 
with stability chart (left) and the charts and tables of the nomogram adjustment module (right). 
 
 
3.2.3. Refractive Surgery Consultant Elite 
This product is developed by the Refractive Consulting Group, Inc., 28071 North 90th 
Way, Scottsdale, Arizona 85262, USA. The programming was performed in 
conjunction with two established and internationally well known American refractive 
surgeons: Dr Jack Holladay and Dr Guy Kezirian. These Consultants are also contracted 
in part by VISX, a global company that produces laser units (VISX S4 laser; used in the 
controlled trial in this research). This company is owned by Advanced Medical Optics, 
Inc. (AMO), one of the largest suppliers of ophthalmic equipment. The cost of the 
software is USD 8,000.00, which includes licenses for 3 computer installations. Version 
releases are scheduled to occur approximately once yearly. A demo version was not 
available. The features (taken from the manufacturer‟s website) include a database with 
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complex data entry form, laid out in logical order to follow the sequence of a refractive 
patient pathway (Figure 3.2.4.). The software analyses data and produces Waring 
graphs. General nomogram calculations are updated constantly as more data is entered. 
The software includes vector analysis and produces double angle vector diagrams, but 
the developers do not mention if this method is based on the Alpins method or their 
own. There is no publication regarding evaluation of the system, although the system 
has been used for the calculation of results for many publications and presentations 
performed by Jack Holladay. 
 
 
Figure 3.2.4. Two screenshots from the “Refractive Surgery Consultant Elite” Software, showing a data 
entry form for patient and surgical data (left) and a spherical equivalent and cylinder scattergram in the 
nomogram calculation module (right).  
 
 
3.2.4. ASSORT 
This system is developed by ASSORT Pty. Ltd., 7 Chesterville Rd., Cheltenham, 
Victoria 3192, Australia. Responsible for the programming is Noel Alpins, a 
Melbourne-based ophthalmic surgeon who is the developer of the Alpins Method. His 
method has been published in many articles and has become the standard for eye 
surgeons. The price for one license of the ASSORT software is USD 4,900.00. A major 
feature of the program is the possibility of planning and analyzing astigmatism surgery 
(Figure 3.2.5.). The Alpins method of astigmatism analysis is displayed both 
numerically and graphically (Figure 3.2.6.). The software does not produce the standard 
Waring graphs. A demo version was not available. 
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Figure 3.2.5. Two screenshots from the ASSORT Software, showing a data entry form (left) and a vector 
chart with parameters from vector analysis (right). 
 
 
Figure 3.2.6. A screenshot of the ASSORT software with a polar diagram (top right), a double angle 
vector diagram (middle left) with TIA, SIA and DV, and a table with calculated vector parameters 
(correction index and index of success, in the centre). 
 
 
3.2.5. Refractive Surgery Outcomes Information System (RSOIS) 
This system is no longer in use. It was developed in 2006 for the European Society of 
Cataract and Refractive Surgeons (ESCRS), Temple House, Temple Road, Blackrock, 
Co. Dublin, Ireland. The purpose was to collect laser treatment data from patients 
50 
treated by the members of the ESCRS. The software was based on web technology and 
was freely accessible for all members (member fee €150 per year). The RSOIS was 
mainly a database that offered basic analysis functions (calculations of mean and 
standard deviation from preoperative and postoperative data). The software did not 
produce Waring graphs, nor did it calculate nomograms or vector analysis outcomes. 
Most eye doctors did not like it or use the system, because they understood it as an 
instrument of controlling from an ophthalmic society. They also criticised that the 
system did not provide meaningful outcome analysis. Therefore, the members of the 
ESCRS rejected the system and the Society promised to develop a successor with the 
name “EUREQUO” (European Registry of Quality Outcomes for Cataract and 
Refractive Surgery), which has just been made accessible to members. 
 
 
 
3.3. Review of program languages for system development 
 
For the development of the prototype and the IBRA system, we reviewed and tested 
different program languages and developer platforms.  Table 3.3.1. provides a summary 
of the reviewed systems. 
 
Completely different requirements existed at 2 different stages of the system 
development. Therefore 2 separate reviews of program languages and developer 
platforms were performed over the years. 
 
The first review focused on the integration of the existing FileMaker database concept 
into a new system that could also provide graphical output of the results that, so far, had 
to be performed with EXCEL in a separate step following manual data transfer. The 
new prototype should combine data collection and analysis in one system, and should 
present the results in bar charts and scattergrams. As we were given little time for the 
prototype development, we have omitted the idea of using a „proper‟ program language 
and concentrated instead on 2 commercially available developer platforms, one platform 
based on FileMaker, the other on Microsoft Office programs, including MS Access, MS 
EXCEL and Visual Basic. The optional plug-in “xmCHART” from the Austrian 
company „X2max Software‟ FileMaker promised to enable FileMaker to create bar 
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charts and scattergrams. We decided to continue with the use of FileMaker and started 
the development of the prototype. 
 
Language / Platform Description 
FileMaker Pro FileMaker Pro is a relational database application from FileMaker 
Inc. (Apple Inc.). It can be used simultaneously with a mixed 
Windows and Mac user base; and can run independently with the 
„Runtime Version‟.  The optional FileMaker plug-in “xmCHART” 
from the Austrian company X2max Software enables the creation of 
bar charts and scattergrams. Other plug-ins can produce PDF files 
and can link FileMaker with web-servers via FTP. 
 
Visual Basic Visual Basic (VB) is a programming language and a development 
environment developed by Microsoft. Because of its BASIC 
heritage and graphical features Visual Basic is considered a 
relatively easy to learn and use programming language. Microsoft 
has developed derivatives of Visual Basic, like Visual Basic for 
Applications (VBA), which is included in many Microsoft 
applications (Microsoft Office). In order to run Visual Basic 
applications, the Visual Basic run-time files are required. 
 
C++  C++ (C plus-plus) is a general-purpose, „middle-level‟ 
programming language. C++ is commonly used in the software 
industry.  Some of its application domains include system software, 
device drivers, embedded software, server and client applications, 
and entertainment software. 
 
C# C# (C sharp) builds on the syntax and semantics of C++, allowing 
C programmers to take advantage of .NET and the common 
language runtime.  It is intended to be a simple, modern, general-
purpose, object-oriented, „higher-level‟ programming language, 
developed by Microsoft. 
 
Java Java is a general-purpose, class-based and object-oriented language 
developed at Sun Microsystems.  The language derives much of its 
syntax from C++ but has a simpler object model.  Java applications 
can run on any Java Virtual Machine (JVM) regardless of computer 
architecture. 
 
PHP (HTML) PHP is a common general-purpose language that was originally 
designed for web developments.  It generally runs on a web server, 
taking PHP code as its input and creating web pages as output.  It 
can be used free of charge and many „open source‟ libraries are 
freely available. HTML (“HyperText Markup Language”) is the 
predominant language for Web pages. It provides a means to 
describe the structure of text-based information in a document and 
to supplement that text with interactive forms, embedded images, 
and other objects.  HTML can include embedded scripting language 
codes (such as JavaScript, a scripting language widely used for 
client-side web development) which can affect the behaviour of 
Web browsers and other HTML processors. 
 
Table 3.3.1. Overview of program languages and developer platforms reviewed for the development of 
the prototype and the IBRA system. 
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Three years later, the second review emerged from problems with the use of the 
FileMaker developer platform (more details on the problems with FileMaker are 
provided in chapter 4). To get rid of the limitations this platform forced on us, we were 
searching for an alternative that promised openness and flexibility, which we believed at 
this stage could only be found in the more complex program languages. The successor 
of the prototype software should provide a structure that could guarantee integration of 
any kind of technology in the future. Ideally, the program language should feel 
comfortable with Internet environments, too. Unfortunately, at this stage, we did not 
have any knowledge in any of the newer program languages. After a careful review of 
the languages, we removed C++ and C# from the list as these languages seemed to be 
too complex for programming amateurs to learn. The race between Java and PHP was 
very close, and we finally decided to learn and use PHP for the development of the new 
software system, as we had a couple of good friends who promised to support us in case 
of problems (more details on our specifications and PHP are presented in Chapter 5). 
 
 
3.4. Summary  
Although there are many publications available on results from laser vision correction, 
there are few on optimising refractive laser treatments. We have reviewed and 
summarised the leading publications on presenting refractive outcomes, on nomogram 
adjustments and on vector analysis in refractive treatments.  
 
We have published details and showed screenshots of the 5 software systems available 
worldwide on data collection and analysis in laser vision correction. Over the years only 
3 of these systems seem to be commonly used and updated. Each software has a 
different focus and therefore each offers particular benefits. None of the systems 
includes the functionality we were looking for, i.e. integrating all available analysis 
methods in one system that can be run over the Internet for an acceptable price. 
 
Finally, this chapter explains the 2 review processes needed to be found, one a 
developer platform and one a program language for the development of a new analysis 
system, as aimed in this research. 
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4. PROTOTYPE DESIGN AND DEVELOPMENT 
 
The idea of a software application for the analysis of patient data after refractive laser 
surgery emerged in 2001 at the private practice laser centre at the Cantonal Eye Hospital 
in Lucerne, Switzerland. At this time, a simple FileMaker application was used to 
collect refractive data. The user-interface of this application presented with a single 
page, containing fields for the data collection of 15 different preoperative and 
postoperative parameters from visual acuity testing and subjective refraction. 
 
Waring graphs were designed manually in 3 steps. This time-consuming process had to 
be repeated every time data was extended or changed. The steps were: 
1. Data collection with the FileMaker application on an Apple Macintosh 
computer. (Comment: the refractive surgeons preferred using Macintosh 
computers, while the Hospital Trust supported only Windows based computer 
systems.) 
2. Data export from FileMaker into Microsoft Excel on a Windows PC. (Comment: 
the data was transported via 3.5 inch floppy disks.) 
3. Manual data processing in Excel included sorting, deletion of empty fields, and 
grouping of data and results. Bar charts and scattergrams were created and, 
finally, title, legends and units were applied to the figures (in Excel and 
PowerPoint). 
 
The Director of the Refractive Laser Centre, Professor Isaak Schipper, was looking for a 
specific „add-in‟ to his pre-existing FileMaker application, that could offer automated 
bar chart and scattergram creation using the criteria presented by Waring. 
Unfortunately, it was not possible to create charts using the basic FileMaker software. 
 
One of the possible solutions was to buy a commercial software package for refractive 
outcome analysis. Our favourite was the “Outcome analysis software” from Perry 
Binder. This software was very expensive so, before investing hospital money, we 
decided to give a home-made development one more try. This new prototype was to be 
based either on a step-by-step extension of the FileMaker application (if possible) or on 
a new platform, using a combination of Microsoft Office components (Access, Excel 
and Visual Basic). At this stage we put together a list of needs and specifications for the 
prototype. 
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4.1. Needs assessment and task lists 
The needs assessment had 2 main perspectives: firstly, the surgeon‟s perspective with 
the clinical needs of a data recording and analyzing system; and secondly, the software 
developer‟s perspective with the evaluation of technology specifications and 
requirements that could guarantee satisfying implementation of the clinical needs. The 
system should be different from clinical documentation in many EHRs, which are often 
dictated by billing and legal requirements. 
 
Clinical task list 
From the surgeon's perspective, the clinical task list consisted of the following points: 
 Extension of the existing database (more fields/parameters) 
 Automatic creation of Waring charts 
 Easy to use interface 
 Minimal costs  (maximum £700) 
 Compatible with Apple Macintosh and Windows PC 
 
System task list 
From the developer‟s perspective, the emphasis was set on usability and user-centred 
design rather than system design. Therefore, software documentation or printed manuals 
were replaced with 'wizards' and „help & information‟ boxes in the software, linked to 
the tasks. 
 
The developer‟s task list included: 
 A Microsoft Windows-based software system (hospital requirement) 
 A system that could use the existing data (300 cases) 
 Extension of the existing database 
 Implementation of „macro functions‟ which were able to group and sort patient 
data 
 Review and implementation of the xmCHART plug-in. The xmCHART 2.0 
from the Austrian company X2Max was a macro code extension for FileMaker, 
which could create most charts offered by Excel. 
 Acquiring the knowledge to program the xmCHART plug-in to produce graphs, 
as recommended by George Waring (Waring G, 2000). 
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 Implementation of macros that can create and label a chart from previously 
analysed data in combination with xmCHART 
 Development in accordance with the low budget 
 Easy installation (Runtime) 
 English user interface 
 
After a testing phase we realised that the chart creation with the FileMaker plug-in 
worked very well, and we decided to continue using FileMaker and to take this as the 
platform for the prototype development. 
 
 
4.2. User interface and system design 
We implemented all fields from the original FileMaker database into the new prototype, 
and re-designed the user-interface. We separated data collection and data analysis. 
 
The data collection module was used to create, search and edit treatment records. It 
offered different pages: a patient list, a patient search site and a patient data entry/edit 
site with all the entry fields. 
 
In the data analysis module the preoperative and postoperative refractive and visual 
acuity data of all records were grouped and analysed. The processed data then was used 
for the creation of the Waring charts. The analysis and calculation process was 
programmed using the macro function of FileMaker. The process was started by 
clicking a button. For the creation of the user interface the integrated design functions of 
FileMaker were used. 
 
We were able to link our prototype application with a runtime extension that allowed 
running the application on any Windows or Macintosh based computer system without 
the need of pre-installed FileMaker software. This special version was offered by the 
"Developer Language Kit (DLK)" from FileMaker. 
 
 
 
 
 
57 
4.3. Implementation 
The prototype was called "Proexcimer", a combination of the words "pro" (meaning 
"for") and "excimer" (the type of laser in laser vision correction). The final version of 
Proexcimer consisted of 3 modules: one for patient selection, one for data entry and one 
for the analysis. 
 
Module 1: Patient list and patient selection 
This module showed up after starting the application (Figure 4.3.1.). The patient list 
presented the surname and first name, the date of birth, the diagnosis (myopia, 
hyperopia, astigmatism), the treatment date, the treatment procedure (LASIK, LASEK 
or PRK), the surgeon‟s name, a selection of preoperative and postoperative distance 
visual acuity data, and a field with comments. 
 
 
Figure 4.3.1. Screenshot of the Proexcimer prototype showing a list with patient data. 
 
 
Module 2: Data entry 
In the data entry module the data for the right (OD) and left eye (OS) were collected 
(Figure 4.3.2.). The fields included treatment data, preoperative and postoperative 
refractive, keratometric and visual acuity data, tonometry, haze and glare. The data was 
entered on 8 different sites. 
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Figure 4.3.2. Screenshot of Proexcimer showing preoperative patient data for both eyes. 
 
 
Module 3: Chart creation  
The analysis method could be selected from the overview site showing the 6 integrated 
Waring graphs and an additional cylinder chart (Figure 4.3.3.). The data analysis, 
grouping, and chart creation was started with a "create chart" button. The final chart was 
shown in a media field in the FileMaker application and could be printed or saved as a 
JPG image (Figure 4.3.4.). 
 
 
Figure 4.3.3. Screenshot of the Proexcimer prototype showing an overview of the analysis methods. 
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Figure 4.3.4. Uncorrected visual acuity chart created with the Proexcimer prototype software. 
 
 
4.4. Evaluation of the prototype and conclusions 
The prototype was used for 2 years. Although the general use of the software was easy 
and the application provided us with Waring graphs, there were many small, and some 
larger, difficulties with the system. In particular, the following serious problems 
occurred. 
 
Problems with the FileMaker platform 
 The software did not work and behaved similarly each time. Sometimes the 
charts showed up, sometimes not. Where was the error? Was there a „bug‟ in the 
FileMaker Runtime software? Was it the Windows operating system? 
 The FileMaker Runtime was only available for one operating system (either Mac 
or Win). Every software modification had to be done for each system separately 
each time. If one version was ready for use, the other had to be adjusted exactly 
the same for the other operating system. This caused delays and was a major 
source of inconsistency in the development process. 
 The print configuration could not be saved in FileMaker as a preference. This 
was a common problem, and the FileMaker developer community complained 
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about it for many years. Unfortunately, the printers we used in the clinics and 
offices were all of different makes, further increasing the difficulty for 
standardised printouts. 
 FileMaker Runtime offered the benefit of independence to the FileMaker 
installation, and offered good protection of the scripts of the application in 
„runtime mode‟. The disadvantage was that the Runtime version could not be 
used in a network environment. Therefore, each computer required an 
installation of our Proexcimer application. Similarly, software updates had to be 
done for each computer separately, which was very inconvenient as we modified 
the software quite regularly. 
 FileMaker Server offered network functions, but also had to be installed on 
every computer. The disadvantage of this version was that the applications run 
in „normal mode‟, allowing every user to see and modify scripts and to change 
layouts. In addition, the IT department of the hospital was happy to provide 
network support, but did not want to be involved in the application hosting or 
maintenance. 
 
Problems with the development 
 User activity could not be monitored with the FileMaker Runtime version. 
 For standardised printouts we tried to convert the graphics into a PDF format. 
Unfortunately, PDF implementation was not possible with FileMaker Runtime. 
 FileMaker offered only a basic set of mathematical operations. The consequence 
was that we could not program vector analysis calculations, and were not able to 
produce double angle vector diagrams. 
 The patient-related system of saving the data (1 case = 1 patient) offered good 
overview of a single patient‟s outcome, but was unsatisfactory in analysing 
patient collectives. The treatment-related system (1 case = 1 treatment) was 
beneficial for the analysis of patient groups, and was the method of choice for 
the production of more demanding Waring graphs. The idea of implementing 
nomogram adjustment made it even more clear that, for the future development 
of Proexcimer, we would have to move from a patient-related system to a 
treatment-related one. 
 
The development and maintenance of the prototype was stopped by the end of 2004. We 
gained the strong impression that platform and developer problems were too complex to 
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be solved with any FileMaker or Microsoft Office version. We needed a system that 
was more flexible; a system that could address the following needs and requirements: 
 Network compatibility 
 Platform independence 
 Integration of common standards (pdf, Email) 
 Good code and script protection (copyright issues) 
 Easy maintenance 
 Open source 
 Familiar interface 
 Wide range of mathematical and statistical functions 
 
 
4.5. Summary 
The main clinical needs that led to the development of a prototype system with the 
name “Proexcimer” were the extension of the existing database (more fields/parameters) 
and the integration of automatic Waring graph creation. 
 
The basic modules of the FileMaker Runtime based application included a patient list, a 
patient search function and a patient data entry site. 
 
The prototype was used over a period of 2 years and showed major flaws in the 
stability, functionality and maintainability. All these issues were linked to the FileMaker 
platform. Future development and improvement required significant changes to the 
system. 
 
The main requirements of a successor software were network compatibility, platform 
independence, integration of common standards (pdf, Email), good code and script 
protection, and easy maintenance. 
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5. DESIGN AND DEVELOPMENT OF THE IBRA SYSTEM 
 
In this Chapter we present the development and the implementation of the 'Internet 
Based Refractive Analysis' Software (IBRA), the successor of Proexcimer. 
 
The FileMaker platform was abandoned in 2004 after it became clear that this would not 
allow further development or integration of new ideas and technologies. 
 
This time we wanted to make sure that the new system was future-proof.  We decided to 
undertake a serious review of alternative platforms and program languages. In addition, 
we designed a precise system methodology (Figure 5.1.1.) that followed a waterfall 
model (Royce 1970) with requirements, specifications, design, implementation and 
maintenance. This model was chosen for its linear and sequential development method 
with distinct goals for each phase. This approach was very close to our way of thinking, 
and allowed us easier scheduling and controlling of each development step. It was 
therefore preferred to other models, for example the spiral model. 
 
On the level of implementation and maintenance the „classic‟ waterfall model was 
extended with iterative steps. The iterative approaches allowed us to perform subtle 
changes in the structures that were deficient. To emphasise the iterative character, we 
have drawn bi-directional arrows in the figure to show that, at any time, the 
development could move one phase up or down. This also meets the fact that many of 
the development steps, e.g. verification and validation, were processes with recurrent 
episodes, depending on modifications on the needs, or resulting from a strategy that was 
set up to solve a specific problem. 
 
A characteristic of our development was that the action plans evolved from user 
interface design in the first instance. From the beginning, we had a clear picture how the 
user interface had to appear, showing the data entry fields, the results and the Waring 
graphs. We followed this imaginary picture to its realization and modified it, along with 
technological specifications.  
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Figure 5.1.1. System methodology (modified waterfall model). 
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The individual steps in the methodology can be separated into 3 aspects: process, 
documentation and software. Each aspect is presented with a different shaped frame in 
Figure 5.1.1. The aspect „processes‟ summarised cognitive steps, leading from one step 
to the next in the development. The aspect „documentation‟ was for outputs in printed 
form, including the creation of lists and tables for the developer team, and the creation 
of guidelines for the software user. With „software‟ we characterised steps related to 
coding and testing of program parts. 
 
In the following sections each step is described with details, focusing on the 'why', 
'what' and 'how' our system was developed or changed. 
 
Many of the decisions regarding the different phases were made intuitively and thus 
difficult to put into words. Often retrospectively, the decision and its consequence could 
be recognized as a whole, and could be put into the grid of the waterfall or iterative 
model. 
 
In addition, many decisions were made on a 'right time, right place' model. This means, 
for example, that at the phase of implementation the internet technology became more 
and more popular (right time). Living and working in an area with these „trendy‟ 
changes (right place) was associated with the fact that more and more people were 
gaining experience of using an Internet platform. Being surrounded by such people 
made it possible to gain access to adequate knowledge and support regarding Internet 
programming (HTML and PHP). The decision to use one technology and to deny 
another was strongly influenced by similar trends and environmental premises. 
 
The main reasons why Internet technology was used for the development of our 
software system are listed below: 
 Network use without the need of network hosting 
 Accessible at any location, even wireless (on the move, with the iPhone) 
 Simple and common basic software to run applications (Internet Browser) 
 Usable across different systems (Windows, Mac, UNIX, Palm, Symbian) 
 Familiar user-interface (Google or Medline type) 
 Fast with good Internet access 
 Common use, 'a good friend' can help at the beginning 
 Many tips and recommendations by users in web blogs and forum 
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 Many 'open source' tools available 
 A general belief in 'the future of programming' 
 Uncomplicated monitoring of user activities 
 
 
5.1. Needs assessment (task analysis) 
The limitation of the FileMaker Runtime platform was more evident with increasing 
clinical and operational needs. Some of the main problems of the platform included 
limited network compatibility, unreliable and insufficient core system (Runtime version 
and upgrades), reduced code protection, lack of common standards (PDF file creation) 
and difficulties in the way the operational software application could be maintained or 
monitored. 
 
The IBRA system should address the following general needs and requirements: 
 Network compatibility 
 Open source 
 Good code protection (copyright) 
 Familiar interface 
 Integration of common standards (pdf, Email) 
 Easy to maintain 
 Collection of „treatment data‟ and not „patient data‟ 
 
In addition, different and unexpected needs evolved within the first 2 years of the IBRA 
development. These needs came from surgeons' increasing demands, from educational 
interests and from commercial and promotional intentions. 
 
5.1.1. Surgeon-oriented needs (The need for a professional version) 
IBRA was used for an NHS outcome audit, analysing the refractive data of 400 treated 
eyes in 2005. The result of this audit showed that the outcome scattered widely. We 
assumed that this dispersion could be as a result of inaccurate calculation of the laser 
energy that was used to reshape the cornea, resulting in either too little or too much 
ablation of corneal tissue. Treatment calculations are modified by nomograms with the 
goal of improving laser treatment. Nomogram adjustments were usually calculated by 
the laser manufacturer but could be performed by the surgeon, too. 
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The integration of nomogram adjustments into IRBA would change the software‟s area 
of application; from being only user-related to check the surgeon‟s operating quality, 
IBRA would 'mature' to a program that could also change the patient‟s outcome and 
health. This could lead to a significant bonus for the user. But there were also doubts. 
 
Nomogram calculations are complex and sometimes difficult to understand; they are 
reserved for more advanced and research orientated surgeons. The increased complexity 
of the IBRA functionality could potentially scare general refractive ophthalmic 
surgeons. We tried to solve this problem with a modification of the user-interface. We 
intended to provide only a certain amount of information and functionality on the screen 
that would fit the user‟s need. The software was split into 2 versions. The „standard 
version‟ was for the general user and offered all the Waring graphs. The „professional 
version‟ was for the refractive expert. It offered all the features of the standard version, 
and added the nomogram calculations (Table 5.1.1.). 
 
5.1.2. Educational needs (The need for a database version) 
Ophthalmologists in training have to collect precise data of all the interventions and 
operations they perform. This data collection (also called „logbook‟) reflects the 
educational level of the trainee and is used by the training authority, The Royal College 
of Ophthalmologists (RCO), for assessments. To facilitate the collection, the RCO was 
offering an Excel spreadsheet „logbook‟ that could be downloaded from their website. 
Most trainees downloaded this file, and installed it on the hospital computer for data 
collection.  
 
The local deanery allocates trainees to hospitals. Often trainees have to travel between 
hospitals, and might perform surgery in 3 different theatres. Therefore, it became 
increasingly desirable to have the logbook „always on board‟. IBRA seemed to be a 
feasible alternative, and I was asked by the SHOs and SpRs at St James University 
Hospital in Leeds if IBRA could be used to collect cataract data. 
 
After discussing the needs and options, we modified the IBRA professional version and 
added a site with fields for the collection of data relevant to cataract surgery. We called 
this separate version of IBRA, for the sole purpose of data collection, „database 
version‟. 
 
68 
 
5.1.3. Promotional needs (The need for a ReSTOR version) 
Alcon Inc. is the world's leading American supplier for ophthalmic products with 
headquarters in Switzerland. The manager of the cataract division of Alcon was 
impressed by the features of IBRA, presented in 2004 at a congress in Lucerne. At this 
congress, Alcon was introducing a new multifocal intraocular lens for patients 
undergoing cataract surgery. This lens was called ReSTOR (AcrySof SA60D3). 
 
Following several meetings with Alcon, we were funded for the development of a 
special IBRA version for surgeons that were using this new lens. This „ReSTOR 
version‟ was similar to the database version, but was able to send the collected data 
directly and anonymously to the manufacturer‟s office. This was enabled by the 
implementation of e-mail and pdf functions. 
 
This ReSTOR version was used over 3 years and, in accordance to the agreements of 
the co-operation, removed from IBRA in 2007. An overview of the IBRA versions is 
given in Table 5.1.1. 
 
Version Features of IBRA User group Purpose / Needs 
Database Database only Trainee Ophthalmologists Education related 
(logbook, requirements of The Royal 
Colleague of Ophthalmologist) 
ReSTOR Database 
Mailing tool 
ReSTOR users only Promotion related 
(quality control for Alcon) 
Standard Database 
Standard Graphs 
General Ophthalmologists User related 
(quality control for surgeon) 
Professional Database 
Standard Graphs 
Vector Analysis 
Nomogram 
Refractive Specialist Patient related 
(health outcome change) 
Table 5.1.1. Overview of the different IBRA versions and the related user groups. 
 
 
5.1.4. Commercial and marketing needs (The need for a website and a manual) 
IBRA was presented at 2 international congresses in 2004. Many surgeons in the 
audience were keen to test and buy the IBRA system. However, at this time the software 
was only used at the Eye clinic in Lucerne. But there seemed no reason why the system 
couldn't be commercialised. The flexible platform and Internet technology created ideal 
conditions for easy access to the system from any location, even from abroad. On the 
other hand, placing the software on the market could move us much further up the 
ladder of responsibility; and accounting would become another requirement. 
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Should we go into business with IBRA? It took us several months to decide that 
licensing of IBRA was in our interests too. It could increase the level of awareness and 
acceptance, and would provide us with some financial cover of the taken investment. 
 
The marketing and business issues were manifold: getting legal advice, founding a 
limited company,  creating 'Terms and Conditions for the use of IBRA', developing 
structures for selling, renewing and updating existing licenses, programming a billing 
system with credit card payment, writing a manual and user instructions, providing user 
support, etc. 
 
We could address most of the issues in 2006 by handing over the development and 
ownership of IBRA to Zubisoft GmbH, a company that was founded in 1998 by Bruno 
and Hans Zuberbuhler (Hans being the father of Bruno) for the distribution of office 
software for constructors and decorators. 
 
A formal product website was created (www.zubisoft.com), providing information 
about the company, the software and its features, and the purchase options. Finally, a 
user-friendly documentation (Introduction) was created in German and implemented 
electronically into the IBRA system. 
 
5.1.5. Maintenance and security needs (The need for a user administration system) 
The start of the ReSTOR project and the commercial activities increased the number of 
surgeons that were using the IBRA system. This demanded improvements to our 
administrative site: easier user registration, emailing of username and password, 
changing of access codes, and other functions. For these reasons a web-based 
administration application was programmed that could manage registration, billing with 
invoice creation, username and password creation, validation management and 
communication with the users, e.g. sending e-mails with information about server 
maintenance times or software upgrades. In addition, this admin tool allowed the 
monitoring of users' access to the system, recording login dates and times, and allowing 
us to control the system use. This was an issue that evolved from an increased demand 
for system security. 
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5.2. Specifications (task flow diagram) 
Access to IBRA was granted to persons having identified themselves by entering their 
username and password. For security reasons each database access was monitored. 
Following the login, the user reached the menu of IBRA. The user could choose from 3 
main functions, grouped in different modules: 'Cases' for data recording and analysis of 
a single patient data; 'Analysis' for standard and advanced analysis of data from patient 
collectives; and 'Nomogram' for outcome and predictability calculations (Figure 5.2.1.). 
A download function was linked to the „Cases‟ module, allowing storage of the patient 
data on the user's computer. Downloaded data was saved in .csv format. This facilitated 
further data processing in Microsoft EXCEL, SPSS or Minitab Software. 
 
 
 
Figure 5.2.1. Summary of the functions of the software application with the three main modules "Cases", 
"Analysis" and "Nomogram". 
 
 
5.3. User interface and system design 
In a survey most Proexcimer users, and other surgeons, were asked about their user 
interface preferences relating to refractive analysis software. The results showed that 
71 
functionality was considered as more important than „fancy design‟. The user-interface 
had to be easy to use, easy to understand, and standardized in relation to the data fields. 
 
We decided to develop a user-interface that was „static‟, and that did not allow user-
specific interface modifications; a user-interface that was the same for every user and 
that could provide a high level of standardization, thus minimizing misunderstandings 
and data entry errors. We chose simplicity and cut back on flexibility. 
 
A fundamental feature of the software was to use a well-known Internet browser 
(Microsoft Internet Explorer) as part of the user interface; assuming that all users were 
familiar with the use of the Internet and Microsoft operating systems. This could ease 
barriers many users have in starting to use new, „unfamiliar‟ software. In addition, we 
implemented parameters that were well known by refractive surgeons. 
 
The simplicity and familiarity of IBRA resulted in a brief learning curve. IBRA could 
be used immediately after introduction, both in the laser theatre and in the eye clinic. 
 
Installation on local computers was not necessary and fast Internet access was the only 
condition. Software updates were performed on the web server only. The user did not 
have to change any software components, and could work with the latest version of the 
application following new login into IBRA. 
 
IBRA was programmed using the computer languages PHP, HTML and JavaScript, and 
the MySQL database (Figure 5.3.1.). 
 
 PHP stands for 'Hypertext Preprocessor' and is a reflective programming 
language used mainly in server-side application software. PHP requires the Zend 
engine (Zend Technologies, Israel) as a core scripting engine to parse and 
compile the program code. 
 
 HTML stands for 'Hypertext Markup Language' and is the predominant 
language for the creation of web pages. It provides a means to describe the 
structure of text-base information in a document, and to supplement the text with 
interactive forms, embedded images, and other objects. HTML needs a web 
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browser to interpret the program code, to display and interact with the text and 
images and to communicate with the web server. 
 
 JavaScript (Sun Microsystems, Inc., USA) is a client-side script language based 
on the concept of prototype-based programming. It enables scripting access to 
objects embedded in applications, such as HTML or PHP applications. 
JavaScript is loosely based on the language 'C' and relies on the JavaScript 
engine, which is embedded in the host environment, e.g. Microsoft Internet 
Explorer. 
 
 MySQL (MySQL AB, Sweden) is a multi-threaded, multi-user SQL database 
management system. PHP has an application programming interface (API) that 
allows applications to access MySQL databases. The software tool 'MySQL 
Administrator' was used to structure and modify the database. 
 
 
Figure 5.3.1. Structure of the hardware and software system with script languages (HTML, PHP and 
MySQL) and the databases management system (DBMS). 
 
 
The patient data was recorded on the hard disk of the server. The storage system on the 
main server was a RAID level one configuration. This 'mirrored drive system' provided 
fault tolerance from disk errors and single disk failure. Array continued to operate so 
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long as at least one drive was functioning. For safety purposes, the data was saved 4 
times a day on a second server at a different geographic location. The data transfer from 
the client computer to the server was protected with a 128-bit (or longer) key for 
encryption, using a SSL (Secure Sockets Layer) cryptographic protocol. This could 
provide IBRA users with similar technology used by online banking services. 
 
In a later stage we implemented PDF printout functions, and programmed more 
complex outcome charts, e.g. for vector analysis. We choose software components that 
were easy to implement into IBRA, safe and available in the public domain with online 
tutorials and test files. For example, the 'FPDF' program is a „freeware‟ software 
(www.fpdf.org) which we used as a PHP class extension for the creation of PDF files. 
 
 
5.4. Overview of development 
The prototype of refractive analysis software (Proexcimer) was used from 2002 until 
2004 and then replaced by the IBRA system. 
 
The IBRA system underwent different upgrading processes between 2004 and 2007, 
correcting code errors and extending the software with new database and analysis 
functions, resulting in the version of IBRA that was used for this research and the 
evaluations. 
 
The main extension was the implementation of the nomogram calculation module. The 
main structural change was the splitting of the IBRA basic system into 4 different 
versions (database, standard, professional and ReSTOR). On the administrative side, a 
credit card payment system (MasterCard and VISA) was implemented in IBRA, and an 
admin tool was developed for easier registration and billing of users. After years of 
building-up we started to reduce the variety of data entry fields, as the problem of 
having too much information surpassed that of having too little (Schiff 2010). The 
forum function (for communication between IBRA users) was rarely used, and was 
therefore also removed from IBRA. The ReSTOR version was removed from IBRA 
following completion of the co-operative work with Alcon.  
 
A summary of the development of the software system is shown in Table 5.4.1. 
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In 2007, the IBRA analysis system became the main refractive analysis software of the 
Refractive Laser unit at Moorfields Eye Hospital NHS Foundation Trust. A system 'start 
button' was implemented on the 'Clinical Services' website at Moorfields (Figure 5.4.1.). 
 
 
Year Name / Version Technology used Functions Influenced by 
2002 Proexcimer 
(Prototype) 
FileMaker Runtime 
X2max Chart Plug-in 
Database, 7 Graphs 
 
Surgeon 
2004 IBRA Prototype HTML, PHP, JavaScript, 
Plug-ins (jpgraph) 
Database, 8 Graphs 
+ Forum 
Surgeon 
2005 IBRA v1 HTML, PHP, JavaScript, 
Plug-ins (jpgraph, fpdf) 
Database, 10 Graphs 
+ Vector Analysis 
+ pdf printout 
- Forum 
Surgeon 
Research 
2007 IBRA v2 HTML, PHP, JavaScript, 
Plug-ins (jpgraph, fpdf) 
Link with Bank 
Database, 10 Graphs, Vector 
Analysis 
+ Nomogram analysis 
+ Data export .csv format 
+ Credit Card payments 
Auditing 
Teaching 
Marketing 
Table 5.4.1. IBRA development. 
 
 
 
Figure 5.4.1 Implementation of the IBRA system into “Clinical Services” at Moorfields Eye Hospital 
NHS Foundation Trust in 2007. 
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5.5. Modules of implementation in the operational product 
Following access to the Zubisoft website and login with the username and password, the 
user reached the main menu of IBRA (Figure 5.5.1.). 
 
5.5.1. Main menu 
The user could choose from 4 main functions (modules): 
 Cases: to record and analyse single patient treatments (cases) 
 Analysis: to analyse group data and to produce the Waring graphs 
 Nomogram: to analyse group data and to calculate nomogram adjustments 
 User: to change user data (e.g. password) and to set preferences (e.g. laser types) 
 
 
Figure 5.5.1. Screenshot of the “Menu” of the IBRA system. 
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5.5.2. The 'List of Cases' 
A screenshot of this module is shown in Figure 5.5.2. At the 'List of Cases' site the user 
could add, duplicate or edit a case. By selecting the patient name, the user could modify 
an existing case record, for example by adding postoperative results to the database. 
The top part of „List of Cases‟ offered functions for viewing, sorting and searching 
cases. This part was an analogous design to the Medline website, to provide familiarity 
with case handling. The pull-down menu on the left showed a selection of lists with 
different sets of parameters, for example a list of preoperative and postoperative visual 
acuity data or a list of postoperative refractive data. 
For security and privacy reasons, we entered initials in the fields of surname and first 
name, and used the hospital patient identification number (PID) instead of the National 
Health Service identification number (NID). The PID is a patient identification key that 
is generated randomly and used solely within one particular hospital; therefore, one 
patient can have many different PIDs. If anyone gained (unauthorised) access to the 
IBRA system, confidentiality would be maintained as they would not be able to identify 
an individual patient based on the recorded data. 
 
 
Figure 5.5.2. Screenshot of the “Cases” module with the site “List of Cases”. 
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5.5.3. Data recording 
For each case, a maximum of 242 parameters could be recorded. A case was defined as 
a single intervention or operation, usually a refractive laser eye treatment or a cataract 
operation. 
The parameters were arranged on different pages. The pages included details of the 
patient and the operation (Figure 5.5.3.), data from preoperative and follow-up 
examinations (Figure 5.5.4.) and information regarding any complications and their 
management. 
Postoperative data was recorded from visits at 7 days, 1 month, 3, 6, 12 and 24 months. 
The most important data for the creation of Waring graphs was the spherical value, the 
cylinder magnitude, the axis of the cylinder, the calculated spherical equivalent (SE), 
the uncorrected visual acuity (UCVA) and the best-corrected visual acuity (BCVA). 
Other data that could be entered into the database was as follows: pachymetry, 
endothelial cell count (ECC), tear film break up time (BUT), intraocular pressure (IOP), 
contrast sensitivity (Pelli-Robson), root-mean-square (RMS, total and cumulative higher 
order), haze and overall satisfaction. 
The parameters were all saved in the same MySQL table, allowing downloading of the 
data into one file. An Excel spreadsheet was created automatically when the data was 
downloaded from IBRA. 
 
 
Figure 5.5.3. Screenshot of the 'Cases' module with the page 'Excimer Data' for data recording of 
treatment parameters, e.g. type of laser treatment, date of operation and target refraction. 
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Figure 5.5.4. Screenshot of the 'Cases' module with the page 'Preop. Data' with data entry fields for 
preoperative parameters, such as distance and near visual acuity, refractive and keratometric data, contrast 
sensitivity and intraocular pressure. 
 
 
5.5.4. Single visual and refractive analysis 
An overview of one patient‟s main treatment data was provided by the 'Single Analysis' 
feature (Figure 5.5.5.), showing the postoperative course of visual acuity and spherical 
equivalent in graphical form, and also a table with key parameters. The figures were 
arranged with the table on one A4 page and converted to a downloadable pdf file. The 
purpose of this file creation was to provide the patient with a summary of treatment 
results that could be handed out or emailed at the end of treatment. The printed version 
could also serve as a „hard copy‟. 
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Figure 5.5.5 Screenshot of the “Cases” module with the page “Single Analysis” with a visual acuity chart 
(left top), a spherical equivalent chart (left bottom) and a table with all visual and refractive results over a 
period of 24 months (right). 
 
 
5.5.5. Vector analysis 
Refractive data (sphere, cylinder and axis of the manifest subjective refraction) was 
analysed using vector analysis as described by Noel Alpins (Alpins 2001).
 
There were 2 
different modules for vector analysis. The main module was used in conjunction with a 
single case treatment. The other module was for analyzing vector parameters of a series 
of cases and presented the results in a scattergram chart. 
Using vector analysis, a patient's astigmatic changes could be analysed by consideration 
of the change in the astigmatic axis. The most important values were the target induced 
astigmatism vector (TIA), representing the astigmatic change the operation was 
intended to induce, the surgically induced astigmatism vector (SIA), representing the 
actual induced change in amount and axis of astigmatism following surgery, and the 
difference vector (DV), representing the required astigmatic change, the effect a second 
surgery would need to achieve the initial target. Using these values, the main indices for 
quality and precision of the treatment could be calculated, such as the correction index 
(CI= SIA/TIA), the index of success (IOS=DV/TIA) or the angle of error (AE = angle 
SIA minus TIA). 
80 
For better visualisation IBRA created 2 diagrams: the polar astigmatism diagram and 
the double angle vector diagram (Figure 5.5.6.). The calculated parameters were 
presented in a table for each postoperative review. The results (diagrams and table) 
could be printed or saved as a PDF file. 
 
 
Figure 5.5.6. Screenshot of the 'Cases' module with vector analysis (Astigmatism Analysis) for one 
treated eye, showing a polar astigmatism diagram (left top), a double angle vector diagram (left bottom) 
and a table with main indices from the calculation (right). 
 
 
Furthermore, IBRA was able to produce a 'vector chart' from patient groups. The 
software calculated TIA and SIA for each eye, and plotted the results on a scattergram 
with the TIA values on the x-axis and the SIA values on the y-axis (Figure 5.5.7., left). 
The scattergram offered valuable information about the overall astigmatic outcomes. 
Ideally, all results are aligned on the 45 degree line. The percentage of eyes with a 
deviation of less than 1.0 Diopter (D) from this ideal result is an important number that 
defines quality and predictability of the surgery. 
 
Using only SIA values, IBRA calculated and displayed the mean SIA for a group of 
patients, called the 'centroid', in a double angle diagram. The centroid is a true 
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representative of the mean astigmatism, especially when the group is homogenous with 
localized clustering of the SIA points (Figure 5.5.7., right). 
 
 
     
Figure 5.5.7. Left: Scattergram of 2334 treated eyes showing target induced astigmatism vector (TIA) 
versus surgically induced astigmatism vector (SIA) at 3 months follow-up, with linear regression line. 
98% of eyes are within 1D of the TIA (green dots). Right: Scattergram of the mean surgically induced 
astigmatism vector (SIA) in a double angle diagram, called the 'centroid'. 
 
 
5.5.6. Spherical equivalent outcome analysis 
IBRA produced all internationally accepted Waring graphs. The 'Attempted versus 
achieved spherical equivalent (SE) chart' is a scattergram (Figure 5.5.8., left), having the 
advantage of presenting the outcome of every eye, so that no data is hidden in means or 
averages. The x-axis shows the attempted and the y-axis the achieved SE. If the 
attempted and the achieved SE are the same, the point falls on the 45 degree line in the 
scattergram, representing a perfect result. 
 
The 'SE outcome chart' is a bar graph (Figure 5.5.8., right) that represents the 
postoperative spherical equivalent refraction grouped in SE categories, usually in 0.5 D 
steps. This allows the user to see how many eyes fall within a certain category. It further 
allows assessment of the range of refractive results. 
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Figure 5.5.8. Left: Scattergram showing attempted spherical equivalent versus achieved spherical 
equivalent refraction one month following laser excimer treatment of 569 eyes. Right: Histogram of the 
postoperative spherical equivalent refraction of 187 eyes following laser vision correction. In this 
example, 66.3% of eyes were within 0.5D of emmetropia. 
 
In the 'Stability of postoperative spherical equivalent (SE) chart' (Figure 5.5.9.) the 
mean SE refraction with standard deviation is presented over time. The standard 
deviation is important because an increase would demonstrate a considerable instability 
in the refraction, even though the mean value may show minimal change over time. 
 
 
Figure 5.5.9. Screenshot of the “Analysis” module with a stability chart showing the mean spherical 
equivalent and standard deviation over time of a series of selected cases (968 eyes). 
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5.5.7. Defocus equivalent analysis 
The 'Defocus Equivalent (DE) Refraction‟ chart (Figure 5.5.10.) is a cumulative bar 
graph that represents more accurately the reality of the refractive state of the eyes 
(Waring). To obtain the DE for an eye, the spherical equivalent was calculated by taking 
the sphere (respecting the sign) and adding half the cylinder (again respecting the sign). 
Then one-half of the cylinder value was added to the spherical equivalent, ignoring the 
sign. 
 
 
Figure 5.5.10. Defocus equivalent (DE) Refraction 1 month following laser vision correction. 
 
 
5.5.8. Visual acuity outcome analysis  
The 'Uncorrected Visual Acuity - UCVA‟ chart is a cumulative bar graph (Figure 
5.5.11., left). Visualisation of UCVA results is relevant, as most patients aim for 
spectacle independence following laser vision correction. This chart allows accurate 
identification of the number of eyes that see 1.6 (±6/4), 1.25 (±6/5), 1.0 (6/6), and so on. 
Such a distinction can be used to differentiate among refractive surgery procedures, and 
to compare visual acuity results from different studies. 
 
The 'Loss of Lines of BCVA‟ chart (Safety Chart) is a bar graph that shows the change 
in best-corrected visual acuity from preoperative to  postoperative examination, in terms 
of the number of Snellen lines gained or lost (Figure 5.5.11., right). This measure 
answers the question: “If the refractive outcome is not totally acceptable, can patients 
put glasses on again and see as well as they did before surgery?” A loss of 2 or more 
Snellen lines has been generally adopted as the standard for safety. This is the reason 
why this chart is also called „safety chart‟. 
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Figure 5.5.11. Left: Uncorrected visual acuity chart of 575 treated eyes 1 month following laser surgery. 
Right: Best-corrected visual acuity chart with change in Snellen lines (safety chart) for 670 treated eyes 1 
month after refractive surgery. 8.2% of eyes lost 2 or more Snellen lines in this case series. 
 
 
5.5.9. Nomogram calculation 
The nomogram calculation derives from linear regression analysis of postoperative 
refractive data (Figure 5.5.12.). The analysis results in two formulas, one for spherical 
data and one for astigmatic data. The formulas are a mean of the effective result, and 
can be mathematically compared with a theoretical formula (the attempted outcome). 
The difference between the effective and the theoretical formula is the refractive error; 
the deviation from the attempted result. Again, this difference can be expressed by a 
calculation formula. This calculation formula was implemented into IBRA with the aim 
of optimising the effective outcome. 
 
To explain this principle, the following calculations are provided as an example. A 
patient with a refraction of -3.0 D (sph) / +4.0 D (cyl) x 90° wishes to undergo laser eye 
surgery with a target of emmetropia. The nomogram calculation was used in the pre-
assessment clinic to analyse previously treated patients with similar refractive errors. 
The calculation showed that most treated eyes resulted in an under-correction. Without 
changing the laser settings, the above patient would achieve (theoretically) a mild 
under-correction of -0.50 (sph) / +0.75 D (cyl) x 90°. The nomogram calculation in 
IBRA now recommends a boost of the refractive treatment to achieve a result closer to 
the target setting (emmetropia). In this example, the eye was treated with the 
recommended over-correction of 0.25D for the sphere, and 0.5D for the cylinder. The 
final total treatment was: -3.25 D (sph) / +4.50 D (cyl) x 90°. One month following laser 
vision correction the manifest refraction was 0 D (sph) / +0.25 D (cyl) x 90°, which is 
very close to emmetropia. 
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Figure 5.5.12. Screenshot of the 'Nomogram' module showing a predictability chart for the spherical 
equivalent (left) and the astigmatism (right) of 949 treated eyes 3 months after LASIK. 
 
 
5.5.10. Satisfaction analysis 
Preoperatively and postoperatively, every patient was asked to give their visual and 
overall satisfaction with the treatment. The patients' answers were graded from 1 
(excellent) to 4 (very bad) and presented over time in the 'Satisfaction chart' (Figure 
5.5.13.). We often observed an increase in satisfaction after the 6 month follow-ups, 
which might be linked to sensory adaptation processes.  
 
 
Figure 5.5.13. Patients‟ satisfaction over time. 
86 
 
5.5.11. Multicenter functions 
Every case record contained the surgeon's name and the hospital site where the surgery 
was performed. The IBRA system allowed comparisons between different surgeons and 
locations. IBRA enabled users to create, change or cancel associations with other 
surgeons or hospitals, which they could then use for analyses. Every associated surgeon 
had to link their IBRA version to the group by entering a specific identification number. 
Only with this 'agreement to participation' was the software allowed to perform multi-
user comparisons. Following the activation, all linked users gained the possibility of 
analyzing the data from their associate partners. However, incomplete data access was 
granted, and a limitation was integrated. The patient data from linked partners was only 
available for group analyses. At no time could a user select, identify, view or analyse 
one patient‟s data from an associate partner. This multicentre function could also be 
used for quality control issues between different countries or for data collection from 
multicentre clinical trials. 
 
5.5.12. Download functions 
A selection of data could be downloaded and stored from the IBRA system by the user 
at any time (Figure 5.5.14.). The system created a '.csv' format file, which then could be 
used in Microsoft Excel, SPSS or Minitab for descriptive or statistical analysis. 
 
 
Figure 5.5.14 Screenshot of the “Download” module with case selection (left), parameter selection 
(middle) and sort function (right). 
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5.6. Summary 
While most software systems evolved from co-operations between system developers 
and clinicians the development of IBRA was different. Development and clinical 
experience derived from a single person, providing a rational approach with a focus on 
clinical thinking and a system design that was practical and evidence-based. 
 
This Chapter demonstrated the modified waterfall model as it was used for the 
development of the IBRA system. The needs of the system originated from clinical 
assessments, educational duties, commercial and promotional interests, and 
maintenance and security reasons. The chapter described how the different needs 
changed the direction of the system development and how web-based technology was 
used for implementing analysis tools and incorporating decision-supporting parts. 
 
The operational IBRA system was presented with an extensive documentation of the 
main software modules (cases, analysis and nomogram) and the different analysis 
features. 
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6. SYSTEM EVALUATION 
 
6.1. Introduction 
Many examples have shown that electronic health care systems can increase the quality 
and efficiency of health care (Chaudhry 2006). However, there are also reports to show 
how such systems have failed to provide benefits, or have even caused negative effects 
(Han 2005). Systematic evaluation is thus an important requirement to assess the 
quality, value, effect and impact of information technology and applications in the 
health care environment. Evaluations can improve health information applications, 
safeguard high standards of care and enable the emergence of an evidence-based health 
informatics practice; it can even be seen as an ethical imperative for health 
informaticians (Ammenwerth 2004). 
 
The reasons for the present evaluations were mainly pragmatic and ethical in nature 
(Friedman 2007). Following planning, design, implementation and successful testing of 
an operational version of the IBRA system, we were guided by many „needs to know‟. 
We were keen to find out if our concept and the calculation algorithm of the system 
could deliver what they were developed for. Clinical and non-clinical questions were 
used as starting points to design the evaluation processes, in accordance with Professor 
Rigby‟s recommendation: 'Start with aim and purpose, and select the appropriate 
methodology' that matches the question (Rigby 2003). 
 
A synopsis of the aims, evaluation questions, used methods, the impact of the outcome 
and the actors is shown in Figure 6.1.1. 
 
 
6.1.1. Clinical aims and evaluation methods 
The main clinical aim was to analyse the impact of the treatment modifications on 
patients' health. The IBRA system allowed 2 different forms of treatment modifications: 
a general modification for refractive groups (e.g. simple myopia), and a patient-
individual treatment modification. 
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Figure 6.1.1. Overview of the system evaluations, the evaluation questions, the used 
methods, the impact of the outcome and the involved actors. 
 
 
 
Meaningful analyses of treatment modifications with a general adjustment require a 
high number of participants. Appropriate methods of evaluation for this requirement can 
be non-randomised, as this allows easier recruitment with lower administrative 
complexity. Therefore, we decided to use a clinical audit for this evaluation. Clinical 
audit is a process that has been defined as: 'a quality improvement process that seeks to 
improve patient care and outcomes through systematic review of care against explicit 
criteria (refractive outcome) and the implementation of change (treatment modification). 
Main questions: 
Do the treatment modifications change 
patients’ health outcome, on the basis of… 
Clinical evaluations 
…the data 
entry 
management? 
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Where indicated, changes are implemented at an individual, team, or service level and 
further monitoring is used to confirm improvement in healthcare delivery' (Shaw 2002). 
Clinical audit is different from research in that it does not require formal review or 
approval from a Research Ethics Committee. This allowed us to use a retrospective 
analysis method for the first audit cycle to analyse the treatment errors, while the second 
audit cycle was prospectively designed and performed with the aim to analyse the 
outcome after treatment modification. 
 
The concept of patient-individual modifications of the laser treatments is new. The best 
method to test the effectiveness of a new treatment is to undertake a randomised 
controlled trial (RCT), which is seen by many as the gold standard of evaluation 
(Meldrum 2000). The benefit of using an RCT for the evaluation was that it could 
eliminate bias in the treatment assignment and facilitate participant blinding. Another 
advantage of this method is that the randomisation generates an unpredictable sequence 
of allocations and provides comparable groups with valid statistics. For this research, 
the RCT should compare the standard treatment with the new, patient-individually 
adjusted, treatment in laser vision correction. 
 
 
6.1.2. Non-clinical aims and evaluation methods 
The non-clinical aim was to study the interaction between the IBRA system and the 
user. In particular, we focused the evaluation on 3 main questions. The first 2 questions 
addressed users‟ behaviour, while the 3rd question was linked to users‟ opinion. 
1. How did users manage the data entry process? 
2. Which outcome analysis methods were preferred by surgeons?  
3. How was the user satisfaction with the system? 
 
For the analysis of the user behaviour based questions of this research the method of 
data logging was very promising. Data logging is defined as: 'the collection of data from 
monitoring a process that passes through a particular point in a system, using integrated 
sensors, over a period of time' (Oxford Dictionary of Computing). The benefit of data 
logging for our evaluations was that it could take the readings automatically (in the 
background), over a long period of time (12 months), without human intervention, and 
with a high degree of accuracy. For the assessment of the data entry management we 
aimed to record „time stamp‟ data generated at each step of the data entry process. For 
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the evaluation of the analysis methods we planned to monitor the IBRA analysis module 
and to record the type of analysis that was performed over time. The results of both 
evaluations could then be processed by specific software applications and presented as 
tables, scattergrams and bar graphs. 
 
Finally, we decided to use a questionnaire for the remaining, opinion based, non-clinical 
evaluation to assess users‟ satisfaction. The advantage of a questionnaire for this 
research was that the responses could be gathered in a standardised way, so that the 
outcome could become more objective and could be analysed with quantitative 
methods. A well designed questionnaire could allow a relatively quick collection of the 
provided information; the small user group allowed individual management and could 
therefore guarantee a high return rate. For this evaluation process, a specific extra 
literature survey was performed in relation to the type and size of questionnaires, and 
with a view on commercially available questionnaire systems (QUIS, SUMI, and 
others). Detailed information on these systems and the created questionnaire are 
provided in the methods part of Section 6.6. 
 
 
6.1.3. Organisation of the evaluation chapter 
Each of the 5 evaluations is presented in the following in a separate section (6.2. to 
6.6.). We followed the suggestion of Professor Wyatt to aim for publication of the 
results from the evaluation processes, even if negative (Wyatt 2003). Therefore, each 
evaluation is presented in a scientific format to facilitate conversion and conclusive 
reporting. Each section provides a discussion and conclusion of the main findings. 
Chapter 7 discusses the findings of the evaluations in relation to the overall research 
aims and objectives. 
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6.2. Refractive audits to evaluate general health changes 
 
6.2.1. Introduction 
Ophthalmic surgeons continuously try to improve the surgical processes with the aim to 
make the operation safer and the outcome more predictable. In refractive laser surgery 
90% of the success comes from planning the surgery, including careful patient 
selection, extensive preoperative measurements of the eye and adequate determination 
of the treatment parameters. The key to the right patient selection bases on surgeons 
knowledge, skills and experience. It's a process that is learned and improved over many 
years of practice. Most preoperative measurements and tests are performed under 
standardized conditions by experienced and well trained optometrists reducing the 
biasing and errors in the testing phase to a minimum. Finally, the determination of the 
treatment parameters relies much on surgeon‟s experience, but is also linked to 
empirical data from previous treatments and manufacturer‟s recommendations. In a 
more iterative process the predictability improves over time, but will always depend on 
the laser equipment and the surgeon that performs the laser operation. 
 
IBRA has an important supportive role in planning the laser treatment. It analyses the 
refractive and visual outcomes from patients treated with the same equipment and uses 
specific new algorithms to calculate factors that the surgeon can use to adjust the 
treatment parameters. The information IBRA provides is supporting the surgeon in 
making a decision on how much refractive correction the patient will receive, with the 
aim to achieve a higher amount of eyes that are closer to the target. 
 
The aim of this evaluation was to study the IBRA analysis and decision making process 
and to evaluate the effectiveness of the adjustments. Therefore, two extensive, one-year 
audits were planned; the first to determine treatment adjustment factors, which than can 
be used for the second audit.  
 
In particular, the aims and research questions of this evaluation were: 
 To evaluate the system for the purpose of auditing (Can it be used for auditing?) 
 To evaluate the refractive outcome of LASIK (How good is the treatment?) 
 To evaluate strategies that can improve the results (How can the outcome be 
improved? 
 To evaluate the calculation algorithm of IBRA (Do the algorithms work?) 
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 To analyse the refractive outcome of patients following the adjustment of the 
treatment algorithm (Does the use of IBRA change patient‟s health?) 
 
The objectives were: 
 To enter demographic, preoperative, operational and postoperative patient data 
from 2007 into the IBRA database. 
 To use the tools of IBRA for the 2007 refractive outcome analysis. 
 To present the results (Congress and Poster) and provide a platform for 
discussion between refractive experts. 
 To identify patient groups which perform better or worse. 
 To use the calculation algorithm of IBRA to define adjustment factors for 
outcome improvements. 
 To treat the 2008 patients with a modified treatment profile. 
 To enter the demographic, treatment and outcome data from 2008 into IBRA and 
to use the analysis tools of IBRA for the 2008 refractive outcome analysis. 
 To use EXCEL and statistical software to identify changes between the 2007 and 
2008 results. 
 To discuss and interpret the results and the IBRA features. 
 
 
 
 
 
6.2.2. Patients and methods 
 
Methodology 
Two audits were designed in February 2007, started in May 2007 and completed in 
August 2009 (Figure 6.2.1.). For both audits a total of 2011 patients were treated. 
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Figure 6.2.1. Methodology of the refractive Audits 2007 and 2008. 
 
 
Patient demographics 
From May 2007 until April 2008 (12 months, “Refractive Audit 2007”) a total of 1022 
eyes (cases) with refractive disorders were treated. A total of 382 cases were excluded 
(Table 6.2.1.). The remaining 640 cases, all treated with LASIK and a complete 3 
months follow-up, were used for the Audit 2007. 
Laser treatment 
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Data analysis 
(640 cases) 
1
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Laser treatment 
(989 cases) 
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Adjustment 
factors 
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From May 2008 until April 2009 (12 months, “Refractive Audit 2008”) a total of 989 
eyes (cases) with refractive disorders were treated, according to the modified treatment 
algorithm. A total of 449 cases were excluded (Table 6.2.1.). The remaining 540 LASIK 
cases with complete 3 months follow-up were used for the Audit 2008. 
More details about the patient demographics are shown in Table 6.2.2. The only 
parameter that was statistically significant between the 2 groups was the postoperative 
spherical equivalent at 3 months (p<0.001). 
 
 
 1
st
 Audit (2007) 2
nd
 Audit (2008) 
Cases treated with LASEK 89 61 
Cases that received a first enhancement 18 29 
Cases that received a second enhancement 1 3 
Cases with a one month follow-up only 34 6 
Cases with a six months follow-up only 4 6 
Cases with incomplete or missing data 142 271 
Cases in which the refractive outcome was not 
aimed within 0.6 D of emmetropia 
94 73 
Total cases excluded 382 449 
Table 6.2.1. Exclusion criteria for the 2 audits (Refractive Audits 2007 and 2008). 
 
 
 1
st
 Audit (2007) 2
nd
 Audit (2008) P 
Eyes 
- Used for audit 
 
640 
 
540 
 
Age 
- Mean ± SD (years) 
- Range (years) 
 
41.5 ± 10.5 
21.7 ± 76.7 
 
41.6 ± 11.0 
21.7 ± 72.2 
 
0.955 
Sex 
- Female (percentage) 
- Male (percentage) 
 
372 (58%) 
271 (42%) 
 
307 (58%) 
225 (42%) 
 
0.999 
Diagnosis 
- Simple myopia 
- Compound myopic astigmatism 
- Simple hyperopia 
- Compound  hyperopic astigmatism 
- Mixed astigmatism 
 
325 (50.8%) 
186 (29.1%) 
77 (12.0%) 
35 (5.5%) 
17 (2.6%) 
 
317 (58.7%) 
141 (26.1%) 
42 (7.8%) 
30 (5.6%) 
10 (1.8%) 
 
Spherical equivalent 
- Preoperative   mean ± SD (D) 
- Preoperative   range (D) 
- At 3 months follow-up   mean ± SD (D) 
- At 3 months follow-up   range (D) 
 
-3.02 ± 3.00 
-9.25 to 4.75 
0.10 ± 0.43 
-1.75 to 1.75 
 
-3.36 ± 2.79 
-8.875 to 6.00 
-0.14 ± 0.43 
-1.625 to 1.625 
 
0.052 
 
<0.001 
Subjective astigmatism 
- Preoperative   mean ± SD (D) 
- Preoperative   range (D) 
- At 3 months follow-up   mean ± SD (D) 
- At 3 months follow-up   range (D) 
 
-0.87 ± 0.83 
-5.5 to 0.00 
-0.34 ± 0.31 
-2.75 to 0.00 
 
-0.79 ± 0.78 
-6.75 to 0.00 
-0.26 ± 0.30 
-2.50 to 0.00 
 
0.127 
 
0.876 
Uncorrected visual acuity (LogMAR) 
- Preoperative   mean ± SD 
- At 3 months follow-up   mean ± SD 
 
0.92 ± 0.33 
0.00 ± 0.13 
 
0.80 ± 0.34 
0.01 ± 0.14 
 
0.322 
0.668 
Best-corrected visual acuity (LogMAR) 
- Preoperative   mean ± SD 
- At 3 months follow-up   mean ± SD 
 
-0.04 ± 0.08 
-0.06 ± 0.08 
 
-0.04 ± 0.08 
-0.07 ± 0.07 
 
0.243 
0.657 
Table 6.2.2. Patient demographics of the analysed groups (Refractive Audits 2007 and 2008). 
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Laser treatment (LASIK) 
The corneal flap for LASIK was performed with a Hansatome microkeratome (Bausch 
& Lomb), a Moria M2 (Moria) microkeratome or with the Intralase Femto Laser. The 
size and depth of the flap was dependent to the spectacle refraction and the corneal 
curvature and was set between 120-180 µm thickness and 8.5-9.5 mm diameter. The 
corneal ablation was performed with a VISX S4 Excimer Laser (AMO) by a single 
surgeon (DSG). The target refraction was individualized for each patient. For patients 
that were aiming for independence to glasses for distance vision, the target was set 
slightly on the myopic side, with the purpose of undercorrection. The total treatment 
was limited to leave a residual corneal stromal bed of 250µ. 
 
Postoperative measurements 
The patients were refracted by in-house optometrists and uncorrected and best-corrected 
distance Snellen visual acuity was measured with the Snellen chart (UK version). 
Corneal astigmatism was assessed by Pentacam topography and wavefront 
measurements were performed with the WaveScan (AMO). All data was filled-in on 
special preoperative and postoperative assessment forms in the paper-based patient 
record. 
 
Data entry into IBRA 
The paper-based patient records were used for the data entry process. The preoperative, 
operative and postoperative parameters were entered into the Internet Based Refractive 
Analysis Software (IBRA). A minimum of 42 parameters for each treated eye (case) 
was collected. This was a time consuming process that was performed over more than 2 
years and that required 4 hours of data entry every week. 
 
Determination of the treatment parameters for the first Audit (2007) 
The method of determine the settings for the laser treatments of the first audit was well 
established and represented the standard treatment at this time (Figure 6.2.2.). 
The sphere value of the manifest refraction was used as treatment sphere when the 
difference between the manifest and the WaveScan sphere was less than 0.5 diopters 
(D). The cylinder value of the manifest refraction was used as treatment cylinder when 
the difference between the manifest and the WaveScan cylinder was less than 0.25D. 
The axis value of the manifest refraction was used as treatment axis when the difference 
between the manifest axis, the WaveScan axis and the axis of the Topography was less 
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than 10°. If the differences between the sphere, cylinder or axis parameters were bigger 
than the mentioned limits, the preoperative examination was repeated. Finally, the 
determined parameters were entered in the laser unit for the refractive treatment of the 
patients. 
 
           
Figure 6.2.2 Determination of the standard treatment setting (Refractive Audit 2007). 
 
 
 
Optimising the treatment for the second Audit (2008) 
IBRA was used to analyse a total of 643 eyes from the first audit. The software 
compared the achieved versus the attempted spherical correction for all treated eyes and 
for subgroups of eyes with different preoperative refractive errors, based on focus of the 
principal meridians (Table 6.2.3.). 
 
Groups Spherical equivalent (D) Astigmatism (D) 
Simple myopia <0 <1.0 
Compound myopic astigmatism <0 ≥1.0 
Simple hyperopia >0 <1.0 
Compound hyperopic astigmatism >0 ≥1.0 
Mixed astigmatism negative or positive abs(0.5*cyl) ≥ abs(SE) 
Table 6.2.3. Determination of the refractive disorder groups from preoperative spherical equivalent (SE) 
and astigmatism (cylinder). 
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Linear regression of the spherical correction was calculated for each of the 5 groups, 
which then was used to calculate the amount of spherical adjustment for each eye for 
the main groups (Table 6.2.5). 
These factors were used to modify the treatment parameters for the second audit. 
Because the outcome should preferably be rather myopic (0 to -0.25D) then hyperopic 
we decided not to use the full amount of correction to prevent hyperopic outcomes. 
 
Treatment parameters for the second Audit (2007) 
The sphere value, cylinder value and axis were determined as for the treatment of the 
patients of the first audit. The sphere value then was modified based on the adjustment 
factors from the regression analysis of the results (Figure 6.2.3). The treatment 
parameters were used for all patients of one particular refractive disorder group. 
 
 
 
 
     
 
Figure 6.2.3.  General modifications of laser treatments, based on linear regression analysis of the 
spherical equivalent and used as a fix amount (blue arrow) for all patients of one particular refractive 
disorder group. 
 
 
Comparison of the Audit outcomes 
The second audit used the same exclusion criteria. IBRA then analysed the outcome of 
532 eyes. Additionally, the refractive results from both audits were compared and 
statistically analysed with the aim to determine the influence and precision of the 
treatment adjustment on the refractive outcome. 
 
Main measure 
The main measure was the refractive change, expressed by the change of spherical 
equivalent. 
 
 
Refractive Data 
 
SE    
General Modifications 
Spherical equivalent Cylinder:  none 
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Data analysis and results 
We focused on the analysis and presentation of the 3 main refractive disorders, counting 
for 92% of all diseases; including simple myopia, compound myopic astigmatism and 
simple hyperopia. IBRA was used for the refractive analysis and for the creation of the 
figures. For the postoperative analysis the results from the 3 months follow-up were 
used. This is the time interval in which the corneal changes have settled and the 
outcome has become stable. 
 
Statistics 
Microsoft EXCEL, Unistat and Minitab software packages were used for statistical 
analyses. For comparative statistics, the Wilcoxon matched pairs test was used. For 
independent samples, the Mann-Whitney U-test was used. P-values less than 0.05 were 
considered statistically significant. 
 
Presentations 
Preliminary results were presented under the title “Importance of outcome analysis in 
laser in-situ keratomileusis - Refining algorithms using IBRA” at the Annual Congress 
of the Royal College of Ophthalmology in Birmingham (19.05.2009). Some of the 
results were presented under the title “Refining algorithms in laser in-situ 
keratomileusis using IBRA” at the Centre for Health Informatics, City University 
London (05.05.2009). An article with the title “Nomogram adjustments for myopes and 
hyperopes in LASIK” was submitted for publication to the Journal “Ophthalmology” in 
June 2010. 
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6.2.3. Results 
 
Refractive outcomes produced with IBRA 
The refractive outcomes have been analysed with the „spherical equivalent distribution‟ 
analysis (Figure 6.2.4.) and the „spherical equivalent predictability‟ analysis. 
In Figure 6.2.5. we present the refractive outcomes for the audit 2007; in Figure 6.2.6. 
the refractive outcomes for the audit 2008. A comparison of the postoperative spherical 
stability and the uncorrected visual acuity of the 2 audits is shown in Figure 6.2.7. 
 
 
 
Figure 6.2.4. Screenshot from the analysis module in IBRA with selection criteria. The produced chart in 
the centre is shown as high resolution image B1 in Figure 6.2.5. Changing the selection criteria (see red 
circles) accordingly allowed producing all other charts. 
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  A1   A2  
 
  B1   B2  
 
  C1   C2  
 
  D1   D2  
 
Figure 6.2.5. Refractive outcome 2007 produced with IBRA. A1 and A2: all cases; B1 and B2: simple 
myopia; C1 and C2: compound myopic astigmatism; D1 and D2: simple hyperopia. 
 
103 
  A1   A2  
 
  B1   B2  
 
  C1   C2  
 
  D1   D2  
 
Figure 6.2.6. Refractive outcome 2008 produced with IBRA. A1 and A2: all cases; B1 and B2: simple 
myopia; C1 and C2: compound myopic astigmatism; D1 and D2: simple hyperopia. 
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  A1   A2  
 
  B1   B2  
 
Figure 6.2.7. Refractive outcome 2007 and 2008 comparison of all treated cases regarding refractive 
stability (A1 and A2) and cumulative uncorrected visual acuity (B1 and B2). The charts are produced 
with IBRA 3 months results. 
 
 
Refractive outcomes analysed with EXCEL 
The calculated percentages and linear regression coefficients were taken from the charts 
and filled in a table separated by the refractive groups (Table 6.2.4.). Based on these 
refractive audit 2007 parameters the amount of spherical adjustment was determined for 
each group individually and summarised in table 6.2.5.  
 
Group N Mean SE 
± SD 
± 0.5D of 
emmetropia 
> 0.5D 
over-correction 
Constant 
a 
Constant 
b 
Simple myopia 325 0.05 ± 0.39 91% 6% 0.97 0.27 
Myopic astigmatism 186 0.13 ± 0.48 76% 17% 0.95 0.53 
Simple Hyperopia 77 0.12 ± 0.44 79% 17% 1.03 -0.32 
Table 6.2.4.  Postoperative results from the first audit in 2007 for the 3 min refractive disorder groups. 
 
 
Group Spherical adjustment (D) 
Simple myopia -0.25 
Compound myopic astigmatism -0.40 
Simple hyperopia +0.20 
Table 6.2.5. Patient groups and spherical adjustment 
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Statistical comparison between the outcomes 
Data was exported with IBRA into a Microsoft EXCEL format. EXCEL then was used 
to calculate the mean and standard deviation of the postoperative spherical equivalent. 
In an additional step the data was exported from EXCEL into Unistat statistic software 
for the creation of box plots (Figures 6.2.8.-6.2.10) and for statistical comparison 
(Mann-Whitney U Test) of the spherical equivalent of the 2007 and 2008 groups. 
 
Group N Mean SE 
± SD 
Diff 
to 2007 
P Value ± 0.5D of 
emmetropia 
Diff 
to 2007 
> 0.5D 
over- 
correction 
Diff 
to 2007 
Simple 
myopia 
317 -0.16 ± 0.40 -0.21 <0.0001 83% -8% 2% -4% 
Myopic 
astigmatism 
141 -0.17 ± 0.46 -0.30 <0.0001 79% +3% 3% -14% 
Simple 
Hyperopia 
42 0.03 ± 0.52 -0.09 0.3032 71% -8% 19% +2% 
Table 6.2.6. Postoperative results from the second audit in 2008 with comparison to the 2007 results for 
the 3 main refractive disorder groups. 
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Figure 6.2.8. Comparison of the 3 months postoperative spherical equivalent (in D) of eyes with simple 
myopia between the first (C1) and second (C2) audit. The refractive aim was emmetropia or mild myopia 
(0 to -0.25 D) for the treated eyes of both groups. Statistically, the difference between the two groups was 
highly significant (Mann-Whitney U Test: p<0.0001). 
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Figure 6.2.9. Comparison of the 3 months postoperative spherical equivalent (in D) of eyes with 
compound myopic astigmatism between the audits in 2007 (C1) and 2008 (C2). The refractive aim was 
emmetropia or mild myopia (0 to -0.25 D) for the treated eyes of both groups. Statistically, the difference 
between the two groups was highly significant (Mann-Whitney U Test: p<0.0001). 
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Figure 6.2.10. Comparison of the 3 months postoperative spherical equivalent (in D) of eyes with simple 
hyperopia between the audits in 2007 (C1) and 2008 (C2). The refractive aim was emmetropia or mild 
myopia (0 to -0.25 D) for the treated eyes of both groups. The difference between the two groups was 
statistically not significant (Mann-Whitney U Test: p=0.3032). 
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6.2.4. Discussion 
The IBRA software allowed determining patient cohorts effectively with the use of 
group codes, e.g. „ma‟ for myopic astigmatism. To reduce the bias for the nomogram 
calculation and to increase the homogeneity of the data we used multiple selection 
criteria. The final inclusion criteria determined eyes undergoing a first LASIK treatment 
with the aim to achieve a refractive result close to emmetropia and with a complete 3 
months follow-up. This limitation reduced the number of cases available for the analysis 
by 47%. Because of the high amount of operations performed every year the remaining 
numbers were still good (640 cases for the first and 540 cases for the second audit).  
 
Refractive groups 
The refractive outcome analysis of the first audit was performed for each of the 5 
groups with different refractive disorder: simple myopia and hyperopia, compound 
myopic and hyperopic astigmatism and mixed astigmatism. The prevalence of these 
refractive disorders is not equal. The 3 main disorders (simple myopia, simple 
hyperopia and compound myopic astigmatism) count for more than 92% of all cases. 
For this evaluation we focused on the main groups for the calculation of spherical 
adjustment factors and for comparison between the 2 audits. 
 
Outcome for patients with simple myopia 
The refractive analysis of the cases from the first audit has identified an overcorrection 
in the spherical treatment of patients with simple myopia. The mean spherical 
equivalent of eyes treated in 2007 was hyperopic. This did not meet the target refraction 
programmed at the beginning. 
Hyperopic overcorrection in the treatment of myopic disorders can occur with different 
refractive lasers. Lopid-Gortzak et al (2008) addressed the problem of overcorrection 
with an (advanced) modification of the nomogram for the used Technolas 217 (Bausch 
and Lomb) laser. He could show that this reduced the rate of hyperopic overcorrection 
over that in earlier studies.  
Regression analysis performed with IBRA showed a correlation between the attempted 
and the achieved spherical correction with an average overcorrection of +0.27 D. This 
overcorrection had a linear tendency over the full range of diopters. This means that 
eyes treated for -2.0D myopia showed the same mean overcorrection as eyes treated for 
-7.0D myopia (difference of only 0.1D). 
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Feder (2007) recommends for myopic patients the use of the Bansal-Kay myopia 
nomogram if treated with conventional LASIK; and to use no nomogram adjustment 
when treated with CustomVue wavefront guided LASIK. In the Bansal-Kay myopia 
nomogram for VISX S3 laser the amount of reduction increases with age and the 
amount of correction in the spherical equivalent (3
rd
 grad polynomial function). The 
myopic nomogram produced with IBRA for wavefront guided treatments showed little 
age dependency and did decrease with the amount of correction in the spherical 
equivalent (Figure 6.2.11.). We could prove that there is age and SE dependency for 
nomogram adjustments in myopic wavefront guided treatments, but less than previously 
reported; and that from an overall point of view the use of the IBRA nomogram can 
further improve the refractive outcome. Unfortunately, no reports are published on 
nomogram adjustments for wavefront guided treatments with the VISX S4 laser. 
Once the exact amount of overcorrection was indentified we could use the IBRA 
algorithms to calculate the amount of adjustment for the treatment modification. For the 
second audit we decided to reduce the spherical treatment for simple myopes by 0.25D 
to achieve a more myopic outcome. The mean spherical equivalent of the second audit 
showed the desired change and a myopic shift of -0.21 D (p<0.0001) was measured 
(84% of the intended change). This was proving that the used nomogram adjustments 
worked effectively in achieving the desired refractive change. 
 
 
Figure 6.2.11. VISX simple myopia nomogram adjustment in the spherical equivalent (in D) based on 
Bansal-Kay (BK) and calculation from IBRA for 2 groups of age. 
 
Adjustment in SE 
Intended treatment 
in SE 
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Outcome for patients with compound myopic astigmatism 
We performed similar calculations for patients with compound myopic astigmatism. 
This is a patient group that usually performs worse than patients with simple myopia 
and that potentially could benefit more from nomogram adjustments. 
The analysis of the refractive outcome from the first audit showed a mean spherical 
overcorrection of +0.53 D, comparing the achieved and the attempted spherical 
correction. We decided to reduce the spherical treatment for patient with myopic 
astigmatism for the second audit by 0.40 D, with the aim to shift the patients from the 
hyperopic into the myopic mean spherical equivalent. The final results showed a 
significant myopic shift of -0.30D (p<0.0001; 75% of the intended change). 
 
Outcome for patients with simple hyperopia 
For eyes with simple hyperopia the first audit showed a spherical undercorrection of -
0.32 D. The mean postoperative spherical equivalent was still hyperopic at 3 months. 
For the nomogram adjustment we decided to increase the spherical treatment by +0.20 
D with the aim to achieve a myopic mean postoperative spherical equivalent. Although 
we could measure a myopic change due to our adjustment, the SE difference between 
the first and the second audit was statistical not significant (p=0.3032). 
We believe that the reason for this failure of the adjustment for the hyperopes could be 
linked to the ablation profile and to problems with accommodation surgeons are faced 
when treating patients with hyperopia. Zaldivar et al (2005) showed that the use of five 
surgical and technical modifications to the hyperopic LASIK procedure resulted in 
improved refractive outcomes and a lower rate of regression. These five changes were 
nomogram refinements accounting for accommodation, use of a 7.0-mm optical zone 
and a 9.5-mm transition zone, a targeted mean flap diameter of 10.5 mm, sequential 
interruption of the laser ablation, and cleaning of the interface. 
  
Benefits and limitations of spherical nomogram adjustments 
Computer simulation showed that individual nomograms significantly can improve the 
predictability of the refractive outcome. However, they are currently limited to 
approximately 90% within ±0.5 D (Mrochen 2005). 
With this evaluation we gained similar experience. For the first audit we achieved 91% 
of eyes within ±0.5 D of emmetropia for the treatment of patients with simple myopia. 
With the nomogram adjustment we could optimise the spherical equivalent and could 
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move it to the myopic side. The same time the percentage of eyes within ±0.5D of 
emmetropia decreased to 83% with a higher amount of undercorrected eyes. Histogram 
analysis of the results showed for both audits similar distributions with nearly identical 
(level adjusted) distribution curves (Figure 6.2.12.). The very similar standard 
deviations for the spherical equivalent (±0.39 for 2007, ±0.40 for 2008) explain the 
similarity of the curves. Due to the treatment modifications the curve from the second 
audit shifted to the left, into the myopic range. 
In summary, the performed nomogram adjustment changed the outcomes for all 
individual cases in the same way, as attempted. However, the modifications do not 
affect the standard deviation and therefore the shape of the distribution curve. As we 
aim for a mild myopic outcome any shift away from emmetropia (distribution curve 
aligned with the 0 D line) will consequently reduce the amount of eyes that will be 
within the ±0.5 D range of emmetropia. One of the future investigations should try to 
influence the distribution itself (the standard deviation) so that the results end-up closer 
together and showing a steeper curve. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2.12. Distribution (level adjusted) of spherical equivalent 3 months after LASIK for patients 
with simple myopia. 91% of eyes of the first audit were within 0.5 D of emmetropia. Because of the 
myopic shift from the nomogram adjustment only 83% of eyes of the second audit were within 0.5 D of 
emmetropia. The distribution of the audits showed very similar curves which is a result from the quiet 
identical postoperative standard deviation of the spherical equivalent. 
 
 
 
-0.5D     +0.5D 
 
1st Audit 2007 
(91% ± 0.5D) 
 
2nd Audit 2008 
(83% ± 0.5D) 
 
0 Spherical equivalent 
Myopic shift 
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Benefits and limitations of IBRA 
For this evaluation an extensive amount of data was entered into the web based software 
system. For each of the total 2011 treated eyes a standard set of 42 parameters was 
collected in a stepwise method. The data entry required approximately 8 min for each 
case, resulting in a total amount of 266 hours for this process. This is equivalent to 33 
working days; or because the evaluation was carried out weekly over a period of 2 
years, it is equivalent to half a day of data entry every week. This is a significant time 
commitment that, if performed by the surgeon, would require special planning and 
allocation in the agenda. 
This evaluation showed that IBRA was able to record and process large amounts of 
refractive data effectively. IBRA was able to analyse refractive outcomes in multiple 
forms and the system platform presented to be highly reliable, safe and with similar 
performance during the full period of evaluation. It showed that the general 
performance was dependent on the speed of the broadband connection. However, the 
data could be accessed at any time and no data was lost or was not saved by the web-
based system. IBRA could persuade with flexible use of the database from any location 
with Internet access and with easy handling. The produced refractive charts were clear 
and conform to the standards. 
The unique point of IBRA is that it provides the surgeons with functions that help 
identifying patient groups that underperform and offers then algorithms that calculate 
adjustment factors for outcome optimisation. This transforms IBRA from a quality 
assessment to a quality controlling system. 
Even if the tested version of IBRA requires significant manual input to gain the results 
from the different analysis and patient groups, future versions should be able to simplify 
and implement processes with more automatisation. The gain in precision in the 
planning process of patients‟ treatment should lead to a higher predictability and 
positive health change. 
 
Future development of IBRA (conclusion) 
IBRA has shown to be a precise instrument to improve the postoperative mean spherical 
equivalent refraction. It has shown that it does not influence the standard deviation of 
the result, and therefore the scatter and steepness of the distribution curve. Other 
reasons are responsible in influencing the scatter of the results. We believe that these 
reasons include age, healing processes and astigmatic changes. Age and cylinder 
refraction can be addressed with IBRA.  An evaluation should be made as to whether 
112 
age-related nomogram adjustment of sphere combined with cylinder correction bears 
the potential for reducing the standard deviation of the outcome. This could potentially 
increase the amount of eyes within 0.5 D of emmetropia. 
The present evaluation has not shown a change in cylinder, as expected. Generally, 
cylinder modifications have to be performed patient-individual. This is a more risky 
undertaking, because changes in cylinder are much less tolerated by patients when they 
go wrong. And one of these changes is the problem of cylinder overcorrection, which 
leads to an uncomfortable change of the cylinder axis of 90 degrees. A randomised 
controlled trial on patient-individual treatment modifications will further evaluate 
cylinder adjustments in laser vision correction (see Section 6.3). 
The current results have not shown an influence on the mean visual acuities. The 
improvements from nomogram adjustment might be too small, and corrections from 
hyperopia to emmetropia usually do not change the uncorrected visual acuity as young 
patients have the ability to accommodate for good sight. 
 
 
6.2.5. Conclusions 
We have shown that IBRA can identify patient groups with over- and undercorrection 
effectively; that it can calculate accurate nomograms for adjustments of future 
treatment, and that these modified treatments can lead to the desired health outcome 
change. 
The integrated algorithms work effective for simple myopia and myopic astigmatism, 
but do not work well for hyperopia. Further, we have proven that the concept of 
nomogram adjustment can bring benefit to wavefront guided treatments. This stays in 
contrast to a widely recommended practice (Feder 2007). 
A third audit cycle is not required as we achieved the refractive goal with the second 
audit. 
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6.3. Patient-individual modification of laser settings in the treatment of astigmatic 
myopia with laser in-situ keratomileusis 
 
 
6.3.1. Introduction 
 
Background and rationale 
Refractive eye laser treatment is a specialised field of eye surgery that focuses on 
improving the optical state of the eye, using an excimer laser beam to reshape the 
surface of the cornea. In successful treatments, the induced refractive change equals the 
preoperative refractive error.  
 
This research (2007 Audit) has shown us that some refractive disorder groups 
performed better than others. For example, 79-81% of eyes with simple myopia were 
within 0.5D of the target refraction, while only 56-59% of eyes with myopic 
astigmatism achieved this result.  
 
The implementation of nomogram calculations into the IBRA system increased the 
functionality, and allowed surgeons to calculate adjustment factors for nomogram 
optimisations. Theoretically, this should improve the outcome of patient groups, and 
also individuals such as patients with compound myopic astigmatism. 
 
The 2008 Audit with spherical modification showed improvement of the predictability, 
but the myopic astigmatism group still achieved a lower performance than the other 
studied patient groups. We believed that the higher level of over-correction and 
distribution in eyes with astigmatic myopia was a result of inaccurate determination of 
treatment settings. We assumed that, without taking individual modifications of the 
cylinder treatment into account, the predictability could not be further improved for this 
group. An additional positive treatment effect we attributed to individualization of 
treatment settings. 
 
At that time, commercially available software was not able to analyse refractive data 
patient-individually. To meet these needs, we developed a new calculation formula 
which we implemented into a separate module for the IBRA system. Based on the 
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patient‟s preoperative refraction, the formula individually calculated the amount of 
change in the treatment setting necessary to reach the target refraction more precisely. 
 
The use of the new system had the potential to further improve the refractive outcome 
(patient health change). This was clinically needed to increase postoperative 
uncorrected visual acuity, to increase patient satisfaction, to decrease the number of 
follow-up visits and to decrease the rate of re-treatments. Such a treatment could also 
improve cost-effectiveness in refractive laser eye surgery. 
 
A literature review showed that this was the first research worldwide that clinically 
evaluated the benefit of patient-individual modifications of laser treatment settings. 
 
Aims 
The aim of this research was to improve the health outcome of patients with astigmatic 
myopia. 
 
Objectives 
The objectives of the research were to plan and undertake a randomised controlled trial 
to evaluate patient individual treatment modifications with cylinder adjustments, as 
provided by the IBRA system. 
 
Study design 
The design of the RCT was developed in co-operation with the Research and 
Development (R&D) Department at Moorfields Eye Hospital NHS Foundation Trust 
(„Moorfields‟) and Professor David Gartry, Head of the Refractive Department at 
Moorfields. The research protocol was approved by Professor Roger Hitchings, Director 
of the Research Department at Moorfields, and sent to The Royal Marsden Research 
Ethics Committee. 
 
The following documents were submitted to the Ethics Committee on 14 July 2008:  
 Application Form (IRAS online system)  
 Investigators‟ CV 
 Study Protocol 
 Covering Letter 
 Letter from Sponsor (Moorfields for R&D support) 
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 GP / Consultant Information Sheets 
 Participant Information Sheet 
 Participant Consent Form 
 Laser Treatment Information Sheet 
 Laser Treatment Consent Form 
 
Following a presentation of the project at the Ethics Committee meeting, and a revision 
and clarification of the trial protocol, we received a letter confirming favourable opinion 
(Appendix 6). Our trial was given the REC reference number 08/H0801/99. The trial 
started on 2 October 2008. Additionally, we submitted the protocol and confirmation 
letter to the Ethics Committee of the City University London where it was also 
approved. 
 
Professor Gartry took over the part of study introduction and asking patients to 
participate, while I was responsible for preoperative assessments, postoperative follow-
ups and data collection. For the randomisation, the R&D Department provided us with 
closed envelopes containing labelled paper to show either 'Standard' or 'IBRA' 
treatment. To simplify the process of calculating adjustment parameters, we used the 
developed formula and created a table with adjustment factors that could be used at any 
time and location without the use of the formula or a computer (Appendix 7). We 
treated the first participant in November 2008. 
 
Research Funding 
Parallel to the planning of the research, we applied for funding for the PhD research and 
for the clinical trial. We sent applications to Moorfields Special Trustees, where the 
research was qualified as important and necessary, but where funding was not permitted 
because of its „private practice nature‟, „not showing an impact on current NHS 
treatment regimes‟. We also sent an application for funding to the Swiss National 
Science Foundation (SNF), who responded with a negative decision for personal 
funding because the research was not performed in co-operation with a Swiss 
University, and also a negative decision for project funding because the project did 'not 
have an impact on the health change of Swiss Nationals.' Finally, Moorfields granted us 
free R&D support and statistical advice. Professor David Gartry allowed us to use his 
private practice set-up and his private patients for the controlled trial at no extra cost. 
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6.3.2. Methods 
 
Summary of the original treatment protocol 
The study design was a single-blinded, randomised controlled trial comparing standard 
treatment and modified treatment in laser vision correction (Figure 6.3.1.). 
 
The aim was to establish the clinical effectiveness of patient-individual nomogram 
adjustments in a high-volume refractive laser practice (Figure 6.3.2. and Figure 6.3.3.). 
 
Patients were recruited in private practice surgery at Moorfields Eye Hospital NHS 
Foundation Trust. Randomisation was carried out independently by the R&D 
Department at Moorfields. Ethic approval was awarded by The Royal Marsden 
Research Ethics Committee. Research Management and Governance approval was 
obtained from Moorfields. 
 
The main inclusion criterion was astigmatic myopia, as defined as astigmatism of ≥1.0 
D with a negative spherical equivalent (also 'compound myopic astigmatism'). Patients 
with corneal or retinal disorders were excluded from the trial. All participants received 
an information sheet (Appendix 2) to take home. If the participant agreed to take part in 
the study, the Chief Investigator (DSG) or Principal Investigator (BZ) obtained 
informed consent (Appendix 3 and Appendix 4) and arranged the appointments and, in 
accordance with the participant, defined the refractive target of each eye. 
 
Depending on the treatment group, the participants either received standard wavefront 
LASIK treatment or modified (IBRA) wavefront LASIK treatment, both performed in a 
similar way with the VISX S4 laser, performed by the Chief Investigator. Slit-lamp 
examination was performed within 24-48 hours to confirm the LASIK flap position and 
3 months later, together with subjective refraction and uncorrected and best-corrected 
visual acuity assessment. The data of the 3 month review was collected with the data 
collection sheet (Appendix 5) and entered into Excel and Minitab for descriptive and 
statistical analysis. 
 
Main outcome measure was the percentage of eyes achieving a postoperative spherical 
equivalent (SE) within 0.5D of the target SE.  
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The original research protocol with detailed descriptions of the treatment settings and 
calculations for both groups is shown in Appendix 1. 
 
Changes to the method and protocol 
The research methods and the protocol were not changed during the study period. 
 
Settings and data collection 
 Refractive Surgery Unit, Moorfields Eye Hospital (MEH), London 
 Department of Research and Development (R&D), MEH 
 Centre for Health Informatics (CHI), City University London 
 Health and Safety Executives' (HSE's) Research Ethics Committee (REC) 
 
 
Figure 6.3.1.  Research design. 
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Figure 6.3.2.  Modification of the treatment settings, based on the standard treatment refraction (sphS, 
cylS and axS). 
 
 
 
 
 
 
 
Figure 6.3.3.  Patient-individual modifications of the laser treatments, based on analysis of spherical and 
astigmatic outcome data. Each patient received individual adjustments (blue arrows) for the sphere and 
cylinder correction. 
 
 
Refractive error:      Comments: 
SEerror [%]    =   18 * SE-0.72 + 0.5 * Cyl    SE = preop. spherical equivalent 
Cylerror [%]   =   32 * Cyl-0.31     Cyl = preop.e cylinder 
 
Modification of the treatment setting: 
SE change [D]   =   SE/100*SEerror + 0.25*Cyl/100*Cylerror 
Cyl change [D]   =   0.5*Cyl/100*Cylerror 
 
Example: 
Use of above formulas for an astigmatic myopic eye. 
Preoperative SE= -5.25 and Cyl=-2.25. 
SEerror  = 6.58 %     SE over-correction 
Cylerror  = 24.89 %    Cylinder under-correction 
SE change = 0.49 D      taken off the standard treatment SE 
Cyl change = 0.28 D       added to the standard treatment cyl 
 
Figure 6.3.4.  Formulas for the calculation of the refractive error and the modification of the treatment 
setting, with comments (right side) and example. 
 
Patient-individual Modifications 
Spherical equivalent Cylinder 
Refractive Data 
 
 
SE     Cyl  
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6.3.3. Recruitment 
 
Recruitment of participants 
During the recruitment phase of the study, between November 2008 and December 
2009 (13 months), 79 eyes of 45 participants were randomised into the 2 study groups. 
 
Termination of recruitment and study 
Unfortunately, the slowdown in recruiting participants forced us to terminate the 
recruitment process prematurely.  The „Declaration of the end of a study‟ form was 
submitted to the R&D Department in February 2010, containing an action plan, 
including the review of all participants and the collection of the 3 month postoperative 
results of all treated eyes (Appendix 8). We were aware that the numbers were too low 
for complex statistical analysis (underpowered), and we aimed for descriptive analysis 
of the results. 
 
Follow-up assessments 
At the end a total of 73 operated eyes (92%) were reviewed at the 3 month visit (Figure 
6.3.5.; CONSORT style, Schulz KF 2010). We sent a reminder letter to the remaining 
participants, but did not receive any feedback and ultimately could not state the reasons 
for their „not attending‟. 
 
Demographics 
No significant difference was seen between the 2 groups regarding gender and age 
profile (Table 6.3.1.).  
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Figure 6.3.5.  Flow diagram of the progress through the phases (CONSORT) with number of eyes (n) of 
the two randomised groups meeting the main inclusion criteria (myopic astigmatism and no ocular 
comorbidity). 
 
 
 
 IBRA Standard P (Chi2) 
Eyes 41 32  
Mean Age ± SD (y) 39.5 ± 9.6 38.3 ± 10.3  
Age <40 49% 53% 0.713 
Female 68% 75% 0.530 
Male 32% 25% 0.530 
Table 6.3.1.  Participants demographics. 
 
 
 
 
 
 
 
Randomisation 
(n=79) 
IBRA intervention 
(n=45) 
Standard intervention 
(n=34) 
Myopic astigmatism 
(n=231) 
Enrollment 
Assessed for eligibility 
(n=705) 
Not meeting inclusion criteria 
(n=474) 
Allocation 
Follow-up 
Analysis 
Lost to follow-up 
(n=4) 
Declined to participate (n=141) 
Astigmatism > 4D (n=8) 
Others (n=3) 
IBRA group 
(n=41) 
Standard group 
(n=32) 
Lost to follow-up 
(n=2) 
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6.3.4. Results 
 
Descriptive data 
A total of 73 eyes were analysed (Raw data: Appendix 9). Of these, 32 eyes were 
treated with the standard regime and 41 eyes with the new treatment algorithm. 
Statistically, no difference could be seen between the 2 study groups regarding 
preoperative spherical equivalent, astigmatism and best-corrected visual acuity (Table 
6.3.2.). 
 
 IBRA Standard P (U-Test) 
Preoperative spherical equivalent (D) 
 Mean 
 SD ± 
 Range 
 
-5.27 
2.49 
-10.0 to -0.6 
 
-5.03 
2.32 
-12.0 to -1.8 
 
0.352 
Preoperative astigmatism (D) 
 Mean 
 SD ± 
 Range 
 
-1.54 
0.64 
-4.0 to -1.0 
 
-1.51 
0.65 
-3.5 to -1.0 
 
0.548 
Preoperative BCVA (LogMAR) 
 Mean 
 SD ± 
 Range 
 
-0.03 
0.06 
-0.1 to 0.2 
 
-0.06 
0.07 
-0.2 to 0.1 
 
0.082 
Table 6.3.2.  Preoperative refractive and visual data.   
 
Primary outcome 
Primary outcome measure was the percentage of eyes achieving a postoperative 
spherical equivalent (SE) within 0.5D of the target SE. 51% of eyes of the IBRA group 
achieved a postoperative SE within 0.5D of the target. Statistically a significantly better 
outcome was shown by eyes from the standard group, achieving a rate of 78% (Table 
6.3.3. and Figure 6.3.7. left; p=0.027). No difference between the 2 groups was seen 
when comparing eyes achieving their target within 1D, or when comparing eyes 
achieving emmetropia within 0.5D.  
 
 IBRA Standard P (Fisher‟s) 
Postoperative SE (D) 
 Mean 
 SD ± 
 Range 
 
-0.56 
0.61 
-2.1 to 0.63 
 
-0.32 
0.40 
-1.3 to 0.25 
 
0.049 
Predictability 
 Eyes within 0.5D of target SE 
 Eyes within 1.0D of target SE 
 Eyes within 0.5D of emmetropia 
 Eyes within 1.0D of emmetropia 
 
51% 
83% 
59% 
78% 
 
78% 
97% 
78% 
94% 
 
0.027 
0.072 
0.087 
0.099 
Table 6.3.3.  Postoperative spherical equivalent (SE) and predictability 
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The mean postoperative SE of the IBRA group was -0.56D, which was significantly 
lower than the mean postoperative SE of the standard group at -0.32D (Table 6.3.3. and 
box plot Figure 6.3.6.; p=0.049). 
 
This myopic shift of the IBRA group was also seen in the SE histogram (Figure 6.3.7., 
middle). Generally for both groups the higher the preoperative SE was, the higher the 
postoperative SE resulted (Figure 6.3.7. right). 
 
 
 
Figure 6.3.6. Postoperative spherical equivalent of the IBRA and Standard groups (p=0.049). 
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SE Predictability SE Distribution SE Change 
 
 
IBRA 
 
 
Standard 
 
 
IBRA 
 
 
Standard 
 
 
IBRA 
 
 
Standard 
 Figure 6.3.7. Spherical equivalent  predictability, distribution (histogram) and scattergram. 
 
 
 
Secondary outcomes 
There was no difference between the 2 groups related to the mean postoperative 
cylinder or the predictability of astigmatic changes (Table 6.3.4. and Figure 6.3.8. left). 
 
 IBRA Standard P (Fisher‟s 
exact test) 
Postoperative subjective cylinder (D) 
 Mean 
 SD ± 
 Range 
 
-0.35 
0.32 
-1.0 to 0 
 
-0.37 
0.34 
-1.0 to 0 
 
0.836 
Postoperative cylinder distribution 
 Within 0.25D 
 Within 0.50D 
 Within 0.75D 
 Within 1.00D 
 
63% 
76% 
93% 
100% 
 
50% 
78% 
90% 
100% 
 
0.340 
1.000 
1.000 
 
Table 6.3.4.  Cylinder changes (astigmatism). 
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Cylinder Predictability Cylinder Change 
 
 
IBRA 
 
 
Standard 
 
 
 
IBRA 
 
 
 
Standard 
Figure 6.3.8. Astigmatic predictability and changes. 
 
The mean uncorrected visual acuity of the standard group was better, but the difference 
was statistically not significant (Table 6.3.5 and Figure 6.3.9 and Figure 6.3.10 left; 
p=0.489). There was no difference in the mean postoperative best-corrected visual 
acuity. The IBRA group performed significantly better in the „safety distribution‟, with 
numbers of eyes losing or gaining Snellen lines of best-corrected visual acuity (Table 
6.3.5 and Figure 6.3.10 right). 
 
 IBRA Standard P (Fisher‟s 
exact test) 
Postoperative UCVA (LogMAR) 
 Mean 
 SD ± 
 Range 
 
0.12 
0.25 
-0.2 to 0.7 
 
0.01 
0.14 
-0.2 to 0.3 
 
0.102 
Postoperative BCVA (LogMAR) 
 Mean 
 SD ± 
 Range 
 
-0.07 
0.07 
-0.2 to 0.2 
 
-0.08 
0.08 
-0.2 to 0.2 
 
0.489 
Postoperative BCVA 
 Lost 1 Snellen line or more 
 Unchanged 
 Gained 1 Snellen line or more 
 
0% 
58.5% 
41.5% 
 
25% 
46.9% 
28.1% 
 
0.003 
Table 6.3.5.  Uncorrected and best-corrected visual acuity 
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Figure 6.3.9. Postoperative uncorrected visual acuity (LogMAR; p=0.102). 
 
Uncorrected visual acuity Best-corrected visual acuity (safety) 
 
 
IBRA 
 
 
Standard 
 
 
IBRA 
 
 
Standard 
Figure 6.3.10. Visual acuity outcomes. The safety chart of the IBRA group is significantly better. 
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Complications 
None of the treated eyes incurred any serious complication. In 7 eyes (17%) of the 
IBRA group and 2 eyes (6%) of the standard group, a re-treatment (enhancement) was 
requested by participants who were unhappy with the postoperative uncorrected visual 
acuity and myopic spherical equivalent (Table 6.3.6). Statistically, there was no 
difference between the 2 groups related to enhancements. 
 
 IBRA Standard P (Fisher‟s 
exact test) 
Enhancements 
 For myopic postoperative SE 
 
7 (17%) 
 
2 (6%) 
 
0.163 
Table 6.3.6.  Enhancement rate 
 
 
 
6.3.5. Discussion 
 
Recruitment and selection 
During the first 6 months recruitment was satisfying and we could meet the recruitment 
goals. The following 6 months showed a slowdown in the recruitment. We attributed the 
problems to economic and patient-related factors. 
 
As a consequence of the financial crisis in 2009, we saw fewer patients in the private 
practice. In addition, these patients were more careful with spending money and 
requested „confirmation‟ that their „investment‟ in their eye treatment guaranteed best 
outcomes. Generally, patients expected perfect laser vision correction. However, the 
nature of randomised controlled trials is such that this cannot necessarily be guaranteed, 
and many patients were confused and sometimes frustrated having been informed about 
the trial and its aim „to find the best possible treatment‟. They could not understand that 
„the best surgeon‟ was not sure about the „best treatment‟. At this stage many patients 
decided to postpone their operation until the question of the best treatment could be 
answered. Some very sceptical patients even criticised the surgeon‟s competency and 
wanted to look for another surgeon „who would provide them with the best treatment‟. 
 
To improve recruitment, we tried to change current practice. We modified the 
scheduling and the information part of the assessment. We took more time to explain all 
the details, and we discussed the background of the trial in greater depth. However, we 
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still wanted to remain neutral and we did not want to influence patients in their decision 
making process. 
 
Unfortunately, despite the extra effort and changes, no significant improvement in the 
recruitment rate ensued, and we discussed the situation with the R&D department with a 
view either to further changes or termination. We agreed to set an interim recruitment 
target over a period of 2 months but, ultimately, we were unable to meet this target. 
 
Overall we recruited 73 participants with pre- and postoperative data for analysis. 
Clearly, we recruited fewer patients than the original sample size estimate of 128 
participants with 90% power (or 98 participants with 80% power). We therefore 
performed mainly descriptive analysis. We calculated p-values for presentation 
purposes only, with the idea that it might help in the determination of outcome 
tendencies. 
 
Clinical outcomes 
With the individual nomogram adjustments, we aimed to improve the predictability of 
the treatment. Each patient received an individualized treatment adjustment aiming for a 
postoperative spherical equivalent (SE) more myopic and closer to emmetropia. A 
second aim was to reduce the scatter, and to bring the outcomes closer together (smaller 
standard deviation), by adjusting the cylinder component. 
 
The analysis of the data showed that participants receiving the IBRA treatment showed 
a significant myopic change in SE. The postoperative SE of the IBRA group was 0.24D 
more myopic then the SE of the standard group. Based on the formula that was used for 
the calculation of the adjustments, this myopic shift was intended to be between 0.22D 
and 0.47D, in linear correlation to the preoperative sphere (0.22D for sphere with -8.5D; 
and 0.47D for sphere with 0 to -0.5D; average of 0.37D). As we aimed more for mild 
under-correction, the achieved myopic shift of 0.24D was satisfying (65% of intended 
change) and in accordance with our first aim of achieving myopic correction. 
 
The distribution of the postoperative SE of the IBRA group, as compared to that of the 
Standard group, showed a higher standard deviation and a wider range (0.61D compared 
to 0.4D). In combination with the myopic shift, this resulted in a significantly lower 
percentage of eyes ending up within 0.5D of the target SE (51% for the IBRA group and 
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78% for the standard group). This was in opposition to our second aim, and we could 
not find an explanation for the increase in scatter. Generally, the IBRA treatment (as 
used for the 2007 Audit) showed an over-correction for participants with a low 
preoperative SE, and an under-correction for those with a high preoperative SE. No 
such tendency could be seen for the standard treatment in the controlled trial. 
 
Apart from spherical modifications, the IBRA treatment included adjustments for the 
cylinder, based on our assumptions. This should have contributed to a decrease of the 
distribution. However, the analysis of the postoperative mean cylinder of the 2 groups 
did not show a benefit from the performed cylinder adjustment. In fact, there was no 
difference between the 2 groups from a statistical point of view. The intended cylinder 
changes of up to 0.36 D (average of 0.14D), depending on the preoperative cylinder, 
seemed to disappear in the overall treatment (mean induced cylinder change was 0.02D, 
only 14% of the intended change). 
 
In 2007, the average postoperative SE for patients with myopic astigmatism was 0.13 D 
(± 0.48 D), and 59% of eyes were within 0.5D of the target SE. Participants of the 
standard group of this RCT were treated with the same 2007 Audit parameters, but their 
results were much more myopic and generally better; the mean postoperative SE was -
0.32 D (± 0.40 D) and 78% of eyes achieved their target SE within 0.5D. How can we 
explain this difference? Although we are not aware of any software or hardware change 
of the laser unit we assume that, with the move from the older location on the 2nd floor 
at Moorfields Eye Hospital to the new treatment suite on the 5th floor in February 2009, 
the machine started performing slightly differently, resulting in a myopic shift (we 
consider this also as a source of bias). This, of course, had an implication on our IBRA 
treatment too, showing significant under-correction with a postoperative SE of -0.56 D 
(±0.61 D) and only 51% of eyes achieving the target SE within 0.5 D. Linked to the 
higher myopia, the participants‟ UCVA was lower. 
 
Taking into account all changes, including the attempted myopic change from the IBRA 
algorithm, the wider scatter of the IBRA outcomes, and the unintended myopic shift 
from the laser machine, we have to conclude that the better treatment in this trial was 
the standard treatment. Compared to the literature our results meet the standards, which 
are between 50-75% for eyes achieving the SE target within 0.5D. 
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Safety and enhancements 
None of the eyes of either group had signs of infection or inflammation. None of the 
eyes of the IBRA group lost one or more Snellen lines of best-corrected visual acuity 
(safety analysis). In fact, the IBRA group showed a significantly better best-corrected 
visual result with a higher percentage of eyes remaining unchanged or gaining one or 
more Snellen lines (p=0.003). The reason for this remained unclear. 
 
Although the IBRA modifications worked as planned, the unintended additional myopic 
correction from the laser machine made the ultimate outcome short-sighted. The higher 
amount of eyes with significant postoperative myopia in the IBRA group reduced the 
potential for good uncorrected visual acuity, and increased the rate of re-treatments 
(enhancements). For this trial, we consider this myopic over-correction as adverse 
event, although the difference between the numbers of enhancements between the 2 
groups was statistically not significant. 
 
Strengths of the study 
This study has shown that the used formulas work in a safe way and that the nomogram 
adjustments were effective in changing the spherical equivalent as attempted. 
 
Weaknesses of the study 
The individualisation of the nomogram adjustment did not influence the scatter 
positively, or reduce the postoperative astigmatism. The other main weakness was the 
reduced sample size. Although the number of participants was quite high for a 
randomised trial in private practice, the study ultimately remained underpowered and 
the statistical results have to be viewed with this understanding. 
 
Limitations of the study and generalisability 
The formulas we developed in this research were based on preoperative and 
postoperative data from our laser centre with a particular equipment and treatment 
regime. As equipment and treatments differ from surgeon to surgeon, the presented 
formula cannot be used in another set-up without modifications. However, we believe 
that other laser equipment would not behave differently and that the change we intended 
to achieve would not be better or worse with different set-ups. Therefore, we do not 
recommend repeating this trial in the same form. 
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The patient individual approach for cylinder adjustments did not show a significant 
improvement in patient outcomes (scatter) and the individual spherical changes were 
not superior to general modifications, as presented in the audit cycles in Section 6.2. 
 
 
6.3.6. Conclusions 
Patients judge the success of refractive laser treatments by post-operative visual acuity 
and the end of spectacle dependence, both of which are ultimately determined by the 
refractive outcome. This in turn depends on the spherical equivalent distribution around 
emmetropia and the postoperative amount of astigmatism, both important measures of 
the effectiveness and precision of laser vision correction. 
 
This research has proven that individual nomogram adjustments are effective and safe in 
changing the refractive outcome. The adjustments worked much better for spherical 
changes, and seemed to be nearly ineffective for small cylinder changes. Overall, the 
individualisation did not show a benefit over general nomogram modifications, as 
performed for the refractive Audit in 2008. They did not show an improvement 
regarding the scatter of the results either. Patients with myopic undercorrection were 
more likely to request further treatments (enhancements). 
 
Recommendations for health-care provision 
The best way to change the refractive outcome of patients with combined myopic 
astigmatism is to analyse a series of results (approx. 50 treated eyes) and to perform 
simple linear regression analysis from attempted versus achieved spherical equivalent 
refraction. The surgeon can then use the y-intercept („b‟) from the calculated equation of 
the straight line (y = m*x + b) for general nomogram modifications. If the slope („m‟) is 
far from the ideal 45 degree line (value of 1.0), an additional fix amount of adjustment 
can be added to the nomogram adjustment for patients requiring a higher amount of 
correction. The best threshold for adding extra nomogram adjustments has been shown 
to be around 6D of correction. 
 
The introduction of Revalidation by The Royal College of Ophthalmologists brings with 
it a need for large amounts of comparative data which can be referred to by practising 
clinicians. Selecting and setting standards as a basis for revalidation can be challenging, 
especially with the large number of variables involved. It is known, for example, that 
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refractive outcomes of LASIK are influenced by the surgeon's experience and 
familiarity with the technique (Teus 2007). 
 
Implications and recommendations for future research 
Improving the scatter of treated eyes remains an unsolved task. New approaches and 
research are required to investigate the possible impact of other factors, including 
healing conditions, ophthalmic treatment (antibiotic and anti-inflammatory eye drops), 
ablation profiles, and more detailed patient characteristics (ethnic origin, living and 
working situation, etc). 
 
Implications for IBRA and its development 
This research has shown that it is possible to implement a calculation algorithm into 
IBRA which provides the surgeon with automated nomogram adjustments. However, 
the implementation of individual adjustment factors into patient treatment is more 
complex, and has shown little benefit to the refractive outcome. We therefore 
recommend not to develop individual nomogram adjustments further, but to focus on 
general treatment modifications based on refractive disorder groups. This concept 
should be implemented into the next IBRA version and may include the creation of 
adjustment tables for the different refractive groups.  
 
 
6.3.7. Acknowledgements 
We would like to give special thanks to Professor David Gartry for his generosity in 
undertaking this difficult trial within his private laser practice, a highly competitive field 
of ophthalmology. 
 
 
6.3.8. Other information 
Registration number:  08/H0801/99 
Original protocol:  Appendix 1 
Funding:  Professor David Gartry (Chief investigator and surgeon) 
   Research Department, Moorfields Eye Hospital 
 
 
 
132 
6.4. Management of refractive data entry processes 
 
6.4.1. Introduction 
The introduction of electronic medical records has changed the format used to document 
individual patient care and medical history. Traditionally, medical records have been 
written on paper and kept in folders. With electronic records, the database of the system 
is updated either by manual or automated data entry. In Ophthalmology, data is entered 
manually. In other fields, for example in multicentre research, optical character 
recognition (OCR) has become a viable technique for automated data entry (Hardin 
2005). 
 
Generally, data entry systems face 2 major challenges: 
 Minimising data entry errors (validation) 
The introduction of computer based data entry forms and data collection tools 
have led to improvements in accuracy of the entered data. In 1999 Hunter et al. 
compared paper-based and electronic acquisition of data in an audit analysing 
laparoscopic surgical procedures. An independent chart review of 22% of all 
records showed that the electronic data acquisition had superior data and coding 
accuracy (p<0.01). Another method to improve the data entry process is to 
validate the entered data at the stage of data entry. Kruse (2008) showed that 
built-in functions of validation can effectively detect entry errors, and can provide 
rapid feedback to the collector. Additional positive influence on the data accuracy 
can be achieved by training the data collectors. This can include written 
instructions (e.g. a handbook for standardised data collection), a review of a 
standard data set and its definitions, a system walk-through and specific practice 
(Jansen 2005; Arts 2003). 
 
 Optimising time requirements for the data entry process (efficiency). 
The challenge of data entry efficiency is complex and determined by the user-
interface, the system response (e.g. speed), the data set, and user-individual 
factors such as cognitive skills with data handling, technical abilities, and time 
pressure. Different approaches are used to assess the resource utilisation. One 
method is to compare the efficiency of performing a specific task on 2 different 
systems by the same users. Another approach is to observe and compare different 
users performing the same data entry processes with only one system. Efficiency 
133 
can then be determined by evaluating the time requirements or number of steps 
required to manage the data entry. Information gained from such assessment can 
enable improvement of human computer interaction (user interface). Typical 
optimisation processes include a reduction of the total number of steps or the 
percentage of mental effort, required for the tasks (Saitwal 2010). 
 
Recently the cost of data entry processes, and cost-effectiveness in providing the same 
data recording accuracy, has become an important criterion (Murphy 2009). In 2009, 
Pavlović et al. could prove that electronic data collection processes were able to 
decrease data collection costs by up to 55%; whereas in less developed countries 
organisational, managerial and social challenges must be addressed beyond technical 
and financial aspects (Ndira 2008). 
 
For this research we were looking at the collection of refractive data, formed by a 
distinctive set of parameters, such as the sphere, cylinder, cylinder axis, and others 
(Kaye 2002). The recording of refractive data is a specific process, comprising 
completion of a certain number of data entry fields, usually with results from 
preoperative and postoperative subjective refraction. We have chosen to assess time 
requirements at different steps of this data collection process from multi-user single-
system assessment. 
 
Data can be collected in different ways. Some surgeons prefer to enter the data stepwise 
alongside patient visits, while other surgeons prefer to collect a staple of patient records, 
after the patient has been discharged, to enter the data in one go. From personal 
experience, the time needed for data collection is usually overestimated by the collector 
(surgeon); and underestimated by the developer of the system. In fact, there is a general 
perception amongst refractive surgeons that data collection and entry into software 
systems is time consuming, and therefore detracts from the delivery of good clinical 
care. 
 
Not long ago, the collection and analysis of refractive outcome data, as provided by 
IBRA, became an increasingly important requirement of refractive surgery practice. 
This data can be used to demonstrate the high quality results of an individual to the 
patient, and also to external commissioners. The Quality and Revalidation Initiatives of 
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The Royal College of Ophthalmologists underpin this importance in the provision of 
auditable outcomes of surgery. 
 
The aim of this evaluation was to analyse the time taken to input data into the IBRA 
system, and also to analyse different methods of data entry and their relative efficiency. 
 
The objectives were: 
 To compare the different methods of data collection (stepwise, one-step). 
 To analyse the time effort for different steps of the data collection. 
 To identify the most efficient way of collecting data. 
 To analyse time and learning curve effects. 
 To identify flaws in the process of data collection, which may then help to 
improve future versions of IBRA. 
 To record a minimum of 1,000 data entries for this evaluation process. 
 
 
6.4.2. Methods 
This was a user-related, behaviour-based system evaluation. Three specific software 
modules were designed and implemented into the basic IBRA code for logging (Module 
A) and analysis (Module B and C) of data entry processes of each user. Because a high 
amount of data was expected to be recorded, all logging processes were developed as 
automated routines. 
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Data logging 
Module A was used to measure the time each individual user required to enter data into 
the database at 3 different parts (sections) of the data collection pathway (Figure 6.4.1). 
The first part of data collection was related to the demographic patient data (T1). During 
the second part the user entered the preoperative and surgical data (T2); and the third 
part was for the collection of postoperative (follow-up) data. The total time required to 
enter a full set of data for one case (= one treatment of one eye) was calculated by 
adding the times of all 3 parts (T Total = T1+T2+T3). 
 
 
 
 
 
 
 
 
     Empty data set                  Full data set 
 
 
 
T1  Time to enter demographic patient data 
T2  Time to enter preoperative and surgical data 
T3  Time to enter postoperative data 
T Total  Time to enter a full data set for one case (=T1+T2+T3) 
 
Figure 6.4.1. Data logging at different steps of the data entry process. 
 
 
The data recording started in December 2008. All recorded data was stored in a MySQL 
database (Table 6.4.1.). In particular, the following set of data was collected each time a 
user was entering data into IBRA (= 1 data entry process): 
 id: individual file id 
 date: date of the data entry 
 userid: the user‟s id 
 caseid: the patient‟s case id (treatment id) 
 part: step of the data collection (T1, T2 or T3, see above) 
 time: the time in seconds taken for data entry for this part 
 
 
 
 
 
Demographic data Preoperative and 
surgical data 
Postoperative 
data 
T1 T2 T3 
T Total = T1+T2+T3 
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Table 6.4.1. Structure and data example of the MySQL database from the logging process. 
 
 
Data analysis and presentation 
For the analysis and presentation of the logged data, Module B was developed based on 
PHP programming. Module B was able to calculate mean, standard deviation and range 
of the time taken in seconds for each part of the data entry process (T1, T2 or T3). 
These results were presented in table form on a web site accessible only by the 
investigators. 
With the implementation of Module C, the logged data could be presented in 
scattergram form, with  the x-axis showing the date of the data entry and the y-axis 
showing the length of time needed. The programming of this module required the open-
source, graph-creating, PHP library „JpGraph‟ that could be used by the PHP scripts. 
The graphs were presented in a HTML media container on the web site. 
 
Patient data / parameters 
Up to 55 different parameters were entered for each patient treatment (Table 6.4.2.). 
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 Minimal set 
(22 parameters) 
Standard set 
(42 parameters) 
Extensive set 
(55 parameters) 
Patient data 
 
Patient ID 
Surname 
 
Patient ID 
Surname 
First name 
Sex 
Date of birth 
Code 
Diagnosis 
Patient ID 
Surname 
First name 
Sex 
Date of birth 
Code 
Diagnosis 
Past ocular history 
Past corneal history 
Preoperative 
data 
Manifest refraction sph 
Manifest refraction cyl 
Manifest refraction ax 
Distance UCVA 
Distance BCVA 
 
Manifest refraction sph 
Manifest refraction cyl 
Manifest refraction ax 
Distance UCVA 
Distance BCVA 
Wavefront refraction sph 
Wavefront refraction sph 
Wavefront refraction sph 
Pachymetry 
IOP 
Scotopic pupil 
Optical zone 
Manifest refraction sph 
Manifest refraction cyl 
Manifest refraction ax 
Distance UCVA 
Distance BCVA 
Wavefront refraction sph 
Wavefront refraction sph 
Wavefront refraction sph 
Pachymetry 
IOP 
Scotopic pupil 
Optical zone 
Transition zone 
Keratometry K1 
Keratometry K2 Keratometry 
K2 Ax 
Excimer data Eye 
Date of operation 
Method 
Intervention 
Target refraction sph 
Target refraction cyl 
Target refraction ax 
Refractive treatment sph 
Refractive treatment cyl 
Refractive treatment ax 
 
Eye 
Date of operation 
Method 
Intervention 
Target refraction sph 
Target refraction cyl 
Target refraction ax 
Refractive treatment sph 
Refractive treatment cyl 
Refractive treatment ax 
Physician adjustments sph 
Physician adjustments cyl 
Physician adjustments nomo 
Flap technique 
Excimer laser type 
Eye 
Date of operation 
Method 
Intervention 
Target refraction sph 
Target refraction cyl 
Target refraction ax 
Refractive treatment sph 
Refractive treatment cyl 
Refractive treatment ax 
Physician adjustments sph 
Physician adjustments cyl 
Physician adjustments nomo 
Flap technique 
Excimer laser type 
Laser program 
Hinge position 
Ablation aperture 
Ablation depth 
Postoperative 
data (3 month) 
Manifest refraction sph 
Manifest refraction cyl 
Manifest refraction ax 
Distance UCVA 
Distance BCVA 
 
Manifest refraction sph 
Manifest refraction cyl 
Manifest refraction ax 
Distance UCVA 
Distance BCVA 
IOP 
Satisfaction 
Haze 
Manifest refraction sph 
Manifest refraction cyl 
Manifest refraction ax 
Distance UCVA 
Distance BCVA 
IOP 
Satisfaction 
Haze 
Keratometry K1 
Keratometry K2 
Keratometry K2 Ax 
Table 6.4.2. Data collection sets: minimal set, standard set and extensive set. 
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6.4.3. Results 
A total of 1,898 data entry processes were recorded from 11 different IBRA users over a 
period of 12 months. 
 
A first gross analysis of user data entry method allowed us to divide the users into two 
main groups regarding their entry technique. 
 One group of 5 users performed a stepwise data collection with separate data 
entry for demographic data, preoperative/surgical data and postoperative data. 
The data based on a standard data set (Table 6.4.2) and was entered along with 
the patient review. This could be seen in a data entry pattern with recurrent entry 
processes, often in weekly intervals (e.g. Figures 6.4.2.). 
 The 6 users of a second group preferred to enter data in one-go. The 
preoperative, surgical and postoperative data of up to 100 treated eyes was 
entered into IBRA after the final clinical visit. Two users entered a standard set, 
1 user an extensive set, and 3 users entered a minimal data set. 
 
Stepwise data collection 
We analysed 444 processes of demographic data collection. A mean of 62 s was 
required to enter the 7 demographic parameters of a standard data set (Table 6.4.3. and 
Figure 6.4.2.). The analysis of 213 processes of preoperative and surgical data collection 
showed that users required a mean of 257 s to collect the 27 parameters of this part 
(Figure 6.4.3.). Finally, we analysed 705 processes of postoperative data collection. A 
mean of 51 s was required to enter the 8 postoperative parameters of the standard data 
set (Figures 6.4.4.). Summarising all 3 parts resulted in a mean of 370 s (6 min 10 s), 
which was required to enter a full standard data set for one patient (42 parameters). 
 
 
Parameter N Mean ± 1 SD Range Figure 
T1 444   62 s   ± 19 s 30 s  -  100 s 6.4.2 
T2 213 257 s ± 204 s 74 s  -  934 s 6.4.3 
T3 705   51 s   ± 31 s 10 s  -  178 s 6.4.4 
Total  370 s    
Table 6.4.3. Time requirements (mean and SD) to enter demographic data (T1), preoperative and surgical 
data (T2) and postoperative data (T3) for a standard data set with 42 parameters. N = number of analysed 
data entry processes. 
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Figure 6.4.2. Data entry of demographic data of all users (step 1, T1). 
 
 
Figure 6.4.3. Data entry of preoperative and surgical data of all users (step 2, T2). 
 
 
Figure 6.4.4. Data entry of postoperative data of all users (step 3, T3). 
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Learning effects 
The analysis of 180 processes of postoperative data collection for one particular user, a 
beginner, revealed a reduction of time taken over time (Figure 6.4.5). The statistical 
comparison of the time requirements at the beginning and 2 months later showed a 
significant improvement in efficiency (Mann-Whitney U-Test, p<0.0003, Figure 6.4.6). 
Learning effects reduced the time requirement by approximately 26%. 
 
 
Figure 6.4.5. Stepwise data entry. Each blue dot in this figure represents a data entry process. This 
example shows the same user entering postoperative data (T3) into IBRA. The vertical position of the dot 
(y-axis) provides information on the time in seconds required for data collection. The x-axis shows the 
date the entry was performed. The data entry pattern reveals a weekly data entry process (mostly 
Saturdays). Curve fitting analysis (red line) demonstrated a significant reduction of time requirements 
over time (p<0.0003). 
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Figure 6.4.6. Stepwise data entry. The left box plot (C1) shows the time in seconds required to enter 
postoperative data (T3) in the first months of IBRA use. The right box plot (C2) shows the time 
requirements two months later. The reduction was statistically significant (p<0.0003). 
 
 
 
Data entry in one-go 
The analyses of the data entry processes from users performing the „one-go‟ method 
showed users entering 3 different sets of data, each with a different number of 
parameters: minimal, standard and extensive. 
 
Three users entered the minimal data set. This consisted of 22 parameters, allowing the 
calculation of 7 of 10 refractive outcome analyses. Two users entered the 
(recommended) standard set of data consisting of 42 parameters and allowing 
production of all 10 refractive outcome analyses. Finally, one user entered 55 
parameters for each treatment into the IBRA database (extensive set). Although more 
data was entered, this did not increase the numbers of possible outcome analyses. The 
benefit of the additional data was the possibility it offered for future data analysis using 
a combination of IBRA, Microsoft EXCEL and statistic software.  
 
The analysis of 441 one-go data entry processes showed that it required a mean of 131 s 
(2 min 10 s) to enter all 22 parameters of a minimal data set (Figure 6.4.7. and Table 
6.4.4.). The mean time that was required to enter a standard data set with 42 parameters 
was 275 s (4 min 35 s), with a range between 140 s to 519 s. The mean time to enter the 
extensive data set with 55 parameters was 620 s (10 min 20s, Figure 6.4.8.). 
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Parameter N Mean ± 1 SD Range Figure 
Minimal set 
(22 parameters) 
441 131 s   ± 61 s 55 s  -  492 s 6.4.7 
Standard set 
(42 parameters) 
71 275 s ± 103 s 140 s  -  519 s - 
Extensive set 
(55 parameters) 
85 620 s ± 205 s 139 s  -  1258 s 6.4.8 
Table 6.4.4. Time amount required to enter a minimal set, a standard set and an extensive set of data with 
the one-go method. N = number of analysed data entry processes. 
 
 
 
Data entry intervals 
Independent from the entering method (stepwise or on-go), we could identify 2 main 
patterns of data entry regarding the date and frequency the data was entered (intervals): 
some users entered the data on a regular, often weekly basis (see Figure 6.4.5.), and 
others entered the data block wise, e.g. once every 6-9 months (Figure 6.4.7.)  
 
 
Figure 6.4.7. Data entry in one-go (minimal set). Each blue dot in this figure reflects a data entry process 
by the same user. In this example, 221 cases are shown and an average of 139 seconds was required to 
enter a minimal data set with 22 parameters. 
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Figure 6.4.8. Data entry in one-go (extensive set). A total of 112 cases were entered by single users. An 
average of 610 seconds was required to enter an extensive data set with 55 parameters. The data entry 
process was repeated 2 months later. The standard deviation was large, maybe due to a complex search 
process to find the results of all 55 parameters. In particular, the collection of past ocular and medical 
history can take some time; and some patient files consist of more than 1,000 pages. 
 
 
 
 
6.4.4. Discussion 
Electronic health record systems face barriers to their implementation by healthcare 
service providers. One of the main barriers to implementation is the perceived 
additional time required to input data into the system. This study evaluates the data 
entry management and the time requirements for a large series of data entry processes 
by different users. 
 
Primary outcomes 
We have shown that it requires a mean of 6 min 10 s to perform a standard data 
collection with 42 parameters using a stepwise data entry method. The most time 
demanding step was the entering of preoperative and surgical data, requiring three 
quarters (70%) of the total time. This step required completion of 27 of the 42 standard 
set fields (64% of fields) placed at 2 different sites. 
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This evaluation showed that the process of data entry could be sped up for the same 
amount of data by an average of 95s per process when using the one-go data entry 
method instead of the stepwise procedure. With an average of only 275 s for a standard 
data set, this method would allow entry of 13 complete cases into IBRA in 1 hour. 
 
The data entry process can further be accelerated by minimizing the amount of data 
entered. Although this will reduce the amount of outcome analyses that can be 
performed, some surgeons might prefer this compromise. Another disadvantage of 
minimal data sets is that they do not allow complex data separation on the basis of 
patient data or excimer data (see table 6.4.2.). 
 
Learning curve effects 
The results from this evaluation showed that the data entry process was subject to 
learning curve effects, with a reduction in the time requirements by 26%. Although 
cognitive psychology has explained the variability in performance and has shown that 
speed-up is ubiquitous (RITTER), no such evidence has been published for the 
collection of complex refractive data. This study showed that the improvement was 
slow and limited after a period of approximately 8 weeks (flat learning curve, 
HERMANN 1885 and BILLS 1934). Based on these results, and the knowledge that the 
completion of most tasks get faster with practice, we expect a general increase in 
efficiency following an introduction period. 
 
Limitations of the evaluation 
The study uses the responses of a variety of individuals who were unaware of the time 
recording at each step. Clearly this process is subject to ability variation among the 
users. This variation is perhaps unimportant, though, as a variety of skill levels probably 
better represents the reality of clinical practice where some users may be adept at using 
IT systems whilst others may be novices. Secondly, the method of time collection relied 
upon the input of certain pieces of data to be recorded as a complete event. 
 
In a review of the literature regarding this subject, it is clear that there is a concept of 
time efficiency which has been explored in a variety of papers, with differing 
approaches. Most papers adopt either a qualitative or quantitative approach to the 
benefit of health informatics. Our particular study adopts a quantitative approach to the 
time required to complete certain fields of data as a measure of the usability of the 
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system. Of course, this does not examine the quality of the data outputs or the quality of 
the data input process. Indeed, examining one system in isolation will not provide 
objective data about this data system in comparison with others available commercially 
for this particular application. However, this study is not concerned specifically with the 
application, rather the time required and the process of using it, in terms of impact on 
time for a busy surgeon. Thus comparative data is not essential. In future, however, it 
may be instructive to compare this software with other packages to provide comparative 
data. 
 
The methodology of this study did not investigate the role external factors contribute to 
the time efficiency of clinicians. This perhaps needs to be better understood in order to 
evaluate how clinicians are most likely to use such software in their daily practice. Also 
the technical ability of clinicians was not assessed; therefore the group of 11 may have 
had widely differing experience with IT systems. This will certainly have an impact on 
their organizational abilities in terms of when data was entered, and also the speed at 
which they navigate the system. This issue was mitigated to some extent in this study, 
by the demonstration of the learning effect of using the system over time. 
 
The true time impact of EHR systems must consider the data entry process by users, as 
in this study, but also the utilisation of that data after the event, for example the time to 
retrieve that data when required for analysis. This aspect of the system has not been 
measured in this study. Comparison with current manual methods of data extraction 
from written records needs to be performed in order to demonstrate the true time gain 
by the use of these systems. Data input will always take time, partly due to the interface 
but also due to the fact that, in general, EHR systems require a more complete data set 
to be entered than for paper records. The importance of accurate data retrieval has been 
discussed, with regard to the advent of quality care initiatives and the requirement of 
surgeons to demonstrate their clinical competence in terms of the process of 
revalidation. 
 
Implications for future research and the IBRA development 
Further work is needed to establish the minimum data set needed to provide meaningful 
outcomes. This was not the scope of this particular study. In addition, data comparing 
performance of EHRs with other methodologies needs to be produced in order to 
demonstrate the full benefit of this system. The obvious comparison is with the paper 
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record systems, currently in existence. However, it is not possible to measure the 
benefits of accurately recorded data, which requires less storage and is arguably more 
secure than paper records, or the ease of producing outcome measures with data from 
paper records compared with electronic software systems. 
 
The data entry process could be improved with removal of irrelevant entry fields and 
rearrangement of relevant fields on one single entry site. This would allow shorter 
navigation through the system and would reduce search processes. For example, the 
fields for preoperative and surgical data could be placed on the same site. 
 
Currently there is a paucity of research regarding EHR implementation. This is in part 
due to a lack of rigorous methods available to measure meaningful outcomes. Studies 
such as ours use a continuous observation of work processes as captured by time and 
activity monitoring. However this does not assess all aspects of the use of a software 
system. In a highly specialised environment, such as refractive surgery, it is more likely 
that uniform care delivery patterns are established. Therefore, there will be less 
variability in the use of such systems. This factor mitigates, in some way, the need to 
examine other aspects of usage. 
 
Recommendations for new IBRA users 
For beginners, we recommend starting with a minimal data set and entering the data 
with the one-step method. This will require only a mean of 2 min 11s per case, allowing 
entering of up to 27 cases per hour into the system. Once the handling of the system has 
become easier, the amount of recorded data can be increased for more sophisticated 
analyses. 
 
If a user is able to spend more time at the beginning of the process, then we recommend 
entering a standard set of data with the stepwise method. Performing the data entry 
parallel to the clinical appointments will require minimal extra time. With this approach 
the time consuming process of data collection may look and feel easier, promoting 
continuation of the data entry process. Finally, each user has to balance the factors of 
time efficiency and outcome possibilities individually. 
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6.4.5. Conclusions 
The study analysed a large number of data entry processes. The developed software for 
the data logging worked smoothly and was efficient in the logging process and in the 
analysis of the data. The results have shown a considerable amount of time is required 
to enter a standard set of data (a minimum of 370s with the stepwise approach). This 
process improves and reaches its optimum after approximately 8 weeks (26% less time 
requirement). The data entry completed in one-go was identified as the fastest way to 
enter the data into IBRA. Up to 27 cases could be entered with this approach per hour, 
and is therefore recommended for new IBRA users. 
 
The ability to produce accurate data which demonstrates good quality results within 
standards of professional acceptability will form an integral part of the revalidation of 
all specialists. Software systems, such as IBRA, can enable this accurate data to be 
collected and processed with minimal effort by the individual clinician. This outcome 
data may then be used to certify the competence of the practitioner. In addition, the 
system can be used to facilitate clinical research, as a by-product of good clinical care. 
 
Moreover, patients seeking refractive surgery are often well-researched, due to freely 
available information, which is easy to access on the internet. Consequently, 
expectations amongst patients are high and it is therefore important to have evidence of 
excellence in practice. Providing refractive outcome data may enable a patient to be 
more confident in the choice of surgeon performing their surgery. 
 
This evaluation process revealed potential for optimisation of the IBRA system mainly 
in the reorganisation, consolidation and reduction of the data entry fields. Adjusting 
these points in the next IBRA upgrade should not be complicated, and may bear the 
potential to accelerate the process of data entry. This could then be confirmed by 
performing a new, second cycle of evaluation, using the same data logging tools from 
this evaluation process. 
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6.5. System functionality 
 
6.5.1. Introduction 
Most current professional software offers far more functions than the standard user 
needs. Often, an increase in software function and diversity means decreased simplicity. 
The need for navigation through menus and tabs, the higher demand of computing 
power and a reduction in efficiency are some of the possible consequences. In our 
opinion, software should sharply match user interest and need and omit unused 
functions. 
 
The users of refractive analysis software, such as IBRA, are mainly refractive surgeons. 
Sometimes nurses and secretaries provide support with data collection. Analysis 
standards have been set up by surgical and medical associations, e.g. The Royal College 
of Ophthalmologists, and have been reported in books and international publications. 
One standard, which is used by many refractive surgeons for the presentation of 
refractive outcomes after laser eye surgery, was published by George Waring (see 
Waring Graphs in Chapter 3). Mr Waring suggested calculating a set of 6 graphs to 
reflect the visual and refractive outcomes of a series of refractive laser treatments, and 
allow easy comparison between different presentations. All 6 analysis methods were 
implemented into IBRA, and 4 extra charts showing visual outcomes and vectorial 
astigmatic changes were added. 
 
As surgeons are often obstinate in taking on good ideas from colleagues or professional 
bodies, a standard recommendation might still not circulate generally. In addition, 
standard recommendations are made for the general use of a wide international clientele 
and might not, therefore, be sufficient or relevant for surgeons from different countries 
with different conditions or legislations. 
 
The aim of this evaluation was to analyse user analysis preferences by monitoring the 
use of IBRA. We gave IBRA users the choice of 10 different analysis methods, and then 
evaluated the following questions:  
 Which methods are the preferred ones? 
 Which analysis method was used most?  
 Which postoperative review is most relevant? 
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The objectives were: 
 To evaluate the analysis behaviour of IBRA users. 
 To compare user preferences with international recommendations. 
 To evaluate the attractiveness of the 4 extra charts that were implemented into 
IBRA. 
 To evaluate differences between the use of refractive analysis functions in 
England, Ireland and Switzerland. 
 To record the data of a minimum of 1,000 analysis processes, logged by a 
software add-in developed for this evaluation process. 
 
 
6.5.2. Methods 
This was a user-related, behaviour based system evaluation. Specific software modules 
were developed and implemented, and IBRA adjustments were performed for the 
process of data logging and analysis. All processes were created as automated routines, 
requiring minimal maintenance. 
 
Every time a user performed an outcome analysis with IBRA, the system recorded the 
following data: 
 id: individual record id 
 date: date when the analysis was performed 
 userid: the user‟s id 
 type: the type of analysis that was performed (W1-6 = Waring analysis type 1-6): 
 c_pred_se = Predictability of spherical equivalent comparison (W1) 
 c_se = Distribution analysis of spherical equivalent refraction (W2) 
 c_de = Analysis of the defocus equivalent refraction (W3) 
 c_ucva = Cumulative analysis on uncorrected visual acuity (W4) 
 c_safe = Analysis of best corrected visual acuity change (Safety, W5) 
 c_stab = Analysis of spherical equivalent over time (Stability, W6) 
 c_bcva = Cumulative analysis on best corrected visual acuity  
 c_effic = Comparison of the best corrected versus the uncorrected visual 
acuity (efficiency) 
 c_tiasia = Comparison of target induced astigmatism (TIA) and 
surgically induced vector astigmatism (SIA) 
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 c_vector = Astigmatism analysis (vector analysis) 
 visit: interval between operation and postoperative review: 
 0 = preoperative review 
 7 = postoperative review at 7 days 
 1 = postoperative review at 1 month 
 3 = postoperative review at 3 months 
 6 = postoperative review at 6 months 
 12 = postoperative review at 12 months 
 
A MySQL database was configured on the IBRA server for data collection (Table 
6.5.1.). The data  was then analysed with IBRA and exported as a table (Table 6.5.2.) 
into Microsoft EXCEL for further analysis. 
 
 
 
Table 6.5.1. MySQL database structure as used for the evaluation process. 
 
 
 
 
Table 6.5.2. MySQL data export in form of a table. 
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6.5.3. Results 
A total of 2,480 files of analysis processes by15 different users were recorded between 
December 2008 and September 2009. 
 
The usage of the analysis function over time is shown in Figure 6.5.1. Each blue dot in 
this figure represents one analysis process (one file). The files are separate for each 
individual user (vertical axis showing the user id). Some of the users stopped using the 
software before or during the evaluation process. This explains why some of the 
horizontal lines do not show usage of the analysis function (e.g. no blue dots for user 
104). 
 
The red circle encloses a group of processes performed by IBRA users, who were 
intensively using the analysis function to prepare outcome figures for the presentation 
of their refractive portfolio at an exam led by The Royal College of Ophthalmologists. 
This exam took place in March 2009 (green vertical line). Following that event, some of 
the users then stopped using IBRA for the remainder of the evaluation period. 
 
 
 
Figure 6.5.1. Usage of the refractive outcome analysis function of IBRA for the evaluation period of 9 
months (horizontal axis) for each individual user (user id on the vertical axis). The red circle shows a 
group of user activity that was linked to an outcome presentation at the Royal College of 
Ophthalmologists in March 2009 (green vertical line). 
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The recorded data was separated by the type of analysis performed, and the preoperative 
and postoperative visit (Table 6.5.3.). The results show that some of the analysis 
methods were used much more often than others (Figure 6.5.2.). The 4 most commonly 
used methods made up 85.9% of all analysis performed. In descending frequency these 
were: UCVA analysis (30.3%), spherical equivalent predictability (27.8%), spherical 
equivalent distribution (14.4%) and analysis of changes in the best-corrected visual 
acuity (13.4%). All Waring analyses and graphs together made up 91% of the 
performed analysis methods. The additional 4 analysis methods implemented into IBRA 
from various sources were used very rarely and, notably, the 2 vector methods were 
used together in only 0.4% (11 times in 2480 analysis processes). 
 
The 3 month results were used in 69%, the 1 month results in 16.8% and the 6 month 
results in 6.5% of the analysis processes. Only 3% of the analysis processes were 
performed on preoperative data (Figure 6.5.3.). 
 
Analysis method Follow-up period   
 0 7 1 3 6 12 Total  
Predictability   (W1) 5 6 25 614 24 16 690 27.8% 
SE                      (W2) 24 4 24 287 11 6 356 14.4% 
DE                     (W3) 1 0 6 24 8 3 42 1.7% 
UCVA                (W4) 22 9 289 385 24 22 751 30.3% 
Safety               (W5) 4 4 24 225 61 15 333 13.4% 
Stability            (W6) 2 0 13 48 13 8 84 3.4% 
Efficiency 0 1 13 54 4 9 81 3.3% 
BCVA 16 2 16 69 16 13 132 5.3% 
TIA/SIA 0 0 2 3 0 0 5 0.2% 
Vector 0 0 4 2 0 0 6 0.2% 
Total 74 26 416 1711 161 92 2480 100% 
 3.0% 1.0% 16.8% 69.0% 6.5% 3.7% 100%  
Table 6.5.3. Amount of analysis methods performed. 
 
 
Figure 6.5.2. Usage of the analysis methods (in percentage). 
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Figure 6.5.3. Follow-up period chosen for the outcome analysis process (in percentage). 
 
 
The preferences for certain analysis methods were analysed for each user. As some of 
the methods were used much more often than others, we decided to focus on the 6 most 
commonly used types. The remaining 4 types were summarised in the “Rest” position at 
the end of Table 6.5.4. 
 
The location of the laser practice of each user was added in the table (see “Nat” for 
nation in Table 6.5.4.). In summary, the IBRA users had their origin in 4 different 
countries: 
 Switzerland (CH): 3 users were operating on patients and using the IBRA 
system in Switzerland. These users together used the analysis process 51 times. 
 England (E): this was the main group, consisting of 7 users that had their laser 
practice in England and used the analysis processes of IBRA 1740 times. 
 Ireland (I): 4 users were operating on their patients in Ireland, and used the 
analysis functions of IBRA 662 times. 
 Australia (A): One (new) user in Australia used the IBRA system for analysis 
only 7 times. 
 
 
 
 
154 
User Nat BCVA Predictability Safety SE UCVA Stability Rest Total 
0 CH 2 4 1 0 1 0 1 9 
2 CH 1 1 0 0 36 1 0 39 
65 CH 0 0 0 0 2 1 0 3 
100 E 18 423 53 113 136 8 4 755 
102 E 1 2 0 0 1 0 0 4 
103 E 0 0 0 0 3 0 0 3 
106 E 6 0 0 24 6 0 8 44 
107 E 5 66 20 31 55 19 4 200 
111 E 2 8 14 13 22 1 11 71 
116 E 33 122 141 134 212 1 20 663 
108 I 26 30 26 17 69 13 33 214 
109 I 6 10 59 5 54 14 9 157 
110 I 2 5 3 1 6 2 3 22 
118 I 30 19 16 18 143 24 40 290 
119 A 0 0 0 0 6 0 1 7 
Total  132 690 333 356 751 84 134 2480 
  5.3% 27.8% 13.4% 14.4% 30.3% 3.4% 5.4% 100% 
Table 6.5.4. The frequency of the 6 most commonly used analyses methods for each user. Nations: CH = 
Switzerland (3 users), E = England (7 users), I = Ireland (4 users), and A = Australia (1 user). 
 
 
Users from the same country were grouped, and the single user from Australian was 
excluded. Figure 6.5.4. shows the frequency of the most commonly used analysis 
methods in the remaining 3 countries, in percentage of all used methods. 
 
 
Figure 6.5.4. The frequency of the 6 most commonly used analyses methods for each user group. 
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6.5.4. Discussion 
For this evaluation, additional software modules were developed and implemented into 
IBRA for the data logging process. This process was shown to be effective in collecting 
important user data relating to the use of analysis functions. The data was saved in an 
SQL database on the IBRA server, and then exported into Microsoft Excel for further 
processing. A total of 2480 analysis processes were recorded. 
 
This evaluation showed that most users performed refractive outcome analysis on a 
regular basis approximately once a month. We were surprised by this result, because we 
expected most users to allocate one or two episodes a year for this quality controlling 
process. Obviously, and maybe because the analysis processes were automated and did 
not require any further effort, most users showed a high interest in the outcome analysis 
and used this function more regularly. 
 
One group of users showed a different user pattern. These users performed analysis 
intensively for a short period in January and February 2009, but rarely thereafter. An 
interview with each user identified the reason for this behaviour. A certification process 
for refractive laser surgeons conducted by the Royal College of Ophthalmologist (RCO)  
led  these users to operate the IBRA analysis tools intensively to produce the required 
charts. The figures and outcome results had to be sent to the RCO Committee for 
acceptance before March 2009. Once the results had been submitted, the users no longer 
required the analysis functions of IBRA. This was the explanation for the decrease in 
activity after March 2009.  
 
This evaluation revealed that users prefer to perform one of the 6 recommended Waring 
analysis types (91% of all performed analysis). The 2 most commonly used analysis 
functions were the analysis and comparison of attempt versus achieved spherical 
equivalent refraction (SE Predictability; 30.3%) and the analysis of changes in the 
uncorrected visual acuity (UCVA; 27.8%). The 4 additional, non-Waring type, analysis 
methods implemented in IBRA were almost completely ignored. The vectorial analyses 
seemed to be especially unpopular, and were used in only 0.4% of all analyses. Vector 
analysis is complex, and astigmatic outcome results are difficult to interpret. This could 
be the reason why users were looking for more straightforward analysis methods for 
both calculation and interpretation of the results. This theory was supported by the fact 
that the defocus equivalent refraction, which is the most complex analysis method from 
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the group of Waring analyses, was also used much less frequently (in only 1.7% of all 
analyses). 
 
Nearly 70% of the analysis was performed on the 3 month postoperative results. This 
could be linked to published data (Reinstein 2009, Liu 2008) that showed that refractive 
results do not change after 3 months, and remain stable up to 7 years postoperatively. 
This might also explain why stability analysis was used so rarely (in only 3.4% of all 
analyses), for reviewing refractive changes over a period of one year following the 
operation. The low number of analyses performed from the 6 and 12 month data has 
another reason. The treatment effect is considered to be stable 3 months after surgery. 
Therefore, most patients are discharged at this time, making it impossible to record data 
after 3 months. This is the reason why there is much less data to analyse from these 
follow-ups. 
 
A surprisingly small percentage (3%) of analysis was performed on preoperative data. 
Although outcome analysis mainly means analysis of the postoperative results, it is a 
widely accepted practice to compare such postoperative results (e.g. BCVA chart) with 
the preoperative situation (e.g. loss of BCVA?).  
 
This evaluation showed that users from different European countries share similar 
preferences regarding analysis functions, and perform the analysis predominantly from 
the 3 month postoperative data. The most commonly used methods, independent from 
the geographical location, were the uncorrected visual acuity analysis (UCVA), the 
spherical equivalent predictability analysis, the safety analysis and the spherical 
equivalent histogram analysis. These, again, are methods which all form part of the 
Waring recommendation. 
 
Users from Switzerland very rarely used the 2 analysis functions safety and spherical 
equivalent histogram analysis. The reason for this is not clear, and the low user number 
(3) and number of analysed cases provide space for bias. In contrast, users in Ireland 
showed a higher interest for diversification and used nearly all of the available analysis 
functions of IBRA. 
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6.5.5. Conclusions 
We have shown that IBRA was used frequently for outcome analysis. Most users 
preferred to use the 4 main Waring analysis methods, and to perform the analysis from 
the 3 months postoperative data. 
 
Generally, users liked to perform analyses with methods that were simple to use and to 
understand, and that were recommended by others (Waring analysis). The user pattern 
was not significantly different between users in different European countries. 
 
Future evaluations could add the type of surgery (LASIK or LASEK), and the type of 
preoperative refractive disorder group (myopia or hyperopia) to the recorded data. This 
would allow us to study whether different analysis methods are used for different 
patient collectives. This information could be used for IBRA modifications.  
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6.6. Survey on user satisfaction 
 
6.6.1. Introduction 
The use of a web-based software system is not yet common in ophthalmology and can 
cause scepticism regarding a variety of issues including accessibility, speed and 
security. With the use of descriptive evaluation techniques, our aim for the IBRA 
system was to analyse user satisfaction. For this evaluation we decided to use a 
questionnaire, which would offer a wide range of standardization and would not 
influence the user during the evaluation process (less bias). 
 
A literature review demonstrated more than 10 different questionnaires designed for 
software and interface usability evaluation. Five of these surveys are described in more 
detail in table 6.6.1.  
 
The 'Questionnaire for User Interface Satisfaction' (QUIS) and the 'Software Usability 
Measurement Inventory' (SUMI) were shown to be more common. These two 
commercially available survey systems use a standardized questionnaire. They each 
provide a software tool that analyses the collected data from the questionnaires and 
compares the outcome with a reference database. Unfortunately a report for a single 
analysis costs approximately £1,000, exceeding our budget. 
 
Another survey system was ISO 9126. It uses 6 quality characteristics, similar to the 
criteria we wanted to investigate. We choose ISO 9126 as a basis to create a 'home-
made' questionnaire, implementing main component questions from QUIS Version 5.0 
(1998), adding overall questions and modifying the answering structure (QUIS 7.0). 
 
The aims of the survey were: 
 To analyse different aspects of user satisfaction. 
 To assess the handling of the user interface. 
 To determine the reliability (and safety) of the system. 
 To identify the effect of the system on the decision making process for 
treatments. 
 To evaluate value for money. 
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The objectives were: 
 To design a questionnaire, based on structured interview techniques. 
 To administer the questionnaire to system users. 
 To use qualitative research methods to gain and analyse the results. 
 To interpret the results. 
 To formulate recommendations for system modification. 
 
 
Questionnaire Description 
 
a) Questionnaire for 
User Interface 
Satisfaction (QUIS) 
 
The “Questionnaire for User Interface Satisfaction” (QUIS) aims 
to provide a measure of overall satisfaction. Additionally, it 
evaluates some aspects of the user interface based on user 
opinions. It consists of the following 9 scales: screen, terminology 
and system information, learning, technical manuals and online 
help, system capabilities, online tutorials, multimedia, 
teleconferencing and software installations. A short (47 Items) and 
a long version (126 Items) of QUIS are available. The short 
version should be used, if there are limited time resources, or if 
motivational problems of the user can be anticipated. The use of 
QUIS is charged. 
 
b) Software Usability 
Measurement Inventory 
(SUMI) 
 
The “Software Usability Measurement Inventory” (SUMI) is a 
widely tested method of measuring software quality from the end 
user's point of view. SUMI consists of 50 statements to which the 
user has to reply that they agree, don't know, or disagree. The 
evaluation system is backed by a reference database embedded in 
an analysis and report generation tool. The use of SUMI is 
charged per report (basic fee: 1200 Euro per report). 
 
c) Website Analysis and 
Measurement Inventory 
(WAMMI) 
 
The “Website Analysis and Measurement Inventory” (WAMMI) 
questionnaire chooses questions to capture user‟s personal views 
on the usability of an Internet site. The questions of WAMMI are 
tested and standardized and should not be changed therefore. The 
use of WAMMI is charged. 
 
d) ISO 12119 
 
According to ISO 12119[3] each software product consists of the 
following components: product description, user documentation, 
interface (program), software (data) and package. Main focus of 
ISO 12119 is the product description and package. 
 
e) ISO 9126 
 
According to ISO 9126[5] six quality characteristics are 
established for a software product, which are functionality, 
reliability, usability, efficiency, maintainability and portability. 
Each of the product components (ISO 12119) are evaluated as per 
these characteristics. The main focus of ISO 9126 is the user 
interface and software workflow. 
 
Table 6.6.1. Overview of questionnaires for usability and user satisfaction evaluation. 
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6.6.2. Methods 
For the design and administration we followed a 5 step model presented by Professor 
John Stasko (The College of Computing at Georgia Tech, Atlanta). The 5 steps include 
the aims and objectives of the survey (see introduction), the determination of the 
sampling group, the writing of the questionnaire, the administration of the questionnaire 
and the interpretation of the questionnaire (see discussion). 
 
Determining the sample group 
The sample group of the survey was formed by the surgeons, optometrists and 
secretaries who were using the IBRA system. We aimed for a minimum of 10 
participants to be recruited for the survey. 
 
Writing the questionnaire 
A prototype was designed, and handed to 2 IBRA users for a pilot. The prototype 
consisted of a structured question part with predefined answers (forced choice format). 
The questions were short, precise and neutral (as recommended by Boynton 2004), 
taking no longer than 10 minutes to answer (as recommended by Dorman 1997). The 
feedback from the pilot was implemented into the final design. 
The distributed, final questionnaire is shown in Appendix 10. It comprises a cover 
letter, followed by a section with personal questions and then the main section with 6 
questions on general use, 18 questions on different aspects of interface use and 
satisfaction, and 3 overall questions (costs, significance and uniqueness). The questions 
were scored on a 9 point scale. If the question was not applicable, the participants could 
state this with ticking the box 'NA'. 
 
Administering the questionnaire 
The questionnaire was emailed to 7 participants, and handed over personally to 6 
participants. They were each given 2 weeks to complete the survey and return it via 
email. A reminder was sent to those participants who had not returned their surveys 
within 4 weeks. The scored answers were entered into a database (Excel) for further 
analysis. 
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6.6.3. Results 
 
Raw data 
The raw data is shown in Table 6.6.2. 
 
User Sex Age Gr Exp S Exp I Usage Similar G1 G2 G3 G4 G5 G6 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 C1 C2 C3
User 1 f 2 4 4 3 0 8 7 7 7 8 8 8 7 x 8 7 7 7 x 8 7 7 8 7 x x x
User 2 m 3 1 3 1 0 8 7 4 8 8 7 9 8 8 8 8 9 9 x 9 6 9 x x 6 9 9 8 9 5 9 8
User 3 f 4 1 4 3 0 7 7 7 7 5 x 8 8 8 8 8 8 8 x 6 8 9 8 x 5 7 7
User 4 m 2 1 1 2 0 7 7 7 7 7 7 7 7 8 7 7 7 8 7 7 6 7 7 7 8 8 8 7 7 4 7 7
User 5 m 4 1 4 4 0 8 8 8 7 9 8 8 8 8 8 9 8 8 x 9 7 8 x x 9 9 9 8 7 6 9 8
User 6 m 2 2 4 1 1 6 6 5 7 4 3 8 8 8 8 8 8 3 8 8 5 4 8 x 8 8 8 6 6 6 x 3
User 7 m 3 1 4 1 0 5 4 4 8 3 1 4 3 2 7 6 2 2 x 8 4 3 5 4 2 8 8 2 4 4 2 1
User 8 f 2 1 3 2 0 7 7 7 8 8 7 6 5 5 6 7 6 6 7 8 8 7 8 x 5 7 8 8 7 x x 8
User 9 m 4 1 4 1 0 8 2 8 1 1 7 7 8 8 8 8 8 8 x 1 1 1 7 7 8 8 8 8 8 5 9 9
User 10 f 2 4 2 2 1 6 7 4 6 7 8 7 8 8 8 8 8 6 8 8 7 9 x x 9 9 x 3 5 x x x
User 11 m 3 1 4 3 0 7 8 7 8 8 8 5 6 6 7 8 8 8 7 9 8 8 7 7 8 9 9 8 7 6 9 8
User 12 m 2 2 4 3 0 6 8 7 8 5 3 7 5 x 8 8 x 3 3 6 8 9 x 5 6 9 8 x 7 5 8 4
User 13 m 2 2 2 2 1 6 8 8 8 8 2 7 8 6 6 7 7 4 x 8 3 6 5 x 8 8 7 4 5 4 8 6  
Table 6.6.2. Replies from all 13 users (raw data). 
 
 
Participants reply 
The collection of all replies was delayed by 3 months, despite the emailing of multiple 
reminders to participants. When we eventually received all 13 completed 
questionnaires, we used them for the analysis. 
54% of the participants were under age 40 (Figure 6.6.1. A). Eleven of the participants 
were refractive surgeons, one participant was a secretary and one an optometrist. Eight 
of the surgeons had more than 3 years' experience in refractive surgery (Figure 6.6.1. 
B). Most participants had been using the system for more than one year (Figure 6.6.2. 
A). Three participants had experience with other refractive software. 
 
 
 
      
 
Figure 6.6.1. Participants demographics: A: age; B: surgical experience. 
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Figure 6.6.2. Participants demographics: A: Experience with the IBRA system; B: Frequency of IBRA 
use. 
 
Outcomes 
We grouped the different questions in relation to their characteristic (e.g. Terminology), 
and performed group analysis with mean and standard deviation (Table 6.6.3. and 
Figure 6.6.3.). The scoring for each question is shown in Table 6.4.4. The meaning of 
the lowest (1pt) and highest scoring (9pt) is also expressed in the table. Generally, high 
scoring was linked to a positive result. 
 
 Characteristics Mean SD 
 General use 6.4 1.9 
 Screen (presentation) 6.9 1.6 
 Terminology 7.0 1.5 
 Learning 6.6 1.9 
 Capabilities 7.8 1.1 
 Interface (interaction) 6.5 1.8 
 Overall 6.3 1.9 
Table 6.6.3. Mean scoring with standard deviation (SD) for each characteristic. 
 
 
 
Figure 6.6.3. Questionnaire scores for each characteristic (with SD). 
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No Question Selection 
from (1pt) 
Selection 
to (9pt) 
Replies Sum 
(pt) 
Mean SD Range Ind 
G1 The general use of the 
system is... 
terrible wonderful 12 81 6.8 1.0 5-8 1 
G2 The general use of the 
system is... 
frustrating satisfying 12 79 6.6 1.8 2-8  
G3 The general use of the 
system is... 
dull stimulating 12 76 6.3 1.6 4-8  
G4 The general use of the 
system is... 
difficult easy 13 91 7.0 1.9 1-8  
G5 The general use of the 
system is... 
inadequate adequate 12 73 6.1 2.5 1-9  
G6 The general use of the 
system is... 
rigid flexible 11 61 5.5 2.7 1-8 2 
1 Characters on the 
computer screen 
hard to read easy to 
read 
13 90 6.9 1.3 4-9 3 
2 Organization of 
information on the screen 
confusing very clear 13 89 6.8 1.6 3-8  
3 Sequence of screens confusing very clear 12 82 6.8 1.9 2-8  
4 Use of terms throughout 
system 
inconsistent consistent 12 89 7.4 0.8 6-8 4 
5 Computer terminology is 
related to the task you are 
doing 
never always 12 92 7.7 0.8 6-9  
6 Position of messages on 
the screen 
inconsistent consistent 11 79 7.2 1.9 2-9  
7 Computer keeps you 
informed about what it is 
doing 
never always 12 72 6 2.4 2-9 5 
8 Error messages unhelpful helpful 6 40 6.7 1.9 3-8 6 
9 Learning to operate the 
system is 
difficult easy 13 97 7.5 2.1 1-9 7 
10 Exploring new features by 
trial and error 
difficult easy 13 78 6 2.2 1-8  
11 Tasks can be performed in 
a straight-forward manner 
never always 13 86 6.6 2.5 1-9  
12 Help messages on the 
screen are 
unhelpful helpful 9 62 6.9 1.2 5-8  
13 Supplemental reference 
materials 
confusing very clear 5 30 6 1.4 4-7 8 
14 System speed too slow fast 13 91 7 2 2-9 9 
15 System reliability unreliable reliable 13 107 8.2 0.7 7-9  
16 System security unsafe safe 12 98 8.2 0.7 7-9  
17 Correcting your mistakes difficult easy 12 78 6.5 2.2 2-8 10 
18 Experienced and 
inexperienced users' 
needs are taken into 
consideration 
never always 12 79 6.6 1.4 4-9  
C1 How do you assess the 
costs of the system? 
too 
expensive 
to cheap 10 50 5 0.8 4-6 11 
C2 How do you assess the 
significance of the system 
on your practice? 
low high 9 68 7.6 2.2 2-9 12 
C3 How do you assess the 
uniqueness of the system 
in your field of expertise? 
low high 11 69 6.3 2.5 1-9 13 
Table 6.6.4. Questions and questionnaire scores (Mean, SD, and Range). The index numbers (Ind) relate 
to the numbers used in the discussion part. 
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6.6.4. Discussion 
From a general point of view the IBRA system scored well and there was not much 
difference between the characteristics. With an emphasis on highest and lowest scorers, 
and also standard deviation, we will discuss the results from the different characteristics 
in the following parts. The index numbers at the beginning of each paragraph, for 
example (1), refer to the index numbers in the last column of Table 6.6.4. 
 
General use of the system 
(1) The general use of the system was scored as satisfying, stimulating and easy. 
(2) About 50% of the users considered the system to be rigid. This question received the 
second lowest scoring of all questions and showed the highest standard deviation of the 
scoring. In particular, one user experienced difficulties learning to operate the system 
(performing tasks, exploring new features) and submitted a very low score. 
 
Screen 
(3) Good scoring was received relating to the displayed information and the style in 
which the software displayed the characters on the screen, allowing the information to 
be read easily. Information was arranged and organised on the screen clearly, and the 
sequence of screens was assessed as clear. 
 
Terminology 
(4) The users were happy with the formulation of messages, the position in which the 
messages were placed on the screen and the consistency of messages displayed 
throughout the system. They stated that the terminology was related to the task. This 
positive feedback might be based on the fact that the system used a lot of ophthalmic 
terminology. Generally, medical language is complex but precise. This supports 
understanding, and can lead to a reduction in critical incidents. 
(5) Many users were not pleased with the information the system provided regarding 
„what the system is doing‟. This might be linked to the fact that the system is very quick 
in performing tasks and therefore rarely creates long enough  waiting times to ask the 
question „What is the system doing right now?‟. 
(6) Most users realised that the system did not report error messages, and answered the 
question with „not applicable‟. The software was designed in such a way that every task 
produced a result. Some users had problems with the data analysis and found that the 
description of the „selection fields‟ was not clear enough. We believe that IBRA could 
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be improved with a validation system to check field entries, including the ones from the 
selection part, before performing the analysis; and if they are completed incorrectly, the 
system could show an error message with guidance for correction. 
 
Learnability 
(7) There was a wide range of scoring for the questions regarding learnability. Although 
most users stated that IBRA was easy to use, there were 2 users in particular who had 
difficulties in learning and understanding the system, and also in understanding 
functions relating to system performance. 
(8) As the system did not provide a detailed user manual, the response to question 13 
was often „not applicable‟. Similarly, a help message only occurred on one site where 
the task was more complex. 
 
Speed, reliability and security 
(9) Good scorings were seen regarding speed, reliability and security. The system was 
assessed as reliable and safe. These questions scored highest, with the lowest standard 
deviation. As the system is web-based, the speed of the Internet connection, the power 
of the personal computer and the used Internet browser were relevant too. In addition, 
time of day of use of the system was significant, as the Internet generally slows down in 
a hospital network during the normal working hours with more users causing higher 
data traffic. Despite any possible restriction, most users rated the system speed as 
'sufficient' or 'fast'. 
 
User Interface 
(10) The questions 17 and 18 on user-interface and error messages were answered too 
heterogeneously, reflecting the fact that the questions were difficult to answer in the 
provided context (mainly question 18), and that generally the system did not show error 
messages. 
 
Overall questions 
(11) The questions on costs (question C1) could only be answered by participants who 
would buy such a system, i.e. surgeons, who considered the price of the system too high 
(£490 for 1 year's usage). The related question received the lowest scoring in the entire 
questionnaire. 
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(12) As for the costs issue, the question on clinical significance could only be answered 
by refractive surgeons, as only they would use the results from the IBRA outcome 
analysis to modify the treatment parameters (nomograms). The high scoring for this 
question showed a general satisfaction with the system and the provided support in 
decision making. 
 
(13) Although the significance of the system was generally assessed as high, the 
uniqueness of the system was assessed as moderate. The lower scoring was caused by 1-
2 very low scorings from 1 user who had previously assessed the system as rigid. 
 
 
 
6.6.5. Conclusion 
 
Summary of strengths 
This survey showed high user satisfaction, with a mean scoring of 6.7 from 9 points. 
The user interface, the screens and sequences of sites related to tasks were stated to be 
clear. The system was acknowledged to have a significant importance in the decision 
making process (Table 6.6.5.). Users were pleased with the reliability of the system and 
satisfied with the speed of the web-based application. Overall, users provided an 
impressive positive statement on „tender points‟, such as safety and security issues, 
which is important for the wider acceptance of this technology and the future success of 
the IBRA system. 
 
 
Strengths Weaknesses 
  Significance (supports decision making) 
  Security 
  Reliability 
  User-interface and speed 
-  Rigidity 
-  Documentation 
-  Learnability 
-  Price 
Table 6.6.5. Summary of user satisfaction. 
 
 
Summary of weaknesses 
The main criterion was system rigidity. Although rigidity increased the reliability of the 
system (homogenisation of the entered data provided better analysis), the decreased 
flexibility was not appreciated and did not reflect the newest developments of web-
based software applications. Such newer systems, as seen for example on the current 
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BBC website (Glow, a JavaScript library), present information in content boxes that can 
be edited by the user and freely positioned on the screen (drag and drop widget). A 
similar structure could be implemented into IBRA too, but this would require a 
complete re-design of the current user-interface and a change of large parts of the 
program code. 
The price of the system was assessed to be too high; and many users requested a user 
manual and criticized the spare documentation provided with IBRA, as well as the 
limited guidance through the system. 
 
Recommendations for future development 
With future upgrades, some of the criticized points can be improved and, primarily, 
effort should be put into the production of a user manual (or of video tutorials), 
including a section on „Introduction to IBRA‟. A review of the price should follow. 
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7. DISCUSSION 
 
7.1. Achievements related to the research objectives 
In this section we will discuss the achievements of the research in view of the main 
clinical objectives as formulated at the beginning. Generally, we tried to follow the 
objectives as close as possible. 
 
 
Objective 1 
To develop a system that can combine data collection and analysis 
and offer tools for standardised outcome presentation. 
 
The starting point of this research was a simple FileMaker application for data 
collection. The permanent re-development and continuation of improvement, combined 
with a determination for completeness, made this system grow to a multi-functional, 
user-friendly data analysis system. The range of implemented refractive analysis 
techniques, including outcome analysis with Waring graph creation, nomogram analysis 
and vector analysis, made this system unique to the market. 
 
While the analysis of data is much appreciated by the surgeons, data collection is time 
consuming and perceived as a troublesome undertaking. For the first time, the required 
amount of work could be determined in seconds. This research also contributed 
information on data collection techniques and we could indicate the most time effective 
approach. This is important, as a lengthy process could compromise continuation of 
data collection and could lead to early termination of outcome analysis. The results from 
this research identified the data entry process with the one-go technique as the fastest 
way to enter the data into IBRA. Up to 27 cases could be entered with this approach per 
hour, enabling the surgeon to perform 5 of 6 Waring graphs finally. We have submitted 
an article to Eye, a peer-reviewed Journal, to publish our results. 
 
The final version of IBRA offered 10 analysis methods, including the 6 standard 
Waring graphs. With the use of data logging processes we investigated which analysis 
methods are liked by refractive surgeons, and which are not. The results from our study 
showed that the majority of surgeons only use 4 different analysis methods, which are 
all from the set of Waring analyses. The remaining 6 methods were ignored almost 
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completely. The popular analysis methods are among the less complex ones, and we 
believe that it is this that made the difference. These graphs are used because they are 
easy to create and easy to understand; and it appears that surgeons prefer methods that 
do without the fancy stuff and go for the simple and straightforward. 
 
Monitoring user activity and analyzing the outcome analysis procedures allowed us to 
identify key aspects of activity. This research showed that users performed the outcome 
analyses separated for each of the 5 refractive disorder groups, although this was not 
facilitated by the IBRA system automatically. The separation seems to make sense. 
Surprisingly, this concept has never been published and we know that some surgeons 
are clearly not aware of it or would know how to do it. We therefore aim to report on 
this aspect, and we will publish our results and experience in an ophthalmic journal 
within the next 12 months. In addition, we recommend modifying IBRA allowing 
separation and analysis of patient data based on the different refractive disorder groups, 
e.g. all patients with compound myopic astigmatism. 
 
 
Objective 2 
To make the system easily accessible, secure, safe, flexible 
and capable of future developments. 
 
Many surgeons provide services to different hospitals at different locations. The pre-
assessment for laser vision correction is usually performed in the private practice unit. 
The laser treatment is then undertaken in a centre specialised for laser treatments, 
providing the expensive laser equipment to many surgeons. Finally, the follow-up might 
be held in the private unit, in the clinic of a general hospital or at an optician‟s practice. 
As the data is created at different locations, so the software system for the data 
collection needs to be accessible from these locations. For many years the hospital‟s 
Intranet was regarded as the only solution for access of software programs at different 
locations in the same hospital. This research showed the inefficiency of Intranet-based 
systems for refractive eye surgeons. 
 
Web-based software systems are easy to access from any computer with Internet access. 
When this research was started, such systems were rarely seen in hospital environments 
and we were faced with the critical view of the surgeons. Questions about security and 
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reliability challenged the system development of IBRA initially, and we believed that 
these aspects could get out of control and endanger the further system development. The 
increasing popularity of the Internet and the introduction of e-banking systems caused a 
reduction of adverse attitudes over the years. Phenomenally, also, the acceptance of 
web-based system in ophthalmology increased so much that questions on speed 
(question 14), reliability (15) and security (16) scored the highest of all questions in our 
survey; and showed the smallest difference between the replies. 
 
This research lead to the development of the world-wide first refractive analysis 
software that was completely web-based. The results from the user satisfaction survey 
have proven that the perception of Internet technology has changed, and that web-based 
systems can be well accepted even by critical surgeons. We believe that the continuous 
attention to details, the high system reliability, the permanent accessibility, the right 
level of security measures with password protection and encrypted connections, and the 
privacy protection were important precursors for this acceptance. 
 
The web-based programming platform was also received positively from the developer's 
point of view. HTML, PHP and JavaScript offered all the tools to develop complex 
software systems and to extend them with ready-made add-ins, e.g. for the creation of 
charts or pdf files. Many of the tools were freely available and 'home-made' tutorials 
explained how to integrate the extra features into the software system. 
 
The positive user feedbacks and our own convincing experience made us believe that all 
system developers should include the range of Internet technologies into the evaluation 
when planning software projects for medical professionals. 
 
 
Objective 3 
To develop and integrate means that can provide information 
on how refractive laser treatments could be improved. 
 
Without doubt, the Waring graphs are helpful in analysing the quality of laser vision 
correction. For example, they report exactly how many eyes had 6/6 uncorrected visual 
acuity after surgery, or how many eyes were within 0.5 D of emmetropia. The Waring 
graphs may also indicate errors in treatments. For example, if a high percentage of 
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myopic eyes end-up significantly hyperopic, an overcorrection is diagnosed. However, 
the Waring graphs do not provide accurate information on how the treatment could be 
optimised. This is the domain of nomogram calculation. 
 
We performed linear regression analysis and best fit analysis on spherical and 
cylindrical outcome data to determine outcome formulas. These formulas were 
integrated into a calculation algorithm that could determine treatment adjustment 
factors. The surgeon could use these factors at the stage of treatment programming to 
optimise the nomograms of the laser controller software. Although other software offer 
nomogram functions (e.g. Datagraph-med), none of these systems integrated the 
calculation algorithms in a form that could provide adjustment factors for groups or 
individuals; this is unique to IBRA. With the creation and implementation of the 
nomogram formulas, IBRA changed its character from a quality reporting to a quality 
controlling system, supporting the surgeon in decision-making. 
 
 
Objective 4 
To test the system in a clinical environment 
with real patient treatments. 
 
In this research we performed extensive testing of the IBRA system at Moorfields Eye 
Hospital NHS Foundation Trust, and at 4 laser centres in the north of England and 
Ireland. At the end, the IBRA system was used by a total of 11 surgeons. These users 
were all specialists in refractive laser eye surgery and some of them already had 
experience with refractive analysis software. It was therefore interesting to see how they 
would perceive and accept the web-based IBRA system in their daily practice. A survey 
on user satisfaction showed generally high scoring in most fields. In particular, the users 
seemed to like the easy use of the system and attributed a high clinical significance of 
the system. Another point that was much appreciated was the accessibility of the system 
from different locations, and in fact, monitoring of users‟ IP address showed that IBRA 
was used from many different locations (office and home). 
 
As the data is gained at the preoperative, intraoperative and postoperative visits, we 
aimed to find out how the data finally was entered into IBRA by each surgeon. Many 
questions about it persist. For example, how much time does it take to enter the data for 
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one treatment? Is it fast to enter the data in one-go or stepwise with the visits? Will we 
see learning curve effects? Therefore, during a period of 1 year, we monitored the data 
collection processes with data logging technologies, running in the background of 
IBRA. Although we emphasised the importance of collecting a standard set of 44 
parameters for each patient in a step-wise method, the analysis of the monitored 
processes showed that most surgeons did not follow this recommendation and entered 
either a smaller or larger amount of data (22 or 52 parameters), or used a different 
approach (one-go method). This allowed us to compare the different methods and data 
sets and to identify the quickest data entry method, which was the one-go method. 
Further, we could show that there was an experience curve effect reducing the time 
requirements by up to 26%. 
 
This research was the first research in London (maybe the UK) that prospectively 
evaluated the influence of nomogram adjustment on the outcome of patients treated in a 
private setting. To find refractive surgeons willing to undertake research on their private 
patients proved complicated. The refractive surgeons feared that the extra risk of the 
clinical trial could reduce the confidence of their private patients in the offered 
treatment. As a consequence, this could reduce the word of mouth advertising and could 
finally damage the surgeon‟s reputation. In consideration of the facts, we were delighted 
to find, with Professor Gartry, a partner in undertaking a series of prospective outcome 
analyses on his private patients. 
 
This research showed that the IBRA system was an excellent instrument in collecting 
refractive data and undertaking clinical audits on a large series of patients. Our two 
audits included 2011 treated eyes and ran over a period of 24 months. During this time, 
no problems were encountered in using IBRA for the data collection, and notably, there 
was permanent access to the system. 
 
We have shown that IBRA can identify patient groups with over- and undercorrection 
effectively; that it can calculate accurate nomograms for adjustments of future 
treatment, and that these modified treatments can lead to the desired health outcome 
change. The integrated algorithms worked effectively for simple myopia and myopic 
astigmatism, but did not work sufficient for hyperopia. 
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Further, we have proven that the concept of nomogram adjustment can bring benefit to 
wavefront guided treatments. This stays in contrast to a widely accepted opinion and 
practice. 
 
 
Objective 5 
To evaluate the system impact on patient’s health. 
 
The formulas we developed based on theoretical models we created. This has not been 
done before and therefore there was no evidence that it would lead to the attempted 
change. In contrast, if the treatment adjustment would show a malfunction it could even 
damage the eye and worsen the outcome. We had to be very careful with the 
determination of the adjustment factors to minimise the risk as much as possible.  
 
To evaluate our formulas, the nomogram adjustment and their effect on health changes, 
we performed two large studies: a study on 2 consecutive audits evaluating general 
nomogram adjustments for common refractive disorders and a randomised controlled 
trial evaluating patient-individual nomogram adjustments for patients with myopic 
astigmatism. 
 
The results from the studies showed that the new formulas were effective in general 
nomogram modifications, achieving between 75-84% of the intended change. These 
adjustments were limited to the change of the treatment spherical equivalent and applied 
to all patients from a refractive disorder group in the same way. For example, patients 
with simple myopia showed a mean over-correction of 0.27D in the first audit. As a 
consequence, the treatment sphere, as programmed in the laser, was lowered by 0.25D. 
The results of the second audit showed an average effective change of the spherical 
equivalent of 0.21D for the simple myopes. Similar changes were made for 2 other 
refractive disorder groups. 
 
This research showed that all myopic eyes (simple and astigmatic myopia) performed 
well with the treatment modifications, while the hyperopic eyes did not show the 
desired change in spherical equivalent. The reason for this could be the very different 
ablation profile that is applied during the surgery (Figure 7.1.1). Briefly, myopic 
treatments remove tissue from the centre of the cornea in the shape of a discus, finally 
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flattening the cornea. Hyperopic ablation profiles have a ring shaped structure that looks 
like a doughnut; finally steepening the central corneal curvature. Further research is 
required to investigate nomogram adjustment effects in relation to the ablation profile. 
 
Figure 7.1.1.  Ablation profile for myopic treatments (left) and hyperopic treatments (right). 
 
To analyse patient-individual health changes, we undertook a randomised controlled 
trial on 79 eyes with myopic astigmatism. Every patient received a different 
modification, based on spherical equivalent and cylinder value, as assessed 
preoperatively. This clinical trial showed that the 2 groups performed significantly 
differently, and that the difference was caused by the nomogram adjustments. The 
results of this trial confirmed the effectiveness of nomogram modifications on spherical 
changes, but revealed a lack of effectiveness of astigmatic changes. Statistically, we 
could not identify a difference in postoperative astigmatism between the 2 groups, 
though this is what we aimed for. Further research is required to evaluate cylinder 
modifications in nomogram adjustments, and the effect of other parameters that could 
influence the postoperative outcome (e.g. age or healing processes). 
 
Statistically, there was no difference between the randomised groups relating to loss of 
Snellen lines, the number of patients with over-corrections, under-corrections or 
outliers, and the number of patients requiring additional treatments (enhancements). The 
results of this research showed that carefully planned nomogram modifications are safe, 
and can therefore be performed by any surgeon with minimal risk. 
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Objective 6 
To improve the understanding of nomogram adjustments. 
 
From a general point of view, nomogram adjustments require careful data collection. 
We have demonstrated that there are different ways to manage the data collection, and 
have outlined the pros and cons of each of these. 
 
This is the first research that has clinically proven the effectiveness of nomogram 
adjustment in large private practice series. We demonstrated that changes of spherical 
equivalents can be achieved with high precision. On the other hand, patient-individual 
modifications were not superior to general treatment modifications. In part, this is 
linked to the refractive cylinders, which seem to be more resistant to adjustments. 
Further, we learned that hyperopic nomogram adjustments perform differently to 
myopic adjustments and require more investigations. 
 
 
7.2. Publications and Presentations (July 2010) 
This research has been subject to many publications and presentations (Table 7.2.1., 
Table 7.2.4 and Table 7.2.5.). The process of publishing the results and experiences 
from this research is still ongoing. Some articles have been submitted to peer-reviewed 
Journals (Table 7.2.2.), others are in preparation (Table 7.2.3.). 
 
No Authors, Title, Journal 
1 Zuberbuhler B, Schipper I. Proexcimer - Refractive database and analysis for laser excimer 
surgery. Ophta 2003,6,25-27. 
2 Zuberbuhler B, Galloway P, Reddy A, Saldana M, Gale R. A web-based information system for 
management and analysis of patient data after refractive eye surgery. Comput Methods 
Programs Biomed. 2007 Dec;88(3):210-6. 
3 Joung M. Comparing surgery results. Eye World 2008, online article ID 4386.  
4 Finnegan G. Online audit system helps surgeons improve results by tweaking algorithms. 
Etimes Jan 2009 
5 Bucher C, Zuberbuhler B, Goggin M, Esterman A, Schipper I. Corneal limbal marking in the 
treatment of myopic astigmatism with the excimer laser. J Refract Surg. 2009 Sep 2:1-7. 
Table 7.2.1. Published articles on IBRA 
 
 
No Title Submission 
1 Management of data entry processes in refractive laser eye surgery Eye, 22.6.2010 
2 Patient satisfaction after laser vision correction Eye, 19.6.2010 
3 Multi-centre study on refractive outcomes of LASIK and LASEK for 
different refractive disorder groups  
BJO, 29.7.2010 
4 Nomogram adjustments for myopes and hyperopes in LASIK Ophthalmology, 
2.8.2010 
Table 7.2.2. Articles submitted to the Journal 
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No Title Journal 
1 Difficulties in undertake private practice research in the UK BMJ 
2 Visual outcomes in a large multicentre study Eye 
3 Comparison of refractive analysis systems CMPB 
4 How to analyse refractive data - Update on the Waring graphs JCRS 
5 Patient-individual nomogram adjustment in refractive laser surgery - 
a randomised controlled trial. 
Klimo 
Table 7.2.3 Articles in preparation 
 
 
No Date Format Title Venue 
1 07.06.2003 Guest 
Speaker 
Management of patient data after 
refractive surgery 
6th Swiss Refractive 
Congress, Lucerne 
2 09.09.2003 Free 
Paper 
Analysis of patient data following 
LASIK (Laser in-situ 
keratomileusis) 
XXI Congress of the 
ESCRS, Munich 
3 07.06.2004 Guest 
Speaker 
Refractive outcome analysis with 
IBRA 
7. Swiss Refractive, Lucerne 
4 24.06.2004 Free 
Paper 
Internet Based Refractive Analysis 17. Congress of the DOC, 
Nürnberg 
5 May 2008 Guest 
Speaker 
Introduction to IBRA 
 
Annual Refractive Meeting, 
Moorfields Eye Hospital 
6 02.12.2008 Guest 
Speaker 
Refractive Outcome analysis Basic LASIK course, 
Moorfields Eye Hospital, 
London 
7 March 2009 Transfer 
Seminar 
Internet Based Refractive Analysis Centre for Health 
Informatics, City University 
8 06.11.2009 Guest 
Speaker 
Refractive data collection and 
analysis using outcome analysis 
software. 
Optimax Annual Meeting, 
London 
Table 7.2.4. Presentations held at international congresses 
 
 
No Date Format Title Venue 
1 18.09.2004 Poster Internet Based Refractive Analysis 97th Congress of the Swiss 
Ophthalmological Society, 
Lugano 
2 05.05.2009 Poster Refining algorithms in laser in-situ 
keratomileusis using IBRA. 
Centre for Health 
Informatics, City University 
3 19.05.2009 Poster Importance of outcome analysis in 
laser in-situ keratomileusis 
Annual Congress of the 
RCO, Birmingham 
4 25.05.2010 Poster Refractive outcomes of LASIK – A 
United Kingdom multicentre study 
The Royal College of 
Ophthalmologists Annual 
Congress, Liverpool 
5 25.05.2010 Poster United Kingdom multicentre study 
comparing visual outcomes of 
LASIK and LASEK for myopes 
and hyperopes 
The Royal College of 
Ophthalmologists Annual 
Congress, Liverpool 
6 25.05.2010 Poster Patient Satisfaction Outcomes 
following LASIK and LASEK in a 
large United Kingdom multicentre 
study 
The Royal College of 
Ophthalmologists Annual 
Congress, Liverpool 
7 25.05.2010 Poster An Analysis of the time 
requirement for the data entry 
process for refractive outcome 
analysis 
The Royal College of 
Ophthalmologists Annual 
Congress, Liverpool 
Table 7.2.5. Poster presentations 
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7.3. Limitations and recommendations 
 
7.3.1 System related limitations and recommendations 
Although there are many positive aspects about the IBRA system with generally high 
user satisfaction, we were able to identify some points that need to be addressed for 
future development. We have split these corrections into „must have‟ and „nice to have‟ 
features, and we will discuss the individual topics below. 
 
One new insight we gained from this research is the fact that refractive outcome 
analysis has to be performed for each refractive disorder group independently, as these 
groups perform differently clinically. This concept cannot be addressed by IBRA 
accurately. Although the system allows multiple ways of case selection, the separation 
of the different groups has to be done manually by coding the groups. This is 
inconvenient, and the next IBRA update will need to address this problem with a new 
analysis module. This module could implement another finding of this research: the fact 
that most surgeons use only 4 Waring analyses for the outcome presentation, and that 
they read out key results from each analysis, e.g. how many patients (in %) were within 
0.5D of emmetropia. For the IBRA update, we recommend presenting the outcomes in a 
table where the rows mark the 5 refractive groups and the columns are formed by the 
key results from the 4 analysis methods. We believe that IBRA should offer this or a 
similar table soon, as it will make a major contribution to the provision of refractive 
outcome analyses. 
 
This research underpins the fact that refractive analysis is only as good as the data that 
was entered before. The analysis of the data of the 2 audit cycles with more than 2000 
treatments showed that the data was not distributed homogenously, mainly for 2 
reasons. Firstly, the wrong data was entered. This data error can be overlooked, 
especially if the entered false data still looks potentially reasonable, e.g. with 
punctuation errors such as the spherical equivalent of -12.5D instead of -1.25D. 
Secondly, every treatment has a natural distribution of results, and the existence of 
outliers is normal in any distribution. Many of the outliers in ophthalmology are linked 
to medical conditions. One common condition in high myopic eyes is called amblyopia, 
a disorder of the visual system that is characterized by poor or indistinct vision in an eye 
that is otherwise physically normal. This could lead to the situation of a patient having 
6/12 uncorrected visual acuity with the right eye and 6/6 with the left eye, although both 
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eyes are emmetropic. How can we identify outliers and how can they be separated 
between data entry errors or disease? We strongly believe that IBRA should have a tool 
that allows, in a first action, to identify outliers and marginal data. The identified data 
then can be checked manually for entry errors or ocular history. In a second step the 
software should be able to mark the outlier data so it can be excluded from the general 
analysis. This would certainly provide a better representation of the average population, 
and could increase the precision of the general nomogram calculation. Such an outlier 
module should be implemented into IBRA as soon as possible. 
 
Other points that could improve the system in the future are listed below. 
 One user made an interesting request. He was asking for a way to gain an 
overview of one particular patient‟s treatment; summarising the multiple 
treatments this patient underwent in one table or figure on a single page. 
Currently, IBRA does not offer such a patient related presentation of the data. 
All presentations are treatment related and are presented in lists of cases (1 case 
= 1 treatment). While patients normally only have 2 treatments (one for the right 
eye, one for the left), reflected by 2 cases, the existing summary in the case list 
might provide a satisfying overview. On the other hand, up to 10% of patients 
undergo 2nd or 3rd treatments and might have up to 6 treatments in total. We 
believe that the request from the user is significant, and we plan to develop a 
module for IBRA that will show a summary of the treatments (cases) of a 
specific patient in a simple form. This would allow the surgeon to review a 
patient's treatments as a whole and might provide valuable insight, especially in 
situations where the treatment was less than optimal. 
 This research showed that the collection of a minimal data set (22 parameters) in 
a one-go technique was the quickest way to enter the treatment data. Currently, 
these 22 parameters are spread over 4 different pages. We believe that we can 
accelerate the data entry process with a re-arrangement of the 22 parameters on a 
single „summary page‟. This would minimise navigation through the pages, and 
would simplify the search for specific fields out of the offered selection. 
 Some surgeons use an electronic patient record (EPR) system in their private 
practice. These systems allow the extraction of data from connected, 
„freestanding‟ diagnostic equipment, such as perimeters and auto-refractors. The 
measured data then can be presented with the EPR tools for analysis. This is 
particularly helpful in the management of glaucoma patients (pressure curve) or 
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cataract patients (visual acuity curve), which make the „bread and butter‟ of a 
private practice. Besides the clinical application, the EPR system is used to 
arrange the next appointment, to code the diagnosis and treatment, and to 
invoice the patient. Generally, the EPR system has become irreplaceable in 
many private practices, and a link between the EPR and IBRA is desirable. This 
would minimise the chance of double data entry processes and increase the 
acceptance of IBRA among users who already have an EPR. The data transfer 
could be performed either via SFTP (SSH File Transfer Protocol) or FTPS (FTP 
over SSL), which adds SSL encryption to FTP (as specified in RFC 4217). 
 Potentially, IBRA could also be linked to laser controller software, allowing 
adjustment of laser settings directly from the IBRA user-interface. This option 
bears high potential but could be risky in the case of malfunction of the 
application. We contacted 2 manufacturers (WaveLight and Bausch&Lomb) 
with the idea. The concept was regarded as interesting, but no manufacturer was 
happy to invest in such an implementation at this time. 
 Another interesting field of development could be the involvement of patients in 
the process of data recording. A software module could be implemented into 
IBRA that would allow patients to access their treatment cases and to provide a 
feedback related to the course of healing, comfort (pain) or visual change. With 
this additional information the system could become more content-rich yet 
remain succinct and efficient for the surgeon. 
 
 
7.3.2 User related limitations and recommendations 
The user satisfaction survey showed generally high scores. One field that was identified 
with potential for improvement related to „supplemental reference materials‟. We have 
to admit that the documentation is an issue we neglected for a long time. At the 
beginning of the development we believed that, in keeping the user-interface as simple 
as possible, the software would also be easy to use. With the implementation of vector 
analysis and nomogram calculations, the software became much more complex and the 
IBRA screen was now filled with selection fields, data entry fields and action buttons. 
Although we re-arranged the user-interface, the application might remain confusing for 
the more amateur computer user. We acknowledge that documentation is required. We 
believe that good documentation could be a great help in understanding all the features 
of IBRA, and that it could include recommendations related to the management of data 
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collection and analysis, as gained from this research. As IBRA is based on Internet 
technology, we think that the documentation should either take the form of a brochure 
in pdf file format or, in line with time and technology, a video tutorial from screen-
recording. As this is important, it is one of the tasks we will address with the next 
upgrade of IBRA. 
 
A second important issue is linked to user support. The lack of documentation, as 
reported above, had a significant consequence to our support system. We received many 
emails, mainly from new users of the software, requesting information regarding the 
data entry process and analysis methods. To facilitate an easier start-up, we tried to visit 
the user and to demonstrate the software on their computer. This was possible at 
Moorfields in London, but how could we do this with users in Dublin, Leeds or 
Germany? Another concept was required. A feasible alternative method, which we tried 
a few times, was to use IBRA simultaneously from different locations (while we used 
IBRA at the University, the user accessed IBRA in the clinic). To allow synchronicity 
of use we were also linked via phone line, allowing us to explore and discuss the 
functions of IBRA step by step. A full demonstration of the features of IBRA took 
about 30 minutes. Those surgeons introduced to IBRA in this way very much 
appreciated this method and send less emails with support requests. The negative side of 
this system was that it required planning of appointments for the demonstration and that 
we could not see what the user was doing on the screen. Sometimes, when there was a 
problem with the use on the surgeon‟s side, we simply couldn‟t find out why it 
happened. This made us look into other technologies and, in particular, one system 
caught our attention; it was the use of the TeamViewer software. This system required 
the installation of the main program on our computer, and an installation of a smaller 
application on the user‟s computer (download from the IBRA website). The main 
program was then connected to the user‟s computer via the Internet, allowing desktop 
sharing and remote control, as if we were sitting right in front of the user‟s computer. 
System tests in our office were very successful. However, this system has not been 
tested with real users, as it is uncertain how surgeons would react to such an „intrusive‟ 
support system, although the increasing complexity of IBRA and number of users will 
require further refinement of the support system. This has to be developed parallel to the 
development of the software features, and it is likely to make a similarly important 
contribution to the success of the whole system. 
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7.3.3 Patient related limitations and recommendations 
The most difficult task in this research was the recruitment for the randomised 
controlled trial. This process was tough, slow and complicated from the beginning. 
Further aggravation came with the finance crisis in 2009, which hit all social levels and 
even made people with higher incomes more cost-aware. Finally, after 18 months of 
recruitment we were very disappointed and moved when we had to terminate the trial 
prematurely due to lack of recruitment. 
 
We believe that, besides „reputation factors‟ the high demands of private patients might 
be the reason why generally no controlled trials are performed in private settings. In 
fact, this was the first trial performed at the refractive unit at Moorfields Eye Hospital, 
one of the largest eye hospitals in the world. We now intend to publish the results of our 
experience and its impression on private practice research in the British Medical 
Journal, in order to provide other surgeons with an insight into the potential risks and 
obstacles of private practice research beforehand. 
 
This research provided us with excellent outcome data, and new knowledge related to 
nomogram adjustment. We could prove that general adjustments (Figure 7.3.1.) work 
well for some patient groups. We could further show that individual nomogram 
adjustments (Figure 7.3.2.) work well for spherical adjustments, but did not sufficiently 
adjust the cylindrical component. Further investigations are required to analyse new 
concepts and strategies of nomogram adjustments, and to evaluate other factors (e.g. age 
and healing factors) that could be implemented into formulas, promising a positive 
effect on the outcome, e.g. in the reduction of the scatter of the results (Figure 7.3.3. and 
Figure 7.3.4). This research provides an essential platform for any future research. 
 
 
 
 
     
 
Figure 7.3.1.  General modifications of laser treatments, based on linear regression analysis of the 
spherical equivalent with a fix amount of adjustment (blue arrow) for all patients. 
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Figure 7.3.2.  Patient-individual modifications of the laser treatments, based on analysis of spherical and 
astigmatic outcome data. Each patient received individual adjustments (blue arrows) for the sphere and 
cylinder correction. 
 
 
 
 
 
 
 
Figure 7.3.3.  Next step in patient-individual modifications of laser treatments with one additional 
criterion, e.g. age, pachymetry, ablation, or residual stromal bed. Beside of individualisation of the 
treatment sphere and cylinder an additional adjustment process is programmed dependent on the extra 
criterion, e.g. younger patients receive lower adjustments. 
 
 
 
 
 
 
 
 
Figure 7.3.4.  Future concept of patient-individual modifications of laser treatments with additional 
criterion from non-invasive investigation and with biological criteria from invasive tests, such as blood 
test, prick test or cell analysis from mucosal swab. Patients with positive test results (rectangle) will 
receive extra adjustments (black arrow). 
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The findings on spherical and cylindrical nomogram adjustment from this research are 
to be implemented into the next generation of the IBRA system. We recommend a 
modification of the existing nomogram tool with the aim of providing adjustment 
factors that implement general and patient-individual aspects of nomogram 
modification. Potentially, the best way of presenting the new adjustment factors is to 
create a table that contains some separation by individual factors, for example age at 
surgery or amount of preoperative astigmatism. 
 
The use of the IBRA system since 2004 has led to a large collection of refractive data 
from the participating surgeons in the UK and Ireland. In total, we were able to collect 
the data of 22,000 treated eyes. Generally, the collection and analysis of refractive 
outcome data has become an increasingly important requirement of refractive surgery 
practice. The Quality Standard and Revalidation initiatives of The Royal College of 
Ophthalmologists underpin this importance in the provision of auditable outcomes of 
surgery. We will try to use and publish our data to demonstrate outcomes to patients and 
to external commissioners. We hope that our contributions may be included in the 
creation of future standards to describe outcomes in refractive laser surgery. 
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8. CONCLUSIONS 
 
This research has provided us with a unique web-based software system for the 
management of outcomes in laser vision correction, and with a framework within which 
the method of nomogram adjustment could be evaluated. The system was used manifold 
in real private practice settings, and showed effective modification of patient health 
outcome. This research has made a major impact on surgeon management of laser eye 
surgery. Overall, we have met the promises and aims of this research „to record, analyse 
and improve the health outcome in patients undergoing laser vision correction‟ in all 
points. 
 
A summary of unique features of this research includes: 
 The research system is the only system on the market that offers standard, vector 
and nomogram analysis in one integrated solution. 
 We have developed unique calculation algorithms for the calculation of patient-
individual nomogram adjustments. 
 This is the only refractive analysis system that has been systematically evaluated, 
including a randomised control trial. 
 This is the first time that a refractive analysis system has scientifically proven 
effectiveness in producing a positive health change in a large number of treated 
eyes. 
 This research showed that carefully applied nomogram adjustments are safe and 
can be performed by any refractive surgeon using refractive analysis software. 
 This is the first fully web-based refractive analysis system. 
 We have performed the first ever randomised control trial in the high-volume 
private practice refractive laser unit at Moorfields Eye Hospital. 
 We have performed an up-to-date review on available refractive outcome 
software. 
 
The results of this research have contributed to the process of defining an optimal 
treatment regime for patients with complex refractive disorders undergoing laser vision 
correction. The formulas and calculation algorithms we developed and used are 
adaptive, and can be implemented into future research with minimal changes. Further 
research is required to analyse new concepts and strategies of nomogram adjustments 
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and to evaluate factors other than refractive ones (e.g. healing factors) influencing the 
outcome of laser vision correction. 
 
We have demonstrated that surgeons from different countries have similar requirements 
regarding refractive analysis, and we have provided information on the effectiveness of 
data entry methods related to refractive data.  
 
In total, we collected results from more than 22,000 laser treatments. The analysis of 
this multi-centre data may provide a useful contribution to the upcoming „Revalidation 
Standards‟ of The Royal College of Ophthalmologists. 
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2. PROJECT SUMMARY 
 
The treatment of myopia (short-sightedness) with refractive eye laser surgery has 
become widely available. The Refractive Audit 2007 analyzed 2310 eyes after laser in-
situ keratomileusis (LASIK) and showed that the treatment of eyes with myopia (simple 
myopia) was superior to the treatment of eyes with combined myopia and astigmatism 
(abnormality in the shape of the cornea). Whereas 79% of eyes with simple myopia 
achieved the treatment target within 0.5 diopters (D), only 56% of eyes with astigmatic 
myopia were within 0.5D of the target refraction. It was suggested that a patient-
individual modification of the treatment parameters could improve the outcome in such 
eyes. Based on this idea a software system with a calculation formula was developed 
that enables patient-individual optimization of the treatment settings. The aim of the 
research is to evaluate this new system for LASIK in eyes with astigmatic myopia. The 
methodology includes a randomized clinical trial with two groups. Participants of group 
1 will receive the standard treatment regime; participants of group 2 will be treated 
using the new formula. This research will be conducted at Moorfields Eye Hospital 
within 2 years. It will make a major contribution to a new and affordable technique that 
can improve patient‟s health and the cost-effectiveness in refractive eye laser surgery. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
204 
3. BACKGROUND AND RATIONAL 
 
Background 
Refractive eyes laser surgery is a specialized field of eye surgery that focuses on 
improving the optical state of the eye using an excimer laser beam to reshape the 
surface of the cornea. In successful treatments the induced refractive change equals the 
preoperative refractive error. Therefore, in many cases, it can eliminate the need for 
glasses. Otherwise, overcorrection or undercorrection may worsen the preoperative 
situation, may increase the need for visual aids and laser re-treatments. 
A total of 2310 eyes were analyzed for the Refractive Audit 2007 that were treated at 
Moorfields Eye Hospital for myopia (short-sightedness), hyperopia (long-sightedness) 
and astigmatism (irregular or toric curvature of the cornea). Especially the outcome of 
eyes with combined myopia and astigmatism was disappointing. Only 56% of these 
eyes were within 0.5 diopters (D) of the attempted spherical equivalent refraction 
(simple myopia: 79% of eyes, Figure 1). 
 
 
          
 
Figure 1   Predictability of the spherical equivalent (SE) 3 months after laser in-situ keratomileusis for 
277 eyes with combined myopia and astigmatism (left scattergram), compared to 412 eyes with simple 
myopia (right scattergram). Results from the Refractive Audit 2007 at Moorfields Eye Hospital. 
 
 
Rational 
We believe that the higher amount of overcorrection and distribution in eyes with 
astigmatic myopia is a result of the inaccurate determination of the treatment setting. 
We assume that the outcome can be improved in these eyes by a patient-individual 
modification of the treatment setting. Up-to-date, the available software systems are not 
able to analyze refractive data patient-individually, and they are not able to provide the 
surgeon with modified treatment parameters. To meet these needs, we developed such a 
system with a calculation formula at Moorfields Eye Hospital. Based on patient‟s 
preoperative refraction, the formula individually calculates the amount of change in the 
treatment setting that is necessary to reach the target refraction more precisely. 
The use of the new system has the potential to improve the refractive outcome (patient 
health change). This is clinically needed to increase the postoperative uncorrected visual 
acuity, to increase patient‟s satisfaction, to decrease the number of follow-up visits and 
to decrease the rate of re-treatments. Such a treatment can improve the cost-
effectiveness in refractive eye laser surgery. 
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This is the first research that clinically evaluates the benefit of a system that modifies 
the laser treatment settings patient-individually. This is mandatory for clinical trials of 
current and future treatment regimes. 
 
 
4. AIM AND OBJECTIVES 
 
The aim of this research is 
 To improve the health outcome in patients with astigmatic myopia. 
 
The objectives of the research are 
 To plan and undertake a randomized clinical trial. 
 To use the new calculation system and formula to modify the treatment settings. 
 To compare the results of the new treatment regime with the standard. 
 
 
5. METHODOLOGY 
 
Inclusion criteria 
The study population for this randomized clinical trial (RCT) will consist of healthy 
female and male participants. The main inclusion criterion is astigmatic myopia, as 
defined as astigmatism of ≥1.0 D with a negative spherical equivalent (also “compound 
myopic astigmatism”). The research design is shown in Figure 2. 
 
 
 
Figure 2    Research design. 
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Sample size  
To detect as significant at 5% level a difference of this size with 80% power, we would 
need to recruit 49 subjects per treatment group. With a potential loss to follow-up of 20-
30% (coming back rate of 70-80% in the Refractive Audit 2007), the sample size is 
adjusted to a total number of 128 participants. 
 
Information and informed consent 
The appointments will take place at Moorfields Eye Hospital, Arthur Steele Unit, 205 
City Road, London, EC1V 1JN. The Chief will approach all participants or Principal 
Investigator and the study will be explained to them. Participants will be given an 
information sheet (Attachment 1) to take away and discuss with anyone they wish. They 
will also be given the opportunity to ask any questions before they decide whether or 
not to participate. If the participant agrees to take part in the study, the Chief or 
Principal Investigator will obtain informed consent (Attachment 2 and Attachment 3) 
and arrange an appointment for the study procedures to be performed. If participants are 
unable to understand what is involved and are unable to give their informed consent, 
they will not be included in the study. 
 
Pre-Treatment assessment 
The initial consultation can take approx. 50 min and will normally include an 
assessment of the accuracy of the patient‟s subjective refraction, auto-refraction, 
wavefront measurement, computerized corneal topography (corneal shape) and 
pachymetry (corneal thickness), determined by opticians. Further, the consultation 
includes a detailed examination of the eye, performed by the Chief or Principal 
Investigator. The data of the subjective refraction (sph0, cyl0 and ax0), the uncorrected 
and best-corrected visual acuity (ucva0 and bcva0), the wavefront refraction and the 
topography data will be collected for the research. 
 
Randomization 
The Research & Development (R&D) Department at Moorfields Eye Hospital will 
perform randomization of the participants. The R&D Department will allocate each 
participant either to group 1 or group 2. Further, each participant will be given an 
identification number. 
 
Treatment setting determination 
Chief or Principal Investigator, in accordance with the participant, will define the 
refractive target of each eye. The amount of refractive change necessary to achieve this 
target is prescribed by the laser treatment setting. The laser treatment setting consists of 
the parameters treatment sphere (sphS), treatment cylinder (cylS) and treatment axis 
(axS). These parameters will be determined for each participant individually, based on 
the current standard regime for participants allocated to group 1, and based on the new 
treatment regime for participants allocated to group 2. 
 
Standard treatment setting (Group 1) 
The process to determine the treatment setting for group 1 is shown in Figure 3. This 
process is well established and currently in use as standard regime. It was also used for 
the treatment of all patients in 2007 (Refractive Audit 2007). The sphere value of the 
manifest refraction will be used as treatment sphere (sphS) when the difference between 
the manifest and the WaveScan sphere is less than 0.5 diopters (D). The cylinder value 
of the manifest refraction will be used as treatment cylinder (cylS) when the difference 
between the manifest and the WaveScan cylinder is less than 0.25D. And the axis value 
of the manifest refraction will be used as treatment axis (axS) when the difference 
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between the manifest axis, the WaveScan axis and the axis of the Topography is less 
than 10°. If the differences between the sphere, cylinder or axis parameters are bigger 
than the mentioned limits, the preoperative examination will be repeated. Finally, the 
determined parameters will be entered in the laser unit for the treatment of the 
participants. 
 
           
 
Figure 3   Determination of the standard treatment setting (sphS, cylS and axS) as used for the laser 
treatment of patients with astigmatic myopia in 2007 (Refractive Audit 2007). 
 
 
Modified treatment setting (Group 2) 
Participants allocated to group 2 will receive a modified treatment setting. In a first step, 
the treatment sphere (sphS), treatment cylinder (cylS) and treatment axis (axS) are 
determined identically as described above “as standard” for group 1. This standard 
setting is the default for the modification (Figure 4). Based on the preoperative 
refraction (SE and cylinder) the first part of the new formula (Figure 5) calculates the 
estimated refractive error: the amount of SE overcorrection (SEerror, in %) and cylinder 
undercorrection (Cylerror, in %). Subsequently, these values are used by the second part 
of the formula to calculate the amount the standard setting has to be changed (SE 
change and Cyl change, in D). The “SE change” will be subtracted from the treatment 
SE and the “Cyl change” will be added to treatment cylinder; finally resulting in the 
new treatment sphere (sphII) and treatment cylinder (cylII). The setting for the 
treatment axis (axS) will not be changed (axS =axII). The modified treatment sphere 
(sphII) and treatment cylinder (cylII) will be entered in the laser unit for the treatment of 
participants of group 2. 
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Figure 4   Modification of the treatment setting, based on the standard treatment refraction (sphS, cylS 
and axS). 
 
 
 
 
Refractive error:         Comments: 
SEerror [%]    =   18 * SE-0.72 + 0.5 * Cyl      SE = preoperative spherical equivalent 
Cylerror [%]   =   32 * Cyl-0.31     Cyl = preoperative cylinder 
 
Modification of the treatment setting: 
SE change [D]   =     SE/100*SEerror + 0.25*Cyl/100*Cylerror 
Cyl change [D]   =     0.5*Cyl/100*Cylerror 
 
Example: 
Use of above formulas for an astigmatic myopic eye. 
Preoperative SE= -5.25 and Cyl=-2.25. 
SEerror  = 6.58 %       SE overcorrection 
Cylerror  = 24.89 %       Cylinder undercorrection 
SE change = 0.49 D       to be taken off the standard treatment SE 
Cyl change = 0.28 D        to be added to the standard treatment cyl 
 
 
Figure 5   Formulas for the calculation of the refractive error and the modification of the treatment 
setting, with comments (right side) and example. 
 
 
Laser treatment 
Following the determination of the treatment setting the participants of both groups will 
undergo identical wavefront-guided or refraction based laser in-situ keratomileusis 
(LASIK) at Moorfields Eye Hospital, Refractive Laser Suite (4
th
 floor main hospital), 
performed by the Chief Investigator. A superiorly hinged corneal flap of 160µ thickness 
and 8.5 to 9.0mm diameter will be cut with the Hansatome microkeratome (Bausch & 
Lomb, Germany). Alternatively, the FS60 Femtosecond Laser (Intralase, UK) may be 
used for the creation of the corneal flap. In combination with LASIK this procedure is 
called “IntraLASIK”. The flap will be folded upwards and the ablation will be 
performed using the laser treatment setting. Following replacement of the flap the 
interface will be rinsed and antibiotic and anti-inflammatory eye drops will be given. 
The laser procedure will take approx. 40 min for each participant, including the 
preparation of the laser and instruments. After the treatment the participants are allowed 
to go home. Standard eye drops (anti-inflammatory, antibiotic and lubricant drops) are 
used every 2 hours for the first week. 
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Postoperative review 
Careful slit-lamp examination is performed within 24-48 hours to confirm that the 
LASIK flap is properly positioned. Rarely, participants will be reviewed at 4 weeks 
time. The main follow-up appointment is at 3 months time and includes slit-lamp 
examination, subjective refraction (sph3, cyl3 and ax3) and uncorrected and best-
corrected visual acuity assessment (ucva3 and bcva3), determined by opticians. The 
data of the 3 months review will be used for the research. The postoperative review will 
take approx. 30 min and will take place at Moorfields Eye Hospital, Arthur Steele Unit, 
205 City Road, London, EC1V 1JN. Because we anticipate a high loss to follow-up, 
patients who fail to attend will be contacted to obtain qualitative comments, to establish 
whether treatment outcome influences non-attendance. 
 
 
6. DATA MANAGEMENT AND ANALYSIS 
 
Main outcome measure 
Main outcome measure is the percentage of eyes achieving a postoperative spherical 
equivalent (SE) within 0.5D of the target SE. Generally, the SE is the sum of the sphere 
(sph) and half of the cylinder (cyl) value (SE=Sph+0.5*Cyl). With conventional 
treatment settings this has been shown to be 56% (Based on the Refractive Audit 2007 
at Moorfields Eye Hospital). With the new treatment settings we would expect to 
increase this to 79%.  Sphere and cylinder value will be assessed by subjective 
refraction. 
 
Data management 
The data will be collected by the Principal Investigator on data collection sheets 
(Attachment 4) and entered into the SQL database designed by the R&D Department.. 
Personal information will be kept in locked, secure-access filing cabinets or on 
password-protected institute computers. Only research personnel will have access to the 
data. Data will be stored for 2 years, in accordance with the Data Protection Act 1998. 
Data that leaves the hospital will be anonymized. 
 
Data analysis 
Baseline characteristics of the two groups will be compared to assess the adequacy of 
randomisation. A Chi-square test will be used to compare the proportion of patients 
with successful outcomes in each group. Logistic regression will be employed should 
there be any marked difference in any prognostic factor between treatment groups. We 
will conduct an available case analysis but will also contact patients who are lost to 
follow-up to ensure that their reasons for DNA are not associated with the likelihood of 
a good outcome. 
 
Timetable 
The study will be completed within 2 years. 
 
 
7. ETHICAL CONSIDERATIONS 
 
Full ethical commission approval will be obtained. Potential participants will be assured 
that their involvement is entirely voluntary, that they can withdraw from the study at 
any time and that their normal clinical management will not be affected in any way 
should they decide not to take part in the study. 
 
210 
 
8. ATTACHMENTS 
 
 Attachment 1 : Participant information sheet 
 Attachment 2:  Participant consent form 
 Attachment 3:  Consent form IntraLASIK 2008 
 Attachment 4:  Data collection sheet 
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Participant information sheet 
 
You are being invited to take part in a research study conducted by Moorfields Eye Hospital NHS 
Foundation Trust. Before you decide whether or not to participate, it is important for you to understand 
why the research is being done and what it will involve. Please take time to read the following 
information carefully and discuss it with friends, relatives and your GP if you wish. Ask us if there is 
anything that is not clear or if you would like more information. Take time to decide whether or not you 
wish to take part. 
 
This study is approved by and follows the guidelines of the National Research Ethics Service (NRES) 
with the idea to protect the rights, safety, dignity and well being of research participants, whilst 
facilitating and promoting ethical research within the NHS. In addition, this study is approved by the 
Moorfields Eye Hospital Institutional Review Board. 
 
What is the title of the research? 
The title of the research is: “Individual optimization of the laser settings in eyes with astigmatic myopia 
undergoing laser in-situ keratomileusis (LASIK).” 
 
Why have I been chosen? 
You are being asked to participate because you are a healthy person with combined shortsightedness 
(myopia) and astigmatism. 
 
Why is this study being done? 
The refractive laser unit at Moorfields Eye Hospital is a leading laser center in Europe. Regular audits of 
the patient outcome and optimizing of the treatment regime is part of the quality controlling system. 
Whereas the laser treatment of myopia reached the highest possible level of precision, the treatment of 
combined myopia and astigmatism is more difficult because of the nature of the disease. During the last 2 
years, surgeons at Moorfields Eye Hospital developed a new calculation method with the aim to optimise 
the treatment parameters. This should result in a more accurate outcome in patients with myopia and 
astigmatism. This study is part of the evaluation process of this new method. 
 
Do I have to take part? 
We assure that your involvement is entirely voluntary, that you can withdraw from the study at any time 
and that your normal clinical management will not be affected in any way should you decide not to take 
part in the study. If you decide not to participate you can still undergo laser eye surgery. 
 
Will I be paid for participating in the research? 
Participants will not receive money for taking part in the research study. The laser surgery fees apply to 
participants and non-participants alike. 
 
What are the potential benefits of taking part? 
The potential benefit is a better refractive outcome, an improved uncorrected distance visual acuity and a 
lower rate of re-treatments. 
 
What will happen to me if I take part? 
In this study participants will be randomized to one of 2 groups. Participants in group 1 will be treated 
with the standard, well established treatment regime. Participants in group 2 will be treated with the new 
method. The only difference between the two groups is the amount of correction for the myopia and for 
the astigmatism that will be entered in the controller software of the laser unit. No difference exists 
between the 2 groups regarding the preoperative assessment, the operational technique, the postoperative 
treatment and the reviews. All participants will be treated by the same surgeon (Prof. Gartry). 
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What are the risks of the study? 
There are no physical risks associated with this study. There is, however, the potential risk of 
overcorrection or undercorrection in the refractive outcome. 
 
What if something goes wrong? 
Complaints can be addressed to the Chief Investigator or to Moorfields Eye Hospital, Complaints 
Manager, 162 City Road, London, EC1V 2PD. We assure that everything possible will be done to 
manage your concern effectively and efficiently. 
 
Will my taking part in this study be kept confidential? 
Your information will be kept in a secure electronic database at Moorfields Eye Hospital and may be used 
for future studies within the next 2 years. 
 
What will happen to the results of the research study? 
The results of the research will be published in ophthalmological journals (in 2009/2010). It will not be 
possible to identify individual participants in any of the reports or publications. Each participant will 
receive a summary of the results after publication. A copy of the whole article can be obtained from the 
Chief Investigator. 
 
 
Thank you very much for taking the time to read this information. Should you agree to take part in this 
research, your generosity ensures that future generations will benefit. If you have any questions regarding 
the research study or the information sheet, please contact your GP or one of the following investigators. 
 
Chief Investigator: Prof. David Gartry 
Head of Refractive Surgery Unit 
Moorfields Eye Hospital NHS Foundation Trust, London 
Department of Optometry and Visual Science, City University London 
 
Associate Investigator: Prof. Abdul Roudsari 
Head of Centre for Health Informatics 
City University London, City University London 
 
Principal Investigator: Dr. Bruno Zuberbuhler 
Moorfields Eye Hospital NHS Foundation Trust, London 
Centre for Health Informatics, City University London 
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Participant consent form 
 
 
Name of participant: 
……………………………………………………………………………………….. 
 
Patient ID: 
………………………………………………………………………………………… 
 
Title of the project: 
………………………………………………………………………………………... 
 
Members of the research team: 
…………………………………………………………………................................... 
 
 
 I agree to take part in the above research. I have read the Participant Information Sheet, 
which is attached to this form. I understand what my role will be in this research, and all 
my questions have been answered to my satisfaction. 
 I understand that I am free to withdraw from the research at any time, for any reason 
and 
without prejudice. 
 I have been informed that the confidentiality of the information I provide will be 
safeguarded. 
 I am free to ask any questions at any time before and during the study. 
 I have been provided with a copy of this form and the Participant Information Sheet. 
 Inform GP or other health professional 
 
Data Protection: I agree to the processing of personal data that I have supplied for any 
purposes connected with the Research Project as outlined to me. 
 
 
Name of participant 
(print)……………………………..…….Signed………………..….Date……………… 
 
Name of surgeon 
(print)……………………………….…..Signed………………..….Date……………… 
 
Name of witness 
(print)……………………………….…..Signed………………..….Date……………… 
 
 
Three copies should be made, for (1) participant, (2) researcher, (3) hospital notes. 
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CONSENT FORM INTRA-LASIK 2008 
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Consent form IntraLASIK 2008 
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Data collection sheet 
 
Research Title: 
Patient-individual modification of laser settings in the treatment of astigmatic myopia with laser in-situ 
keratomileusis 
 
Chief Investigator: Prof. David Gartry, Moorfields Eye Hospital 
Principal Investigator: Dr. Bruno Zuberbuhler, Moorfields Eye Hospital 
 
 
Patient ID 
 
 
Age of participant 
 
 
Eye 
 
 
Preoperative assessment 
 
Uncorrected visual acuity: 
 
 
Manifest refraction:    sph    cyl   ax 
 
 
Best-corrected visual acuity: 
 
 
WaveScan refraction:    sph    cyl   ax 
 
Operational details 
 
Refractive treatment:    sph    cyl   ax 
 
 
Target refraction:    sph    cyl   ax 
 
 
Comments: 
 
3 months follow-up 
 
Uncorrected visual acuity: 
 
 
Subjective refraction:    sph    cyl   ax 
 
 
Best-corrected visual acuity: 
 
. 
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IBRA treatment adjustment table       
                        PATIENT STICKER 
 
 
Upper value: to be added to the treatment sphere 
Lower value: to be added to the treatment cylinder 
        Treatment cylinder 
  0 -0.25 -0.5 -0.75 -1 -1.25 -1.5 -1.75 -2 -2.25 -2.5 -2.75 -3 -3.25 -3.5 -3.75 -4 
0.0 0.47 0.48 0.49 0.50 0.52 0.53 0.54 0.55 0.56 0.57 0.58 0.59 0.61 0.62 0.63 0.64 0.65 
  0.00 -0.02 -0.05 -0.07 -0.09 -0.11 -0.14 -0.16 -0.18 -0.20 -0.23 -0.25 -0.27 -0.29 -0.32 -0.34 -0.36 
-0.5 0.46 0.47 0.48 0.49 0.50 0.51 0.52 0.53 0.55 0.56 0.57 0.58 0.59 0.60 0.61 0.62 0.64 
  0.00 -0.02 -0.05 -0.07 -0.09 -0.11 -0.14 -0.16 -0.18 -0.20 -0.23 -0.25 -0.27 -0.29 -0.32 -0.34 -0.36 
-1.0 0.44 0.45 0.46 0.47 0.49 0.50 0.51 0.52 0.53 0.54 0.55 0.56 0.58 0.59 0.60 0.61 0.62 
  0.00 -0.02 -0.05 -0.07 -0.09 -0.11 -0.14 -0.16 -0.18 -0.20 -0.23 -0.25 -0.27 -0.29 -0.32 -0.34 -0.36 
-1.5 0.43 0.44 0.45 0.46 0.47 0.48 0.49 0.50 0.52 0.53 0.54 0.55 0.56 0.57 0.58 0.59 0.61 
  0.00 -0.02 -0.05 -0.07 -0.09 -0.11 -0.14 -0.16 -0.18 -0.20 -0.23 -0.25 -0.27 -0.29 -0.32 -0.34 -0.36 
-2.0 0.41 0.42 0.43 0.44 0.46 0.47 0.48 0.49 0.50 0.51 0.52 0.53 0.55 0.56 0.57 0.58 0.59 
  0.00 -0.02 -0.05 -0.07 -0.09 -0.11 -0.14 -0.16 -0.18 -0.20 -0.23 -0.25 -0.27 -0.29 -0.32 -0.34 -0.36 
-2.5 0.40 0.41 0.42 0.43 0.44 0.45 0.46 0.47 0.49 0.50 0.51 0.52 0.53 0.54 0.55 0.56 0.58 
  0.00 -0.02 -0.05 -0.07 -0.09 -0.11 -0.14 -0.16 -0.18 -0.20 -0.23 -0.25 -0.27 -0.29 -0.32 -0.34 -0.36 
-3.0 0.38 0.39 0.40 0.41 0.43 0.44 0.45 0.46 0.47 0.48 0.49 0.50 0.52 0.53 0.54 0.55 0.56 
  0.00 -0.02 -0.05 -0.07 -0.09 -0.11 -0.14 -0.16 -0.18 -0.20 -0.23 -0.25 -0.27 -0.29 -0.32 -0.34 -0.36 
-3.5 0.37 0.38 0.39 0.40 0.41 0.42 0.43 0.44 0.46 0.47 0.48 0.49 0.50 0.51 0.52 0.53 0.55 
  0.00 -0.02 -0.05 -0.07 -0.09 -0.11 -0.14 -0.16 -0.18 -0.20 -0.23 -0.25 -0.27 -0.29 -0.32 -0.34 -0.36 
-4.0 0.35 0.36 0.37 0.38 0.40 0.41 0.42 0.43 0.44 0.45 0.46 0.47 0.49 0.50 0.51 0.52 0.53 
  0.00 -0.02 -0.05 -0.07 -0.09 -0.11 -0.14 -0.16 -0.18 -0.20 -0.23 -0.25 -0.27 -0.29 -0.32 -0.34 -0.36 
-4.5 0.34 0.35 0.36 0.37 0.38 0.39 0.40 0.41 0.43 0.44 0.45 0.46 0.47 0.48 0.49 0.50 0.52 
  0.00 -0.02 -0.05 -0.07 -0.09 -0.11 -0.14 -0.16 -0.18 -0.20 -0.23 -0.25 -0.27 -0.29 -0.32 -0.34 -0.36 
-5.0 0.32 0.33 0.34 0.35 0.36 0.38 0.39 0.40 0.41 0.42 0.43 0.44 0.45 0.47 0.48 0.49 0.50 
  0.00 -0.02 -0.05 -0.07 -0.09 -0.11 -0.14 -0.16 -0.18 -0.20 -0.23 -0.25 -0.27 -0.29 -0.32 -0.34 -0.36 
-5.5 0.31 0.32 0.33 0.34 0.35 0.36 0.37 0.38 0.40 0.41 0.42 0.43 0.44 0.45 0.46 0.47 0.49 
  0.00 -0.02 -0.05 -0.07 -0.09 -0.11 -0.14 -0.16 -0.18 -0.20 -0.23 -0.25 -0.27 -0.29 -0.32 -0.34 -0.36 
-6.0 0.29 0.30 0.31 0.32 0.34 0.35 0.36 0.37 0.38 0.39 0.40 0.41 0.43 0.44 0.45 0.46 0.47 
  0.00 -0.02 -0.05 -0.07 -0.09 -0.11 -0.14 -0.16 -0.18 -0.20 -0.23 -0.25 -0.27 -0.29 -0.32 -0.34 -0.36 
-6.5 0.27 0.29 0.30 0.31 0.32 0.33 0.34 0.35 0.36 0.38 0.39 0.40 0.41 0.42 0.43 0.44 0.45 
  0.00 -0.02 -0.05 -0.07 -0.09 -0.11 -0.14 -0.16 -0.18 -0.20 -0.23 -0.25 -0.27 -0.29 -0.32 -0.34 -0.36 
-7.0 0.26 0.27 0.28 0.29 0.31 0.32 0.33 0.34 0.35 0.36 0.37 0.38 0.40 0.41 0.42 0.43 0.44 
  0.00 -0.02 -0.05 -0.07 -0.09 -0.11 -0.14 -0.16 -0.18 -0.20 -0.23 -0.25 -0.27 -0.29 -0.32 -0.34 -0.36 
-7.5 0.24 0.26 0.27 0.28 0.29 0.30 0.31 0.32 0.33 0.35 0.36 0.37 0.38 0.39 0.40 0.41 0.42 
  0.00 -0.02 -0.05 -0.07 -0.09 -0.11 -0.14 -0.16 -0.18 -0.20 -0.23 -0.25 -0.27 -0.29 -0.32 -0.34 -0.36 
-8.0 0.23 0.24 0.25 0.26 0.28 0.29 0.30 0.31 0.32 0.33 0.34 0.35 0.37 0.38 0.39 0.40 0.41 
  0.00 -0.02 -0.05 -0.07 -0.09 -0.11 -0.14 -0.16 -0.18 -0.20 -0.23 -0.25 -0.27 -0.29 -0.32 -0.34 -0.36 
-8.5 0.22 0.23 0.24 0.25 0.26 0.27 0.28 0.29 0.31 0.32 0.33 0.34 0.35 0.36 0.37 0.38 0.40 
  0.00 -0.02 -0.05 -0.07 -0.09 -0.11 -0.14 -0.16 -0.18 -0.20 -0.23 -0.25 -0.27 -0.29 -0.32 -0.34 -0.36 
    
    Treatment  sphere 
     Sph   Cyl   Ax 
 
Standard treatment 
 
Adjustment 
 
IBRA treatment 
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DECLARATION OF THE END OF A STUDY 
(For all studies except clinical trials of investigational medicinal products) 
 
To be completed in typescript by the Chief Investigator and submitted to the Research 
Ethics Committee that gave a favourable opinion of the research (“the main REC”) 
within 90 days of the conclusion of the study or within 15 days of early termination.  
For questions with Yes/No options please indicate answer in bold type. 
 
 
1. Details of Chief Investigator 
 
Name: Professor David Gartry 
Address: 
 
 
 
 
 
 
 
Email:  
 
 
 
2. Details of study 
 
Full title of study: 
 
 
 
Patient-individual modification of laser 
settings in the treatment of compound myopic 
astigmatism with laser in-situ keratomileusis: 
a randomized controlled trial. 
 
Research sponsor: 
 
Private (Prof Gartry) 
Name of main REC: 
 
The Royal Marsden Research Ethics 
Committee 
Main REC reference number: 
 
08/H0801/99 
 
 
3. Study duration 
 
Date study commenced: 
 
20 October 2008 
Date study ended: 
 
19 February 2010 
Did this study terminate prematurely? 
 
Yes    / No   
If yes please complete sections 4, 5 & 6, if no 
please go direct to section 7. 
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4. Circumstances of early termination 
 
What is the justification for this early termination? 
 
The reason for the termination is the slow and finally stagnating recruitment process. 
 
Background 
The problems in recruiting can be attributed to increasing expectations of highly demanding private 
patients. In the current financial crisis there are fewer private patients and they only intend to undergo 
laser vision correction when they are sure that they will receive the best possible treatment, resulting in 
the best possible outcome. With this idea patients are searching for ‘the best surgeon’ that can fulfil their 
demands. 
 
Over the last 6 months it has become more and more difficult to convince patients to participate on a 
randomized trial that evaluates 2 different treatment regimes to find out which one’s the better. Most 
patients get confused and frustrated after they have been informed about the trial and its aim. They can 
hardly understand that ‘the best surgeon’ is not sure about the optimal treatment. At this stage many 
patients decide to postpone their operation until the question of the best treatment has been answered. In 
addition, some very sceptical patients criticize the surgeon’s competency and search for another surgeon 
‘who knows the best treatment’. 
 
Action taken in the past 
We have tried to change our way of recruiting multiple times. We have changed the scheduling of asking, 
the way of providing information and its content, and we have extended the time spent for explanation. In 
December 2009 we discussed the situation with the R&D department and have agreed to set interim 
recruitment targets. Unfortunately, the recruitment could not be improved (target not met) and by the end 
of January we finally decided to terminate the trial. 
 
Action plan / data 
We intend to trace and review all 45 participants and to collect the 3 months postoperative results of all 
79 treated eyes. We are aware that the numbers are too low for complex statistical analysis 
(underpowered), but we aim to perform descriptive analysis of the results. We will present our results in 
the final report within the next 12 months. If the results are conclusive we will aim for publication. 
 
 
 
5. Temporary halt 
 
Is this a temporary halt to the study? Yes /   No 
If yes, what is the justification for 
temporarily halting the study? When 
do you expect the study to re-start? 
e.g. Safety, difficulties recruiting participants, trial 
has not commenced, other reasons. 
 
 
 
 
6. Potential implications for research participants 
 
Are there any potential implications 
for research participants as a result 
of terminating/halting the study 
prematurely? Please describe the 
steps taken to address them. 
 
No implications expected. 
 
 
7. Final report on the research 
 
Is a summary of the final report on 
the research enclosed with this form? 
 
Yes /   No, we will provide a report < 12 
months. 
 
If no, please forward within 12 months of the end of the 
study. 
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RAW DATA FROM THE CLINICAL TRIAL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Raw data Randomised Controlled Trial - Standard group 
 
No pid dob eye doo targetref targetcyl targetax shapingsph shapingcyl shapingax ducva0 ducva3 dbcva0 dbcva3 dsph0 dsph3 dcyl0 dcyl3 dax0 dax3 pachy0 pupil satisf3 
1 74272 19.06.1965 os (L) 12.01.2009 -0.02 0.14 115 -3.98 -0.89 115 0.16 1 1 1.25 -4 -0.5 -1 0 115 0 545 6 1 
2 75378 30.11.1947 os (L) 24.11.2008 -0.46 0.31 164 -3.29 -0.81 164 0.25 0.5 0.8 0.63 -3.75 -0.5 -1 -0.5 165 160 583 5.2 1.5 
2 75378 30.11.1947 od (R) 24.11.2008 -0.16 0.09 175 -2.34 -1.09 175 0.32 0.63 1 0.8 -2.5 -0.25 -1 -0.5 175 170 599 5.3 1.5 
5 76734 31.10.1979 od (R) 20.12.2008 0.18 -0.02 35 -4.18 -0.98 35  1.25 1.25 1.25 -4 0 -1 0 65  537 6.9 1 
6 74614 29.07.1971 os (L) 20.12.2008 -0.48 -0.04 170 -4.52 -1.96 170  1.6 1.25 1.6 -5 0 -2 0 170  548 5.7 1 
6 74614 29.07.1971 od (R) 20.12.2008 -0.38 0.09 21 -4.62 -1.09 21  1.25 1.25 1.25 -5 -0.25 -1 0 20  562 5.9 1 
10 74272 19.06.1965 od (R) 12.01.2009 -0.11 -0.04 64 -3.89 -0.79 64 0.16 1.25 1 1.25 -4 0.25 -1 -0.5 65 70 543 6.2 1 
11 77258 11.05.1965 od (R) 14.02.2009 0.28 0.05 97 -3.28 -1.55 97  1.25 1.25 1.25 -3 0 -1.5 0 105 0 526 4.4 1 
13 75412 30.04.1980 os (L) 28.02.2009 -0.17 0.23 5 -8.08 -1.23 5 0.1 0.5 1 1 -8.25 -0.75 -1 -0.75 5 0 556 6.6 2 
16 79107 07.07.1987 od (R) 07.03.2009 0 0.04 89 -1.25 -1.04 89  1.25 1 1.25 -1.25 0 -1 -0.25 85 170 551 5.7 1 
17 78897 28.02.1984 os (L) 14.03.2009 -0.38 0.16 150 -3.37 -1.41 150 0.08 1 1.25 1 -3.75 0.25 -1.25 -0.25 150 70 559 7.3 1 
21 79787 19.05.1961 od (R) 21.03.2009 -0.31 0.01 112 -2.44 -3.51 112 0.08 1 1 1.25 -2.75 0 -3.5 -0.5 115 105 512 5.6 1 
22 78775 02.10.1981 os (L) 21.03.2009 -0.03 -0.21 161 -4.22 -1.29 161 0.1 1.25 1.25 1.25 -4.22 0 -1.5 -0.25 160 5 520 6.9 1 
23 78775 02.10.1981 od (R) 21.03.2009 -0.23 -0.01 22 -4.52 -1.49 22 0.1 1.25 1.25 1.25 -4.75 -0.25 -1.5 -0.25 25 0 531 7.1 1 
27 80140 24.10.1975 od (R) 28.03.2009 0.02 -0.07 123 -4.27 -1.18 123  1.25 1.25 1.25 -4.25 0 -1.25 0 123 0 633 5.5 1 
28 77870 06.08.1967 os (L) 18.04.2009 -0.15 0.19 159 -4.1 -1.44 159  1 1.25 1.25 -4.25 -0.25 -1.25 -0.5 160 175 573 5.2 1 
29 77870 06.08.1967 od (R) 18.04.2009 -0.21 0.04 7 -4.29 -1.04 7  1.25 1.25 1.25 -4.5 0 -1 0 8 0 567 5.3 1 
32 79668 17.09.1967 os (L) 20.04.2009 -0.39 0.15 180 -4.86 -1.15 0  1 1.25 1.25 -5.25 0 -1 -0.75 175 170 499  1 
33 79668 17.09.1967 od (R) 20.04.2009 -0.56 0.08 176 -5.94 -1.08 176  1 1 1.25 -6.5 0 -1 -0.75 170 150 511  1 
34 80826 31.10.1976 os (L) 20.04.2009 -0.69 0.21 159 -4.56 -2.96 159  0.5 1 1.25 -5.25 -0.75 -2.75 -1 162 170 607 4.7 1 
38 81148 25.09.1972 os (L) 25.04.2009 -0.24 -0.24 158 -4.51 -1.96 158  0.63 1.25 1 -4.75 -0.5 -2.25 -1 160 165 590 7.1 1 
39 81148 25.09.1972 od (R) 25.04.2009 -0.34 0.06 21 -4.41 -1.56 21  0.8 1.25 1.25 -4.75 -0.5 -1.5 -0.5 20 5 580 7.2 1 
41 80694 12.02.1959 os (L) 02.05.2009 -0.09 0.08 50 -4.41 -0.83 50 0.05 0.63 1.25 1.25 -4.5 -0.75 -1 0 50 0 537 4.6 1 
44 79818 03.09.1969 os (L) 11.05.2009 -0.19 0.13 13 -3.56 -1.13 13 0.1 1 1 1.25 -3.75 -0.25 -1 0 10  553 6.7 1 
46 80965 16.10.1963 os (L) 16.05.2009 -0.26 0.06 2 -3.24 -2.06 2 0.08 0.63 1 1.25 -3.5 -0.5 -2 -1 178 167 581 6.7 1.5 
48 77882 08.03.1969 os (L) 23.05.2009 -0.18 0.29 55 -1.57 -2.04 55 0.1 1 1.25 1.25 -1.75 0.5 -1.75 -0.75 58 45 564 6.5 1 
49 82289 17.06.1984 os (L) 23.05.2009 -0.09 0.13 180 -3.41 -1.13 180 0.08 1.25 1.6 1.25 -3.5 0 -1 0 180 0 583 7.1 1 
50 81674 09.07.1979 od (R) 30.05.2009 -0.18 0.24 92 -1.07 -1.24 92 0.25 1.6 1.25 1.6 -1.25 0.25 -1 0 95  560 6.7 1 
51 82133 30.01.1982 os (L) 30.05.2009 -0.58 -0.1 78 -0.72 -2.4 78 0.16 1.25 1.25 1.25 -1.25 0.25 -2.5 -0.25 82 80 554 7.1 1 
51 82133 30.01.1982 od (R) 30.05.2009 -0.09 0.28 103 -0.66 -3.03 103 0.2 1 1 1 -0.75 0.25 -2.75 -0.5 110 125 546 7.8 1 
55 56942 31.05.1981 os (L) 24.10.2009 -1.2 0.3 5 -8.8 -2.3 5 0.001  1  -10  -2  175  566 3.5  
55 56942 31.05.1981 od (R) 24.10.2009 -2 0.08 13 -9 -1.83 13 0.001  0.8  -11  -1.75  4  551 3.24  
58 81553 04.03.1970 od (R) 06.06.2009 0.03 0.12 13 -1.28 -1.33 13 0.25 1 1.25 1.25 -1.25 0 -1.25 -0.5 12 20 517 6.3 1 
59 82466 12.08.1981 od (R) 01.08.2009 -0.43 -0.03 169 -6.57 -2.22 169 0.01 1 1.25 1.25 -7 0 -2.25 -0.5 168 20 541 6.9 1 
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Raw data Randomised Controlled Trial - IBRA group 
 
 
No pid dob eye doo targetref targetcyl targetax shapingsph shapingcyl shapingax ducva0 ducva3 dbcva0 dbcva3 dsph0 dsph3 dcyl0 dcyl3 dax0 dax3 pachy0 pupil satisf3 
3 75641 27.08.1968 os (L) 29.11.2008 -0.03 0.11 176 0.28 -1.36 176 0.63  1.25  -0.25  -1.25  175  542 7.1  
3 75641 27.08.1968 od (R) 29.11.2008 -0.53 0.15 5 0.53 -1.4 5 0.63  1  0  -1.25  0  542 7.1  
4 75437 16.10.1955 os (L) 20.12.2008 -0.56 0.14 167 -0.69 -1.64 167  1.25 1.25 1.25 -1.25 0 -1.5 -0.25 168 135 615 5.2 1 
4 75438 16.10.1955 od (R) 20.12.2008 -0.52 0.34 15 -1.48 -1.34 12  1.25 1 1.25 -2 0.25 -1 -1 15 17.5 613 5.1 1 
7 13690 28.12.1978 os (L) 09.02.2009 -0.01 0.03 170 -5.74 -1.53 170 0.05 1.25 1 1.25 -5.75 0 -1.5 -0.25 175 0 589 6.4 1 
7 13690 28.12.1978 od (R) 09.02.2009 0.08 0.04 16 -5.83 -1.29 16 0.05 1 1.25 1.25 -5.75 -0.25 -1.25 -0.5 15 0 587 6.3 1 
8 37185 17.02.1972 os (L) 31.01.2009 -0.59 0.18 176 -5.91 -1.93 176 0.05 1.25 1.25 1.25 -6.5 0.5 -1.75 0 175 0 550 4.4 1 
8 37185 17.02.1972 od (R) 31.01.2009 -0.95 0.3 9 -5.3 -3.05 9 0.05 1.25 1 1.25 -6.25 0.25 -2.75 0 10 0 555 4.7 1 
9 78309 30.05.1962 od (R) 07.02.2009 -0.55 0.12 174 -7.7 -1.38 174 0.08  1  -8.25  -1.25  175  569 5.4  
9 78309 30.05.1962 os (L) 07.02.2009 -0.5 0.04 23 -7.75 -0.79 23 0.08  1  -8.25  -1  15  559 4.8  
12 74611 20.03.1972 od (R) 23.02.2009 -0.7 -0.54 176 -2.55 -0.71 163  1.25 1.25 1.25 -3.25 0.25 -1.25 -0.5 180 5 552 5.4 1 
14 75412 30.04.1980 od (R) 28.02.2009 -0.27 0.28 15 -6.73 -1.28 15 0.1 0.32 1 1 -7 -1 -1 -1 10 0 562 6.6 2 
15 79107 07.07.1987 os (L) 07.03.2009 -0.45 0.1 80 -1.3 -1.1 80  1.25 1 1.25 -1.75 0 -1 0 85 0 551 6.2 1 
18 77203 29.09.1985 os (L) 21.03.2009 -0.36 0.18 179 -5.64 -1.43 179 0.01 1.25 1 1.25 -6 -0.25 -1.25 -0.25 10 180 555 8.2 1 
19 77203 29.09.1985 od (R) 21.03.2009 -0.36 0.14 176 -5.64 -1.64 176 0.08 1.25 1 1.25 -6 0 -1.5 -0.25 180 180 531 7.8 1 
20 79787 19.05.1961 os (L) 21.03.2009 -0.61 0.24 55 -2.64 -2.99 55 0.08 1 1 1.25 -3.25 0 -2.75 -0.5 55 105 519 6.1 1 
24 79672 14.12.1958 os (L) 21.03.2009 -0.61 0.12 175 -2.14 -1.37 175  1.25 1.25 1.25 -2.75 -0.25 -1.25 0 177 0 568 6.2 1 
25 79672 14.12.1958 od (R) 21.03.2009 -0.38 0.15 3 -3.37 -1.4 3  0.8 1.25 1.25 -3.75 -0.25 -1.25 -1 58 5 577 6.2 1 
26 80140 24.10.1975 os (L) 28.03.2009 -0.61 0.34 45 -4.89 -1.34 45  1.25 1.25 1.25 -5.5 0 -1 -0.25 44 98 621 6 1 
30 80345 19.12.1960 os (L) 18.04.2009 -0.24 0.16 20 -6.51 -1.66 20  0.4 0.63 0.63 -6.75 -1.25 -1.5 -0.75 20 180 541 4.7 1 
31 80345 19.12.1960 od (R) 18.04.2009 -0.13 0.21 116 -6.33 -1.96 116  0.63 0.8 1 -6.5 -0.75 -1.75 0 104 0 548 5.1 1 
35 80826 31.10.1976 od (R) 20.04.2009 -0.29 -0.35 26 -5.71 -2.15 26  0.8 1 1.25 -6 -0.5 -2.5 -0.75 28 15 610 4.3 1 
36 79155 09.08.1962 os (L) 25.04.2009 -0.59 0.17 175 -6.66 -2.17 175  0.2 1 1.25 -7.25 -1.25 -2 -0.5 172 160 508 6.9 1.5 
37 79155 09.08.1962 od (R) 25.04.2009 -0.88 0.54 180 -5.87 -2.04 180  0.32 1 1 -6.75 -1 -1.5 -0.25 4 0 501 7.5 1.5 
40 80694 12.02.1959 od (R) 02.05.2009 -0.5 0.25 94 -4.5 -1.75 94 0.01 0.8 1.25 1.25 -5 -0.75 -1.5 -0.25 93 110 534 4.4 1 
42 81238 01.10.1977 od (R) 16.05.2009 -0.65 0.46 179 -8.35 -3.21 179 0.001 0.25 1 1 -9 -1.75 -2.75 -0.75 180 170 563 4.8 1 
43 81238 01.10.1977 os (L) 16.05.2009 -0.68 0.44 2 -5.82 -4.44 2 0.05 0.63 1 1 -6.5 -0.25 -4 -0.75 3 5 550 5.3 1 
45 80965 16.10.1963 od (R) 16.05.2009 -0.44 0.24 10 -3.56 -2.24 10 0.08 0.63 1 1.25 -4 0 -2 -0.75 10 5 591 6.7 1 
47 77882 08.03.1969 od (R) 23.05.2009 -0.55 0.34 161 -2.2 -2.84 161 0.08 0.8 1 1 -2.75 0 -2.5 -0.5 160 170 572 6.3 1 
52 81970 04.01.1976 os (L) 01.06.2009 -0.47 0.09 179 -5.03 -1.34 179 0.05 0.32 1.25 1.25 -5.5 -1 -1.25 0 3 0 514 5.7 1.5 
52 81970 04.01.1976 od (R) 01.06.2009 -0.54 0.11 7 -5.71 -1.11 7 0.05 0.32 1.25 1.25 -6.25 -1 -1 0 7 0 511 5.6 1.5 
53 80177 13.04.1963 os (L) 06.06.2009 -0.6 0.17 11 -2.65 -2.17 11 0.08 1 1.25 1.25 -3.25 0 -2 -0.75 12 5 541 5.5 1 
53 80177 13.04.1963 od (R) 06.06.2009 -0.42 0.15 4 -3.33 -1.15 4 0.08 1 1.25 1.25 -3.75 -0.5 -1 0 170 0 538 5.2 1 
54 82942 13.08.1959 os (L) 13.06.2009 -0.41 0.14 179 -6.59 -1.39 179 0.01 0.32 1 1.25 -7 -1.5 -1.25 -0.25 180 110 547 6.4 1 
54 82942 13.08.1959 od (R) 13.06.2009 -0.39 0.15 173 -5.36 -1.4 173 0.05 0.4 1 1.25 -5.75 -1.25 -1.25 -0.25 168 55 559 6.2 1 
56 82355 05.05.1965 os (L) 15.06.2009 -0.42 0.21 23 -3.08 -1.21 23 0.08 0.8 1 1.25 -3.5 -0.5 -1 0 50 0 563 7.1 1 
56 82355 05.05.1965 od (R) 15.06.2009 -0.42 0.31 180 -4.33 -2.31 180 0.05 0.32 1 1 -4.75 -1 -2 -0.25 180 100 562 6.4 1 
57 80457 27.10.1978 os (L) 10.08.2009 -0.13 0.23 173 -5.12 -1.75 173 0.05 0.5 1.25 1.25 -5.25 -0.75 -1.5 -0.75 170 170 553 6.8 1.5 
57 80457 27.10.1978 od (R) 10.08.2009 -0.04 0.24 12 -4.71 -0.49 12 0.08 1 1 1.25 -4.75 -0.5 -1 0 180  549 6.7 1 
60 85443 15.09.1984 os (L) 03.08.2009 -0.52 0.36 37 -0.73 -1.36 37 0.25 1.6 1.25 1.6 -1.25 0.25 -1 0 28  517 6.8 1 
60 85443 15.09.1984 od (R) 03.08.2009 -0.36 0.32 105 -0.89 -1.32 105 0.25 1.6 1.25 1.6 -1.25 0.75 -1 -0.25 103 135 524 7.7 1 
61 83933 06.11.1959 os (L) 28.09.2009 0.06 0.15 78 0.31 -2.15 78 0.5 1 1 1 -0.25 0 -2 -0.25 85 100 530 6.2 1 
61 83933 06.11.1959 od (R) 28.09.2009 0.19 0.38 93 0.44 -1.88 93 0.5 1 1 1 -0.25 0 -1.5 -0.25 95 0 523 6.1 1 
101 64143 05.03.1978 od (R) 19.09.2009 0.01 0.17 93 -1.51 -1.17 93 0.2 1.25 1.25 1.25 -1.5 -0.25 -1 0 95 0 526 7.6 1 
102 83192 18.04.1964 od (R) 10.10.2009 -0.01 0.06 82 -4.24 -1.06 82 0.08 0.8 1 1 -4.25 -0.25 -1 -0.25 82 43 558 6.6 1 
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User satisfaction questionnaire for IBRA 
 
 
London, 11/11/2009 
 
 
Dear IBRA user 
 
The IBRA software has been developed by ophthalmologists, taking their needs into account for the 
functionality of the system. Your opinion is important and can help improving future software versions. 
 
With this questionnaire we would like to ask you about your overall impression on IBRA and about 
your satisfaction with the user interface and system capabilities. This questionnaire is part of my PhD 
research at the Centre for Health Informatics at the City University London under the supervision of 
Professor Abdul Roudsari. I would highly appreciate your participation and support with this user 
satisfaction evaluation.  
 
It takes only 5-10 minutes to fill in your answers directly into the word file. Save the file after your 
completion and email it back to me  if possible within the next 2 weeks. Many 
thanks in advance! Certainly, your data will be kept confidentially. 
 
If you can’t email the file, please send a printed and answered version of the questionnaire to: 
 
 
Please feel free to contact me on  in regards to any queries you may have. 
 
Yours sincerely 
 
 
 
Bruno Zuberbuhler 
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A. Questions related to the user 
 
 
 
 
 
Gender: [  ] Female   [  ] Male 
 
Age:  [  ] 20-29y  [  ] 50-59y 
  [  ] 30-39y  [  ] 60-69y 
  [  ] 40-49y 
   
How would you consider your experience in refractive surgery? 
    [  ] >3 years 
    [  ] 1-3 years 
    [  ] < 1 year 
    [  ] I don’t do refractive surgery (Fellows and secretaries) 
 
Since how long do you work with the IBRA system? 
[  ] Just started 
    [  ] Less than 3 months 
    [  ] 3-12 months 
    [  ] 1-3 years 
 
How often do you use the IBRA system? 
[  ] Less than 1x / month 
    [  ] 1-4x / month 
    [  ] 1-4x / week     
    [  ] Daily 
 
Do you have experience in using similar software?  [  ] Yes             [  ] No 
 
 
B. Overall reactions to the IBRA system 
 
 
 
 
 
 
 
 
 
 
The general use of the system is... terrible                                wonderful 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
 frustrating                          satisfying 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
 dull                                     stimulating 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
 difficult                                easy 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
 inadequate                          adequate 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
 rigid                                     flexible 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
 
 
Instructions for part B to D:  Please fill-in a number (1-9) or an ‘x’ in the box next to your answer. 
NA = Not Applicable 
Examples:  
Your No 
[  7  ] 
NA 
[  ] 
Your No 
[    ] 
NA 
[ x ] 
 
 
Instructions for part A:  Please fill-in an ‘x’ in the box next to your answer. 
Example:     [ x ] Your answer. 
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C. Main component questions 
 
Screen 
1. Characters on the computer screen hard to read                    easy to read 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
2. Organization of information on the 
screen 
confusing                          very clear 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
3. Sequence of screens confusing                          very clear 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
 
 
Terminology and system information 
4. Use of terms throughout system inconsistent                       consistent 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
5. Computer terminology is related to 
the task you are doing 
never                                 always 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
6. Position of messages on the screen inconsistent                       consistent 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
7. Computer keeps you informed about 
what it is doing 
never                                 always 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
8. Error messages unhelpful                             helpful 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
 
 
Learning 
9. Learning to operate the system is difficult                                 easy 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
10. Exploring new features by trial and 
error 
difficult                                 easy 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
11. Tasks can be performed in a 
straight-forward manner 
never                                 always 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
12. Help messages on the screen are unhelpful                             helpful 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
13. Supplemental reference materials confusing                           very clear 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
 
 
System capabilities 
14. System speed too slow                              fast 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
15. System reliability unreliable                            reliable 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
16. System security unsafe                                safe 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
 
 
User satisfaction of the human-computer interface 
17. Correcting your mistakes difficult                                 easy 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
18. Experienced and inexperienced 
users' needs are taken into 
consideration 
never                                   always 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
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D. Conclusions 
 
1. How do you assess the costs of the 
system? 
 
too expensive                    to cheap 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
2. How do you assess the significance 
of the system on your practice? 
 
low                                      high 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
3. How do you assess the uniqueness 
of the system in your field of expertise? 
 
low                                      high 
1    2    3    4    5    6    7    8    9 
Your No 
[    ] 
NA 
[  ] 
 
 
 
 
 
 
Many thanks for taking your time! 
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Appendix 11 
 
ARTICLE ON IBRA IN EUROTIMES MARCH 2009 
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Appendix 12 
 
ARTICLE ON IBRA IN EYEWORLD 2009 
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